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ABSTRACT
1) Monoclonal antibodies directed against both Factor FVIII
procoagulant protein (FVIII C) and fibrinogen were produced and 
characterised
2) Polyclonal antisera directed against a BSA-diazepam conjugate 
was produced These were found to be directed against the
conjugate rather than diazepam
3) IB vitro studies on the effects of both coumarin and 7 -hydroxy- 
coumarin on the growth of cells indicated that neither drug was 
cytotoxic, but they both slowed the growth of cells in vitro 
7-hydroxycoumarm was found to have more potent cytostatic effects 
than coumarin
4) The results from a clinical study on the effects of coumarin on 
liver function indicated that 0 36% of patients experienced an
idiosyncratic hepatotoxicity to coumarin
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SECTION I 
INTRODUCTION
I INTRODUCTION
While inoculation had been used by the Chinese many centuries ago, 
immunology as a modern science began with the introduction of 
vaccination by Jenner m  1798 His simple technique of 
m n o c u l a t m g  people with a minor infection like cowpox, to protect 
them from a more serious infection like smallpox, revolutionised 
medical therapy Preventative medicine based on scientific 
principles was born, and immunology looked as if it was going to 
become the most important discipline in medical science It was 
thought that these advances would lead to the eradication of 
disease and thus, to a disease free society Yet, 150 years later 
very little progress had been made in immunology, with many of the 
major advances in immunology only occurring m  the last 30-40 
years
There are two reasons for this lack of progress m  immunology 
Firstly, immunology, like all branches of science, cannot 
develop in isolation Thus, immunology had to await developments 
m  other branches of science before it could advance further In 
particular, improvements in electrophoretic techniques, advances 
in tissue culture techniques, the development of new protein 
chemistry techniques, and the major advances in genetics, 
especially cloning techniques, played key roles m  the advances 
m  immunology
The second reason for the slow progress in immunology was the 
failure to realise the importance of immunology While it was 
known that antibody production by B-cells was important m  the 
prevention of disease, this was only part of the picture Both 
T-cells and macrophages have important functional and regulatory 
roles m  the immune system The importance of the regulatory 
mechanisms in the immune system have only recently been realised 
(Sinlair and Panoskaltsis, 1988) The role of autoimmunity m  
diseases such as rheumatoid arthritis (Cohen, 1988), as well as 
the problem of graft rejection m  organ transplant surgery, led to 
the development of immunosuppressive drugs The severe 
consequences of immune suppression as seen m  HIV infection, has 
produced a search for new, and more powerful drugs for stimulating 
the immune system (Mengan, 1988) The use of these drugs in the 
treatment of cancer is also currently under investigation (Hadden,
1982)
One of the most important advances in immunology was the somatic 
cell hybridization technique of Kohler and M i l s t e m  (1975) It 
was not long before the commercial, and scientific value of this 
technique was realised The resultant availability of large 
quantities of pure, highly characterized antibodies, as well as 
the advances in immunoassays such as Enzymes Linked ImmunoSorbent 
Assay (ELISA), Enzyme Multiplied Immunoassay Technique (EMIT), and 
RadioImmunoAssay (RIA) brought immunoassay techniques to the 
forefront of the lucrative assay market (Montgomery et al , 1986) 
At present immunoassays are probably the most widely used assays 
for biologically active substances
While monoclonal antibodies quickly became the cornerstone of the 
newly developing biotechnology industry, they did not eliminate 
the need for conventional polyclonal sera The m a m  reason for 
this is their cost Production costs are very high due to the 
specialist techniques, and equipment that are needed This is 
reflected in their retail cost, which is much higher than 
polyclonal antisera Thus, for much work polyclonal antisera are 
still used _
It is in the areas of research and therapy that monoclonal 
antibodies have been of real benefit Monoclonal antibodies have
been very successfully used in the isolation and localization of 
many biologically active compounds, eg blood coagulation factors 
(Fass et al , 1982) This, coupled with gene cloning techniques, 
has been responsible for many of the major advances m  biology,
and medicine m  recent years Monoclonal antibodies are
particularly useful for in vivo use because of their pure and
highly defined nature Clinically they are being used for 
treating drug overdoses (Smith et al , 1982), for tumour 
localization, and for treating cancer (Hersh et al , 1981, Schlom, 
1986)
The work described in this thesis involves three major areas of 
research
(i) The production of monoclonal antibodies to blood coagulation 
factors (Section III)
( n )  The production of antibodies to drugs (Section IV)
(in) Studies on the potential use of c oumann as a therapeutic
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agent This included studies on the effects of coumann on 
m  vitro growth of tumour cells (Section V), and a study on 
clinical toxicity of c oumann (Section VI)
This work touches on a number of different areas of immunology 
including the production and uses of monoclonal antibodies, the 
role of the immune system in toxic effects of drugs, and the 
therapeutic roles for immunostimulants
Replacement therapy in blood factor deficient states has a number 
of problems Firstly, there is the risk of infection from the 
donor plasma, and secondly, there is the problem of production of 
antibodies by the recipient to the administered blood factors 
These problems can be reduced by using purified blood factors 
FVIII was chosen for this work because of the prevalence of 
haemophilia in the world, and in particular, to the high risk of 
HIV infection among haemophiliacs treated with crude FVIII 
concentrates (Ward et al , 1988) Immobilised monoclonal anti­
bodies can be used to isolate pure FVIII (Fass et al , 1982) This 
enables the FVIII to be isolated from plasma m  a pure form, free 
from other blood factors, and infectious particles Thus, 
patients can receive a highly purified FVIII preparation, which 
has a low risk of infection, especially if it is heat-treated as 
well (Hink et al , 1957) The low level of contaminants m  it will 
reduce the risk of antibody formation to other blood factors, thus 
preventing the patient from developing new acquired disorders 
Other uses for monoclonal antibodies to blood coagulation factors 
are in the study of the coagulation process and its disorders, and 
m  immunoassays for plasma levels of these factors A more 
detailed discussion on the uses of monoclonal antibodies to FVIII 
and to fibrinogen can be found in section III 3 10
Both anti-FVIII and anti-fibrinogen antibodies have a use m  the 
study of different cancers vWF is a marker for endothelial cells 
(Jaffe et al , 1973) and can be used m  the detection/classificat­
ion of endothelial tumours Similarly FVIII CAg is a marker for 
hepatocytes, and spleen cells (Wion et al , 1985), and anti-
FVIII CAg antibodies may have a role m  the detection and 
classification of tumours m  these tissues Fibrinogen is 
involved m  the growth and proliferation of tumours, and thus, has 
a role in the study and detection of certain tumours (Brown et 
al , 1988)
The production of antibodies to drugs has many important uses 
They can be used in immunoassays (Budd and Walkm, 1980, Dixon, 
1982) and they have been successfully used in the treatment of 
drug overdoses (Butler et al , 1973) The work presented here
highlights the difficulties m  the production of both monoclonal 
and polyclonal antibodies to drugs, in this case diazepam
In recent years c oumann has become increasingly popular as a 
therapeutic agent due to its properties as an immunostimulant 
(Piller, 1976b, Thornes, 1983b, Zanker et al , 1984) Initially it 
was used in the treatment of high protein lymphoedema (Clodius and 
Piller, 1978), but currently it is undergoing extensive trials for
use m  various forms of cancer (Zanker et al , 1984, Marshall et
al , 1987) Two major questions have prevented more wide spread
use of c oumann m  clinical medicine The first involves the 
mechanism of action of coumann Are its actions solely on the 
immune system, and is coumann, or a metabolite, the active agent? 
A more serious doubt about coumann is its reputation as a 
hepatotoxin from animal studies (Hazelton et al , 1956) In 
section V the effects of coumann, and its major metabolite in 
humans, on the in vitro growth of tumour cells is investigated
The clinical study presented m  section VI reports a form of
hepatotoxicity that appears to have an immunological basis, in a
small number of patients treated with coumann Thus, stimulation 
of the immune system may have a side effect of producing disorders 
of the autoimmune type This could be due to c oumann only, or it 
could be a problem with other types of immunostimulatory therapy 
(Shoham, 1985)
Since the research described here covers a number of distinct 
but related topics, the thesis has been divided into 8 sections 
which, it is hoped, will help clarify the results There is a 
common Materials and Methods section (Section II), and Reference 
section (Section VIII) Sections III, IV, V and VI each have 
their own introduction, results, and discussion sections Section 
I (this section) provides a general introduction to the research, 
while section VII provides an overview of the results
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SECTION II 
MATERIALS AND METHODS
I I  1 MATERIALS AND BUFFERS
II 1 1 MATERIALS
All materials were purchased from Sigma Chemicals, Poole, Dorset, 
UK, unless otherwise indicated All solvents, and acids were pur­
chased from Riedel de Haen, Aktiengesellschaft, Wunstorfer Str 
40, D-3016 Seelze 1/Hannover, W Germany All tissue culture
media, and reagents were purchased from Flow laboratories, Ayr­
shire, Scotland Tissue culture flasks, and plates were also 
purchased from Flow laboratories Other disposable tissue culture 
plastics were purchased from Sterilm Laboratory, 43/45 Broad 
Street, Teddington, Middlesex, UK Tris(hydroxymethyl) methyl- 
amine (Tris), glycine, and SDS were obtained from BDH, Poole, 
Dorset, UK
II 1 2 BUFFERS
The following buffers were used
Phosphate buffered saline (PBS) Phosphate buffered saline,
145 mM NaCl, 2 5 mM NaH2P04( 7 5 mM Na2HP04 , pH 7 2 
PBS-TWEEN PBS with 0 l%(v/v) Tween 20 
PBS-BSA PBS containing l%(w/v) BSA
Perox substrate buffer 0 05 M citric acid-0 25 M Na2P04, pH 5 0 
Carbonate Buffer 0 025 M carbonate/bicarbonate buffer, pH 9 5
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BLOOD FACTOR ASSAYS
II 2 1 BLOOD FACTOR ASSAYS
There are two m a m  types of blood factor assays The first type 
depends on binding of a specific antiserum to a blood factor 
(antigen) This can be m  the form of an ELISA assay, or quan­
titative Immunoelectrophoresis (Giddings and Peake, 1981) The 
second type assays the biological function of the blood factor 
This is usually a coagulation assay (Barrowcliffe and Kirkwood, 
1981), but there are also chromogenic assays of biological 
activity (Blomback, 1981) The results obtained from both these 
assays do not always correspond This is due, m  part, to the 
presence of inactive protein which is quantified m  the 
immunoassay and not in the coagulation assay Thus, m  certain 
types of haemophilia an immunoassay can detect normal levels of 
FVIII, while the coagulation assay detects very low levels of 
activity
The standard used for FVIII assays is normal plasma Normal 
plasma is pooled plasma from a large number of donors and it is 
assumed to have 1 IU of FVIII procoagulant activity per ml
Similarly the level of vWF in normal plasma is 1 IXJ/ml 
Fibrm(ogen) is measured m  terms of mg/ml and is supplied m  a
relatively pure form for use as a standard
II 2 2 ACTIVATED PARTIAL THROMBOPLASTIN TIME (APTT)
This assay uses a FVIII deficient plasma which allows the quantity 
of FVIII to be assayed specifically The assay is based on the 
principle that coagulation cannot proceed beyond FVIII without 
calcium Thus, when a sample containing FVIII is mixed with 
FVIII deficient plasma and an activator, which contains rabbit 
brain cephalm, and kaolin (APTT reagent) , the coagulation
pathway is activated, but coagulation cannot occur due to the 
absence of calcium When calcium is then added the rate limiting 
step will be the quantity of functional FVIII present To ensure 
that that there is no calcium present m  the test, all plasmas 
were collected using sodium citrate as an anticoagulant Reagents 
for coagulation assays were obtained from Warner Lambert and from 
Sigma (see also III 1 13)
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All of the reagents were reconstituted according to the manufact­
urers instructions A 100% standard was prepared by diluting 
normal plasma 1/10 in 0 85% saline A standard curve was prepared 
by diluting the 100% standard in saline to give 100%, 50%, 25%,
12 5% and 6 25% solutions All samples were assayed m  duplicate, 
and the reagents were kept at 37°C throughout the assay Boro- 
silicate glass tubes (Corning) were used for the assay, since they 
are less likely to bind protein non-specifically Great care must 
be taken with the reconstituted reagents due to the risk of 
hepatitis from plasma FVIII-deficient plasma, which is obtained 
from haemophiliacs, poses an additional risk due to the high 
level of HIV infection m  these patients Many commercially 
available FVIII deficient plasmas, especially those sold before 
routine screening was established, are anti-HIV positive, and
could pose a serious risk to the operator
0 1 ml of FVIII-deficient plasma was mixed with 0 1 ml of sample, 
or standard, and incubated for 2 m m  0 1 ml of APTT reagent was 
then added to the bottom of the tube, and allowed to incubate for
5 m m  0 1 ml of calcium chloride (0 02 M) was then added, and
the time taken for a clot to form was measured The tilt tube
method was used, and the time was taken when the first f i b r m
strands became visible The results were plotted on log-log graph
paper
II 2 3 FACTOR VIII ELISA
This assay uses polyclonal antisera to detect the presence of 
FVIII This assay only detects von Willebrands Factor (FVIIIR Ag)
Plates were coated with 5 mg/1 sheep anti-human FVIII antibodies 
(Serotec) m  carbonate buffer (see II 8 1) Plates were washed 3 
times m  PBS-Tween before use Serial dilutions of normal plasma, 
and test sample were made m  PBS-Tween 100 Ml of each dilution 
were added m  duplicate to the plates, and incubated at 37°C for 2
hrs The plates were then washed 3 times m  PBS-Tween, and 100
pi of the peroxidase-labelled sheep anti-human FVIII antibody 
(Serotec), diluted in PBS-Tween, was added to each well The 
plates were incubated for 1-2 hrs at 37°C The plates were washed 
3 times in PBS/Tween, and 100 pi of perox substrate buffer, 
containing 40 mg OPD and 20 pi of H^O^» were ac^ e<* After 15 m m  
at room temperature the reaction was stopped by the addition of 25
pi of sulphuric acid (20% v/v) The absorbance was read at 490 ran 
on an ELISA plate reader (Biotek; EL307)
II 2 4 LAURELL ROCKET IMMUNOELECTROPHORESIS
Quantitative Immunoelectrophoresis, based on the method of 
Laurell (1966), was also used to assay the quantity of FVIIIR Ag 
present m  samples This technique involved electrophoresmg 
samples of FVIII m  an agarose gel containing anti-human FVIII 
antiserum The resulting precipitin lines formed peaks The 
height of each peak was proportional to the FVIII concentration in 
the sample (Zimmerman et al , 1975)
A l%(w/v) solution of electrophoresis grade agarose (Gibco) m
barbitone buffer (25mM diethylbarbituric acid (BDH), pH 8 6, 
containing 75mM T n s  and 0 5 mM calcium lactate (Riedel de Haen)) 
was prepared by boiling the suspension until all of the agarose 
was dissolved This was then stored m  12 ml aliquots at 4°C
These aliquots were then boiled m  a water bath until completely 
melted, and allowed to cool to 50°C when 10 M 1 of goat anti-human
FVIII antisera (Miles) was then added A 12 ml aliquot was then
poured onto glass plates (8 5x9 5 cm) and allowed to cool Some 
plates were stored overnight. m  a humidity chamber before use 
Eight wells were then cut in the agarose using the LKB mould and 
punch
Normal plasma was diluted m  0 85% saline to produce a range of 
concentrations for a standard curve 12 p 1 of the standards, and 
suitably diluted samples, were applied to the wells m  the 
agarose The plates were then placed on the Multiphor 2117
electrophoresis tank (LKB) with wicks soaked m  barbitone buffer 
at each end of the plates The protein was electrophoresed from 
cathode to anode overnight with a current of 10 mA
After electrophoresis the gels were covered with filter paper, 
and a weight was placed on top This was repeated 3 times to dry 
the gel The gels were then washed twice in 0 1 M saline (at
least 15 min each), dried with filter paper, and then dried to a
clear film with hot air They were then stained for 5 min m  
Coomassie blue (see II 10 6) rinsed m  distilled water, soaked m  
d e s t a m  solution for 10 min (or longer if necessary) until clear, 
and again dried under hot air
The heights of the standards were measured, and a standard curve 
was plotted This was used to calculate the concentration of 
FVIIIR Ag m  the unknown samples
II 2 5 FIBRINOGEN ASSAYS
The assay used for fibrinogen was a coagulation assay based on the 
method of Clauss (1957) This uses thrombin to convert fibrinogen 
into fibrin, which then forms a clot With diluted plasma, the 
rate limiting step in the presence of excess thrombin, is the 
fibrinogen concentration This is reflected in the time taken for 
clot formation The assay was performed using a kit from Sigma 
(see also III 1 6)
Reagents were reconstituted according to the manufacturers ins­
tructions Test plasma, and the standard fibrinogen preparation 
were diluted in diluent supplied with the kit 0 2 ml was 
incubated m  borosilicate glass tubes for 1-5 min, at 37°C 0 1
ml of thrombin was then added and incubated at 37°C The time 
taken to clot formation for the standard was measured, and 
plotted on log-log graph paper The clotting time for the samples 
could then be converted to concentration using this standard 
curve
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I I  3 FACTOR V i l i  ISOLATION AND PURIFICATION
II 3 1 REAGENTS
Three sources of factor VIII (FVIII) were used The first was
prepared from fresh frozen plasma (a gift from The Blood
Transfusion Service Board, Dublin) by ethanol cryoprecipitation 
The second was isolated crude cryoprecipitate (kindly donated by
The Blood Transfusion Board, Dublin) The third source was Koate,
a commercially available, high purity FVIII (Cutter Laboratories)
II 3 2 ISOLATION OF FVIII BY CRYOPRECIPITATION
The method used was similar to the ethanol cryoprecipitation
method of Cohn et al , (1946) as modified by Newman et al (1971)
Frozen plasma, which had not been stored for more than 3 months,
was softened by immersion m  a water bath at 37°C for 5 m m  It
was then crushed in the bag and transfered to a stainless steel
container m  an ethanol bath at 0°C Ice cold ethanol (50%v/v) 
was added, with stirring, to a final concentration of 3%(v/v) 
The plasma was then melted under a stream of air but its 
temperature was not allowed to rise above 2°C It was then
centrifuged at 5,000 g for 20 m m  The resulting precipitate was/
washed with 8%(v/v) ethanol at -5°C After washing, the precip­
itate was dissolved (by stirring at 20°C for 30 m m )  m  125 ml 
0 02 M T n s ,  pH 7 0, per litre of starting plasma The solution
was then passed through glass wool to remove any residual
precipitate The T n s  solution containing FVIII was then adsorbed 
with Aluminium hydroxide The Aluminium hydroxide was prepared by 
diluting Aluminium hydroxide gel F500 (Reheis) to a concentration 
of 1 6% (w/w) Al^O  ^ (as determined by titration against lead 
nitrate according to the British Pharmacopeia assay) and heated to 
95°C for 3hr to inactivate it The Tns-Aluminium hydroxide 
mixture was centrifuged at 5,000g for 20 min, and filtered through 
an AP20 glass fibre prefilter (Millipore) to remove any remaining 
particles Trisodium citrate (0 5 M) was then added to a final 
concentration of 0 02 M
II 3 3 PURIFICATION OF FVIII WITH POLYETHYLENE GLYCOL 
The contaminating fibrinogen was then removed by precipitation 
with PEG By increasing the PEG concentration the FVIII was then 
precipitated
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Cryoprecipitate prepared from plasma (see above) or lyophilised 
FVIII concentrate (Blood Transfusion Service Board, Dublin) was 
acidified to pH 6 1 with 0 02 M citric acid, and PEG 4000 (Riedel 
de Haen) was added to a final concentration of 4-5 g/100 ml This 
precipitated most of the fibrinogen, which was removed by 
centrifugation at 5,000g for 5 m m  PEG 4000 was then added to 
the supernatant, to a final concentration of 12 g/100 ml, to
precipitate the FVIII The solution was centrifuged at 6,000g for
10 m m  The resulting pellet was then gently washed (without 
dislodging it) with 8% (v/v) ethanol in 0 02 M Tris, pH 7 0 at -5 
°C The pellet was dissolved in 0 02 M T n s - 0  02 M citrate buffer, 
pH 7 0, and diluted to approximately l/200th of its original 
plasma volume It was stored at -20°C until further use
11 3 4 FURTHER PURIFICATION OF FVIII BY CHROMATOGRAPHY
Both PEG precipitated FVIII and Koate were further purified by gel 
chromatography according to the method of Fay et al , (1982) A 
76x2 5 cm column of Sepharose CL 6B (Pharmacia) was used The 
void volume and total volume were estimated with dextran blue, and 
phenol red, respectively The elution buffer was 5 mM sodium 
citrate containing 1 mM CaCl2, 135 mM NaCl, 5% (w/v) Dextrose, 
0 02% (w/v) sodium azide, and pH 7 35 One bottle of Koate (220
IU), or the PEG precipitate, was dissolved in 5 ml of elution
buffer The 5 ml of Koate or 2 ml of the PEG precipitate were 
eluted from the column with elution buffer and a flow rate of 1 63
ml/min Sixty 10 ml fractions were collected Each fraction was
assayed for protein (OD at 280 nm), and for FVIIIR Ag (ELISA) 
The fractions from the same protein peak were pooled, and were 
stored at -20°C These were later used for screening hybridomas 
for antibody production
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I I  4 PRODUCTION AND PURIFICATION OF FIBRINOGEN FRAGMENTS
The action of p l a s m m  on fibrinogen produces 4 fragments viz X,Y,D 
and E The X and Y fragments are produced first, and have a 
larger molecular weight than the D, and E fragments The method 
used for the production of the early fragments was based on that 
of Nieuwenhuizen and Gravessen (1981), while the method for 
producing the late degradation products was based on that of 
Haverkate et al , (1979)
II 4 1 PRODUCTION OF EARLY FIBRINOGEN DEGRADATION PRODUCTS 
20 mg of fibrinogen purified from Koate by column chromatography 
(see II 3 4) was added to 20 ml of 0 04 M sodium barbitone buffer, 
pH 7 75, containing 0 1 M NaCl, and 10 mM EGTA Digestion was 
started by adding 10 CU of p l a s m m  (Kabivitrum) , and it was 
allowed to proceed for 30 m m  at 37°C Digestion was stopped by 
adding 0 2 ml of 0 1 M phenylmethylsulphonylfluonde (PMSF)
Saturated ammonium sulphate, pH 7 0, was then added to a final 
concentration of 20% (w/v) After centrifugation at 15,000 rpm
for 15 m m  the supernatant was collected and its ammonium sulphate 
concentration was increased to 50% (w/v) The precipitate was
collected after centrifugation at 15,000 rpm for 15 m m
The pellet was dissolved in the minimum volume of 0 15 M potassium 
phosphate buffer (mixed), pH 7 5, and applied to a Sepharose CL 6B 
(Pharmacia) column (76 x 2 5 cm) This was then eluted in the 
same buffer overnight with a flow rate of 0 5 m l / m m  10 ml 
fractions were collected and protein peaks, as determined by 
absorbance at 280 nm, were pooled, and concentrated by the 
addition of solid ammonium sulphate to a concentration of 50% 
(w/v) saturation The precipitates were collected after 
centrifugation at 15,000 rpm for 20 m m  The pellet was dissolved 
in the minimum volume of PBS, and dialyzed overnight
II 4 2 PRODUCTION OF LATE FIBRINOGEN DEGRADATION PRODUCTS 
10 mg of fibrinogen purified from Koate was added to 5 ml of 0 04 
M sodium barbitone, pH 7 4, containing 0 1 M NaCl, 2 mM CaCl2, and 
2 CU of p l a s m m  This was then incubated for 24 hrs at 37°C
1,000 KIU of aprotinm was then added, to stop the action of 
p l a s m m  and the preparation was lyophilised
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The sample was then dissolved in the minimum volume of 0 01M 
sodium bicarbonate containing 10 KITJ/ml of aprotmin, and 
dialysed against this buffer The sample was then applied to a 
Sepharose CL 6B column (76 x 2 5 cm) equilibrated in the same 
buffer
10 ml fractions were collected, and protein peaks, determined by 
absorbance at 280 run, were pooled, and dialysed against distill­
ed water They were then lyophilised, redissolved in PBS, and 
stored at -20°C
11 4 3 PURIFICATION OF FIBRINOGEN CHAINS
Fibrinogen consists of 3 chains - ACX, b 3, and Y These were 
prepared by the method of Doolittle et al , (1977)
100 mg of fibrinogen were dissolved m  10 ml of 6M guamdinium 
chloride • 0 2M T n s , pH 8 2, containing 0 01 M dithioerythritol 
(DTE) After 30 min at room temperature 10 ml of 6M guamdinium 
chloride containing 0 03M lodoacetic acid was added This was 
left for 30 m m  in the dark, and was then dialysed against 6M 
guamdinium chloride for 60mm, also m  the dark The mixture was 
then dialysed against a number of changes of distilled water, at
0 4 ° C
After dialyses the chains were lyophilised, and redissolved in 8 M 
urea-5 mM sodium acetate, pH 5 2 A sample of this was then 
applied to a CM-cellulose column (20 ml), and eluted, using a 
linear gradient, with 8 M urea - 0 125M sodium acetate, pH 5 2 as
the limit buffer 5 ml fractions were collected, and those 
containing protein, as determined by absorbance at 280 nm were 
pooled, dialysed against water, and lyophilised
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I I  5 CONJUGATE SYNTHESIS
Since diazepam is too small to be antigenic, it has to be 
conjugated to a carrier protein This conjugate becomes the 
antigen If there is sufficient epitopes of diazepam present then 
most of the antibodies will be directed to the diazepam The 
conjugation method used was based on that of Peskar (1973) This 
involved conjugating the p-ammoacetanilide derivative of diazepam 
(Ro 20-9748) to BSA Initially this derivative was not available, 
so it was synthesised from Ro 7-3551
II 5 1 REAGENTS
Diazepam (Ro 5-2807) 7-Chloro-1,3-dihydro-5-phenyl-2H-l,4-
benzodiazepm- 2 - one 
Ro 7-3351 7-chloro-ll3-dihydro-5-(4-hydroxyphenyl)-l-methyl 
-2H-1,4-benzodiazepin-2-one 
Ro 20-9748 5-[3-(4-Aminophenylazo)-4-hydroxyphenyl]-7-
chloro-1, 3-dihydro-1-methyl-2H-1,4-benzodiazepm-2-one 
Ro 20-9749 5-[3-(Acetamidophenylazo)-4-hydroxyphenyl]-7-
chloro-1,3-dihydro-1-methyl-2H-1,4-benzodiazepin-2 -one 
Ro 7-3551, Ro 20-9748 and diazepam were gifts from Hoffman 
La-Roche
11 5 2 SYNTHESIS OF Ro 20-9749
The method of Earley et al (1979) was used A solution of 0 45g of 
sodium nitrite (BDH) m  5 ml of water was added to a mixture of
1 2  ml of conc HC1, 5 g ice and 0 9 g £-aminoacetamlide (Riedel 
de Haen) This mixture was then added to 0 5 g Ro 7-3351 m  25 ml 
of Tetrahydrofuran (THF) containing 1ml IN NaOH, and 20 g ice 
The reaction was incubated for 2 5 days at 4°C The crystals were 
recrystallised from methylene chloride - methanol (50 50) mixture, 
and recrystallised from a methylene chloride-petroleum ether 
(50 50) mixture The expected mp was 276-278°C, and the expected 
IR should have a broad peak at 1700 cm'^
II 5 3 SYNTHESIS OF Ro 20-9748
0 6 g of Ro 20-9749 were added to 50 ml methanol, containing 10 ml 
concentrated HC1, and heated for 10 min on a steam bath The 
mixture was left for 2 hr at room temperature and the methanol was 
evaporated The solution was then made basic with ammonium 
hydroxide, and extracted with 50 ml methylene chloride The
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organic layer was collected and evaporated The residue was 
crystallised from methanol, and recrystallised from methylene 
chloride-methanol (50 50) Brown prisms with a melting point of 
262-268°C, and IR peaks at 3450, 3350, and 1682/cm were expected
II 5 4 SYNTHESIS OF Ro 20-9748 (REVISED)
The revised synthesis of Ro 20-9748 by Fryer (personal 
communication) is based on a combination of the 2 reactions above 
It uses Ro 7-3351 as a starting compound to form Ro 20-9748 
without the intermediate step of isolating Ro 20-9749
A solution of 8 6 g of sodium nitrite m  100 ml of water was added 
to a mixture of 100 g of ice, 24 ml conc HC1 and 18 g 
£-ammoacetanilide, with stirring This was then added, with 
stirring, to 100 ml of THF containing 10 g Ro 7-3551, 240 ml IN 
NaOH, and 400 g ice 4 g of sodium acetate was added, and the 
the solution was adjusted to pH 8-9 with conc HC1 After 3 hrs at 
4°C the resulting crystals were collected
This crude material was dissolved m  1400 ml methanol containing 
280 ml conc HC1 After standing for 18hrs the solution was 
adjusted to pH 7-8 with conc ammonium hydroxide and the methanol
was removed under vacuum Water was added, and the solid
collected by filtration This was then air dried and dissolved m  
THF An insoluble tar was removed by filtration, and the filtrate 
was concentrated The residue was dissolved m  dichloromethane 
(DCM), and THF (50 50) mixture and filtered through 200 g of 
Flonsil (Sigma) The product was eluted with DCM followed by 
ether The solvents were evaporated, and the residue was
recrystallised twice from THF/ethanol to give reddish brown 
prisms, MP=265-268°C
II 5 5 SYNTHESIS OF Ro 20-9748-PRQTEIN CONJUGATE
(l) Method of Peskar et al , (1973) 20 mg of Ro 20-9748 were
dissolved in DMF and the pH was adjusted to about pH 1 5 with 1ml 
of IN HC1 All procedures were done on ice A solution of 100 mg 
of sodium nitrite m  1ml water was added slowly to this 50 mg of 
ammonium sulfamate m  1 ml water was then added dropwise This 
mixture was added to 40 mg of BSA m  5 ml of 0 1 M borate buffer 
(0 05 M boric acid containing 0 05 M potassium chloride), pH 9 
The mixture was maintained above pH 8 by the addition of borate
buffer A bright orange colour developed immediately The
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reaction mixture was adjusted to pH 9 and stirred overnight m  the 
dark at 4°C This was followed by dialyses against several 
changes of water The solution was then lyophilised
(ii) Method of Dixon (1982) 0 06 ml of 1 M sodium nitrite was
added to 2 ml DMF containing 20 mg of Ro 20-9748, 0 6 ml water,
and 0 2 ml of 1 M HC1, and the mixture was stirred for 30 m m
0 05ml of 1 M ammonium sulfamate was then added This solution 
was added to 200 mg BSA m  5 ml 0 16 M borate buffer, pH 9 The 
solution became dark blue but turned to brown after stirring for 1 
hr, and was kept at pH 9 by the addition of 1 N NaOH It was 
incubated overnight at 4°C, and then dialysed against several 
changes of 0 05 M sodium bicarbonate This was followed by 
dialyses against several changes of distilled water
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IX 6 IMMUNISATION PROTOCOLS
Two different immunisation protocols were used One was for 
immunising mice for the production of monoclonal antibodies The 
second was for the production of antibody rich ascitic fluid In 
the former instance both FVIII and diazepam conjugate were used 
In the latter only the diazepam conjugate was used
II 6 1 IMMUNISATION FOR FUSIONS
Antigen was prepared by diluting stock solutions to a 
concentration of 1 mg protein/ml (or 10 IU FVIII/ml) m  PBS 0 1 
ml of this preparation was emulsified with 0 3 ml of either 
complete (CFA), or incomplete (IFA) Freunds adjuvant (Gibco) It 
was then injected ip into 8 week old Balb/C mice as follows
Day 0 100 Ug (1IU) m  CFA
Day 21 100 Ug (1IU) in IFA
Day 42 100 pg (1IU) m  IFA
Day 63 100 yg (1IU) m  PBS
On day 66 the mouse was killed, and its spleen was removed 
asceptically  ^ A fusion was then performed using the isolated 
spleen cells, or else the spleen cells were frozen down in liquid 
nitrogen for later use
II 6 2 PRODUCTION OF ASCITIC FLUID RICH IN POLYCLONAL ANTIBODIES 
Antigen was prepared by emulsifying protein with CFA in the ratio 
9 1 (CFA protein) 0 2 ml of this was injected ip into 12 week 
old Balb/C mice as follows
Day 0, 14, 45, 52, 59, and 81
100-500 yg protein in 0 2 ml CFA 
Day 86 0 5 ml of pnstane
Day 91 100-500 ]Jg protein in 0 2 ml CFA
Ascites fluid was tapped from mice when necessary by inserting a 
sterile 21G needle into the peritoneal cavity, and allowing the 
fluid to flow out It was necessary to set up 6-10 mice at a time 
as some died, and many failed to produce ascites (Tung, 1983)
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I I  6 3 TREATMENT OF ASCITIC FLUID
Ascitic fluid was obtained by 2 methods The first was from the 
growth of a hybndoma m  the peritoneal cavity (see II 7 8), and 
as an antibody rich fluid (see above) Ascitic fluid was 
centrifuged at 2,000 rpm for 10 m m ,  and the supernatant stored 
at -20°C until it was processed further If the ascitic fluid 
contained a growing hybndoma, the pellet, which contains the 
cells, was either injected into other mice or frozen
Ascitic fluid produced by the same clone was pooled Similarly, 
ascites produced from immunisation with the same antigen was 
pooled The fatty layer was removed with a pasteur pipette, and 
the fluid was centrifuged at 15,000 rpm at 4°C for 20 m m  All 
subsequent steps were performed at 4°C The fluid was then 
filtered through glass wool, and the pH lowered to 4 9-5 1 with 
HC1 After 1 hr it was centrifuged at 15,000 rpm for 20 m m  to 
remove the precipitated fibrinogen
The pH was raised to 7 0-7 2 with NaOH, an equal volume of 
saturated ammonium sulphate was added, and left for 1 hr The 
ascites was centrifuged at 15,000 rpm for 20 m m  The pellet was 
then washed with 50% saturated ammonium sulphate, and centrifuged 
at 15,000 rpm for 20 m m  The pellet was then dissolved in the 
minimum of distilled water, dialysed against 0 1 M Tns-HCl (pH 
8 0), and was then stored at -20°C
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I I  7 TISSUE CULTURE AND FUSION METHODS
A number of different media were used for the different tissue 
culture procedures Unless otherwise indicated ’’media" refers to 
DMEM containing 2mM 1-glutamine, 100 IU/ml penicillin, 100 jjg/ml 
streptomycin, 2 5 Mg/ml fungizone, and 10% (v/v) FCS
II 7 1 FUSION METHOD
Sp2 myeloma cells were cultured m  antibiotic free media prior to 
the fusion Cells in the mid-log phase were centrifuged at 2,000 
rpm for 10 min The pellet was washed 3 times in serum free 
media Immunised mice were killed by cervical dislocation, 
soaked m  alcohol, and their spleen removed asceptically The 
spleen was cut into 4 pieces, and a total of 10 ml of serum free 
medium was injected into the pieces The cell suspension was then 
centrifuged at 2,000 rpm for 10 m m  and the pellet was then 
resuspended m  2 ml of haemolysis buffer (0 017 M Tris, pH 7 2,
containing 0 144 M NH^Cl) for 5 m m  to lyse the red blood cells
This was then underlayed with 5 ml of FCS, and centrifuged at
2,000 rpm for 10 m m ,  which separates unlysed cells from 
membranes Haemolysis was repeated a second time if the pellet
was still heavily contaminated with red blood cells The pellet
was then washed 3 times m  serum free medium This yields a pellet 
which is free from red blood cells, and also free from FCS, which 
interferes with the fusion process
After counting, viable spleen, and Sp2 cells were were mixed m  a 
10 1 ratio The cells were then centrifuged at 2,000 rpm for 10 
m m  The pellet was resuspended in serum free medium, and 
pelleted at 4,000rpm for 5 m m  All the supernatant was removed,
and 1 ml 50% (w/v) PEG (Riedel de Haen), dissolved m  serum free
medium, and filter sterilised, was added with stirring over 1 
m m  Cells were stirred at 37°C for 1 5-2 m m  3 ml of serum free 
medium were then added over 3 m m ,  followed by 6 ml over 3 m m  
The cells were stirred continuously throughout this procedure The 
cells were then pelleted at 2,000 rpm for 10 m m ,  and resuspended 
in HAT medium (media contamig 13 611 JJ g/ml hypoxanthme, 0 176
¿jg/ml aminopterm, and 3 876 pg/ml thymidine) at a concentration 
of 1 10^ viable spleen cells per ml 100 pi of this was added to
each well of a 96 well plate which had been precoated with a
feeder layer, usually consisting of macrophages (see II 7 2)
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The plates were sealed with parafilm, and incubated for at least 7 
days at 37°C in 5%C02 prior to examination
After 1 week cells were fed by removing 100 yl of media, and 
adding m  fresh HAT media Subsequently cells were fed, when 
necessary, in HT media (HAT media without the aminopterin) until 
they were expanded After expansion they were grown m  supplement 
free media When the cells were almost confluent in the wells, 
the supernatants were harvested, screened by ELISA, and the cells 
m  the positive wells were expanded into 24 well plates Cells 
that grew m  24 well plates were rescreened, and the positives 
were expanded into a 6 well plate, or into additional 24 well 
plates These were then transfered into flasks, and then were 
subsequently frozen down in liquid nitrogen Some of the 
hybndomas were then selected for cloning, and characterisation
II 7 2 FEEDER LAYERS
Schofield mice were killed by cervical dislocation, and their 
bodies were soaked m  alcohol All procedures were then 
performed asceptically The fur was removed from the abdomen, and
10 ml of media (HAT media was used if the feeder layer was for a 
fusion rather than for cloning) were injected intraperitoneally 
The macrophage-rich media was then drawn out with a syringe and 
was allowed to stand for a few minutes so that any contaminating 
faecal matter could be seen, indicating puncture of the intestine 
The cells were then counted, resuspended to a concentration of 
1 5 105 cells per ml, and 100 pi were plated into each well of a 
96 well plate These were incubated overnight at 37°C, and 5% CO^, 
and checked for contamination before use Since some mice produce 
more macrophages than others, cells from more than one mouse were 
pooled Macrophage supernatant was also used as a feeder Human 
endothelial cell supernatant (HECS) was also very effective as a 
feeder layer (Astaldi, 1980) It can be prepared from culture of 
endothelial cell from a human umbilical cord, or can be obtained 
from Costar
11 7 3 CLONING CELLS BY LIMITING DILUTION
Cells were washed down, centrifuged at 2,000 rpm for 10mm, 
resuspended in HAM media (Ham's F12, containing LG, PS, F and 10% 
FCS) and counted For the first cloning they were plated out at a 
concentration of 1, 5, and 10 cells per well For the second 
cloning they were plated out at 0 5, and 1 cell per well A
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feeder layer m  media was also used The cells were plated out 
into two 96 well plates Supernatants from wells containing 
growing cells were then screened by ELISA In the first cloning 
cells from positive wells with the fewest clones (checked by eye) 
were expanded, and aliquots were frozen down A number of clones 
were also cloned a second time During the second cloning 
positive wells with only one clone per well (checked by microscope 
at an early stage) were expanded Aliquots of these were frozen 
down, and were also grown as ascitic tumours
II 7 4 FREEZING AND THAWING CELLS
Cells from confluent flasks (or 24 well plates) were washed down, 
and pelleted at 2,000 rpm for 10 m m  All supernatant was 
removed, and the pellet was resuspended m  1 ml of FCS containing 
5-10% (v/v) Dimethylsulphoxide (DMSO), or m  0 5 ml media to which 
0 5 ml FCS containing 10%(v/v) DMSO was added Cells were then 
added to sterile freezing vials, lowered slowly (1 5-2 hrs) into 
the vapour phase of liquid nitrogen, and eventually immersed m
it When thawing, cells were rapidly thawed at 37°C, added to 10
ml of cold media and centrifuged for 10 m m  at 2,000 rpm The 
pellet was then resuspended m  media, and grown m  a flask (or 24 
well plate) at 37°C in 5% CO2
II 7 5 CELL COUNTS AND VIABILITY TESTING
A cell suspension was added to an equal volume of acridme orange 
ethidium bromide (0 lmg/lOOml of each in PBS), and an aliquot 
was counted in a haemocytometer (Neubauer) Viable cells stained 
green under UV, while the dead cells stained orange
II 7 6 MYCOPLASMA SCREENING
A vial of Normal rat kidney (NRK) cells (Duc-Nguyen et al , 1966)
was thawed out, and grown m  antibiotic free media at 37°C, in 5%
CO2 for at least 3 passages The media was poured off, and 5ml of
t r y p s m  2 5% (w/v) m  Hank's Balanced Salt solution, was added 
for 5 m m  at 37°C Cells were pelleted at 2,000 rpm for 10 m m ,  
and resuspended at 1 10^ cells per ml of antibiotic free media 1 
ml of cells was added to a sterile coverslip in a sterile 35x10mm 
p e t n  dish (Lux), and incubated overnight at 37°C in 5% CO^ 1-2 
ml of supernatant from the cells to be tested were then added to 
the p e t n  dishes, and incubated for 3 days at 37°C in 5% CO2
\
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The coverslips were then removed from the petri dishes, and 
washed 3 times in PBS They were then fixed for 6 m m  in a 1 1  
mixture of methanol, and acetone at -20°C The cells were then 
washed twice in PBS, and stained in Hoechst 33528 (0 05 Mg/ml m
balanced salt solution) for 10 m m  The coverslips were then 
washed twice in PBS, dried, and mounted on slides The cells were 
examined under UV light with a lOOx oil immersion lens (Nikon 
optiphot microscope fitted with a B2 combination filter) 
Uncontammated cells had a strong fluorescence m  the nucleus 
only, while the contaminated cells also had specks of fluoresc­
ence throughout the cytoplasm
II 7 7 CONTAMINATION
All types of contamination occured during the fusions Bacterial 
contamination was probably due to operator error The use of 
antibiotics such as penicillin and streptomycin helped control it, 
but there were often resistant strains of bacteria, and their use 
can often encourage mycoplasma contamination Thus, the use of 
antibiotics was restricted to prevention of contamination m  
fusion plates Bacteria could be detected by cloudy media with a 
low pH (le yellow), and could usually be confirmed by observation 
with a microscope When it occured m  flasks they were disposed 
of When it occured in 96 or 24 well plates the contaminating 
well was drained, and cleaned with alcohol This was usually 
sufficient to prevent spread to other wells Yeast contamination, 
which only occured on a few occasions, was treated similarly
Fungal contamination was very difficult to prevent due to the 
resilient nature of the spores Fungizone (amphotericin B) was 
used to control it, but this was not very effective, especially 
m  the summer months When it occured m  flasks they were 
disposed of When it occured m  plates, uncontammated wells 
could sometimes be transfered to an other plate, without spread of 
the contamination With all types of contamination, the 
incubator was scrubbed with alcohol before reuse >
Mycoplasma contamination was a major problem They are very small 
(0 1-0 25 pm), and are very difficult to detect by direct light 
microscopy or to remove by filtration The parent myeloma often 
grew well in the presence of mycoplasma, but the hybridomas grew 
poorly, and could not be expanded The inability to expand
22
clones is often an indication of mycoplasma contamination. Cells 
were screened for mycoplasma prior to a fusion. When mycoplasma 
contamination occured all cells, media, and reagents were 
disposed of, and the laminar flows were decontaminated with 
formaldehyde. Cells could be salvaged by growing them as ascitic 
tumours, but only if there was sufficient cells (ie a confluent 
flask)(Carroll and O'Kennedy, 1988). Sp2's were cultured in 
antibiotic free media. Tylocine (Gibco), an anti-mycoplasma drug, 
proved ineffective in treatment, or prevention of mycoplasma 
infection.
11.7.8 GROWTH OF CLONES AS ASCITIC TUMOURS
Mice were injected with 0.5 ml of pristane (Aldrich). Ten days 
later confluent cells from a flask were injected ip. When the mice 
developed a swollen abdomen they were killed, 5 ml of saline was 
injected into the abdomen, and the ascitic fluid was removed by 
syringe. The ascitic fluid was centrifuged at 2,000 rpm for 10 
min. The pellet, which contained the hybridoma cells, was 
resuspended in saline, and injected into other mice, or else it 
was frozen in liquid nitrogen. The supernatant was stored at -20 
°C until it was processed further (see II.6.3). The time taken for 
ascitic fluid to develop depended on the number of cells injected, 
the batch of pristane, the individual mice used, and also, on the 
stability of the cell line used. On a second passage in mice, 
pristane was usually not necessary, as the cells were conditioned 
to growth in mice. However, the use of pristane on the second 
passage usually accelerated the growth of the ascites.
For growth of the ascitic tumour compatible mice had to be used, 
ie a mouse of the same strain as the parent myeloma, to prevent 
immunological rejection on the tumour. For most hybridomas this 
meant using Balb/c mice. The disadvantage of this is that they 
are very small, and thus, only a small amount of ascites is 
produced. This problem was overcome by using the FI generation of 
a Balb/C-Schofield cross. These mice are much bigger, and 
produced much more ascitic fluid.
11.7.9 CQUMARIN STUDIES
Cells were cultured in flasks, or grown as ascitic tumours in
Schofield mice. The cells were then harvested, and diluted to 
the required concentration in media. These were then added to the 
wells of 24 well plates, 6 well plates, or 25 cm^ flasks.
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5mM stock solutions of coumarm, and 7-OHC were prepared m  PBS 
(Dulbecco's A) The 7-OHC was autoclaved into solution, and the 
coumarin was dissolved m  ethanol, and added to sterile PBS 
(final ethanol concentration was l%(v/v)) Control solutions 
(diluents) were PBS, and PBS containing 1% ethanol The 
incubation volumes used were 1 5 ml for the 24 well plates, 5 ml 
for the 6 well plates, and 10 ml for the flasks
The 2 cell types used were SP2 myeloma and Landschutz tumour cells 
(LATC) The cells were usually grown in the presence of drug for 
9 days , or until the control wells were confluent Each assay 
was performed in triplicate when 24 well plates were used, and in 
duplicate when 6 well plates or flasks were used Duplicate 
samples from each assay well were examined by fluoresence 
microscopy (II 7 5) and cell counts and viabilities determined
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I I  8 SCREENING OF FUSIONS
II 8 1 ELISA
Screening of hybridomas for antibody production was performed by 
Enzyme Linked Immunosorbent Assay (ELISA) 96 well microtitre 
plates were coated with 100 pi of either 50 mM Tns-HCl, pH 7 4, 
containing 150 mM NaCl, and 40 IU FVIII per litre, or 100 pi of 
coating buffer containing 1-10 mg of protein per litre, and 
Incubated at 37°C for two hours The plates were then washed once 
with PBS-Tween, and then 150 Pi of PBS-BSA, containing 50%(v/v) 
glycerol, was added The plates were sealed, and stored at 4°C 
until required If plates were required for immediate use, they 
were blocked with PBS-BSA for 30 m m  at 37°C
Antigen coated plates were washed 3 times m  PBS-Tween before use 
and 50 pi of PBS-BSA was added to each well 50 Pi of supernatant 
for analysis, and controls (media for the negative control and 
serum from the immunised mouse for the positive control) were 
added to the wells, and incubated overnight at room temperature 
The following day the plates were washed three times with 
PBS-Tween 100 pi of sheep anti-mouse Ig, (3 -galactosidase-lmked 
F(ab')2 fragment (obtained from Amersham and diluted m  PBS, 
containing lOmM MgCl2, and ImM EtSH) was added Incubation for 
1-2 hrs at 37°C followed The plates were then washed 3 times 
with PBS-Tween, 100 pi of substrate (PBS, containing 3 mM 0NPG, 
10 mM MgCl2, and 0 1 M EtSH) was added and the plates incubated 
at 37°C for 1-2 hrs The reaction was stopped by the addition of 
35 pi of 1 M sodium carbonate The absorbances were measured on 
an ELISA plate reader (Bio-Tek, model EL 307) at 405 nm Each 
well from the fusion plate was assayed m  duplicate
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I I  9 CHARACTERISATION OF ANTIBODIES
The characterisation of monoclonal antibodies consisted of three 
stages The first was to determine the isotype of the antibody, 
usually by ELISA The second stage was to determine the specific 
antigen, and if possible the epitope on the antigen to which the 
antibody binds This was determined by electrophoresis, electro- 
blotting, and ELISA The third stage was to determine the pro­
perties of the antibodies These were studied by the effects of 
the antibody on the function of the antigen eg m  a coagulation 
assay for FVIII
II 9 1 ANTIBODY ISOTYPING
Antibodies were typed using a commercial isotyping kit (Zymed 
Laboratories) This contained a series of rabbit anti-mouse 
immunoglobins, each specific for a different isotype The second 
antibody was peroxidase-conjugated goat anti-rabbit antiserum
Antigen-coated plates (see II 8 1) were washed 3 times with 
PBS-Tween, and 100p 1 of purified ascitic fluid (see II 6 3), 
which had been suitably diluted m  PBS-Tween, were added to each 
well The plates were incubated for 2 hrs at 37°C The plates 
were washed 3 times m  PBS-Tween and 1 drop from a bottle of 
rabbit anti-isotype was added to the appropriate wells The 
plates were incubated at 37°C for 1 hr Sufficient wells were 
used to allow each isotype to be assayed m  duplicate The plates 
were then washed 3 times m  PBS-Tween, and 100 jil of enzyme- 
conjugated antibody (diluted m  PBS-Tween) was added The plates 
were incubated at 37°C for 1 hr, washed 3 times m  PBS-Tween, and 
100 p i  of substrate (perox buffer containing 40 mg OPD and 20 PI 
.H2O2 per 100 ml) was added The plates were incubated at room 
temperature for 15 min, and the reaction was stopped with 35 P 1 
of 20%(v/v) sulphuric acid The absorbances were read on an ELISA 
plate reader (Biotek model EL307) at 490nm
II 9 2 FUNCTIONAL TESTS
To test the effect of the antibody on the function of the antigen, 
change m  coagulation time was measured
0 1 ml of purified ascitic fluid was incubated with 0 1 ml of a 
100% normal plasma solution, and left for 3 hr at 37°C The APTT
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assay was then carried out as described m  II 2, and the effects 
of the antibody on coagulation time determined Alternatively,
0 1 ml of a 1/100 dilution of antibody was added to 0 4 ml normal 
plasma, and incubated for 4 hr at 37°C This was then diluted to 
give a reading in the APTT assay
II 9 3 COMPETITIVE ELISA
The polyclonal antibodies to the diazepam conjugate were 
characterised by a competitive ELISA This measured the ability 
of different benzodiazepines to inhibit the binding of the 
antibody to conjugate coated on a 96 well plate
The benzodiazepines were dissolved m  DMSO (5 mg/ml) and then 
diluted m  PBS-Tween 25 ML of benzodiazepine and 75 ^1 of anti­
body were added to each well of a 96 well plate coated with 
conjugate The final concentrations of the benzodiazepines were 
300, 30, and 3 jjg/ml and that of the antibody was 100 Pg/ml The
control well contained antibody and DMSO diluted to give the same 
concentrations as in the test wells Conjugate was also used as a 
control, and BSA was used as a test sample The conjugate and BSA 
were diluted in PBS-Tween Samples were incubated for 2 hr at 37 
°C and washed The effects of the benzodiazepines on binding of 
the antibody were assessed using the &-galactosidase ELISA assay 
(see II 8 1)
t
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II 10 ELECTROPHORETIC TECHNIQUES
II 10 1 AGAROSE ELECTROPHORESIS
A 1% (w/v) agarose gel was prepared in barbitone buffer (see
II 2 4) and boiled to dissolve it The molten agarose was then 
poured onto a glass plate (84x94 mm) and allowed to set An LKB 
sample application foil was laid across the gel and 2-4 PI samples 
were applied to the gel Samples were diluted m  barbitone buffer, 
containing 0 05% (w/v) bromophenol blue The gels were placed on 
the cooling plate of an LKB raultiphor flatbed electrophoresis 
apparatus (2117) The gel was connected to the buffer troughs 
containing barbitone buffer, by paper wicks The gels were run at 
20 V/cm until the bromophenol blue band had reached the end
After electrophoresis gels were fixed and stained in Coomassie 
blue The gels were rinsed m  distilled water prior to destam- 
m g
II 10 2 CROSSED IMMUNOELECTROPHORESIS
This was similar to the Laurell electrophoresis, except that the 
sample was electrophoresed in a horizontal direction prior to 
electrophoresis into the antibody containing gel m  a vertical 
direction
A 1% (w/v) agarose gel containing 50 P 1 of anti-human serum
antibody (Miles) was poured (see II 2 4) After this set 
two-thirds of the gel was cut away, and an agarose gel containing 
anti-FVIIIR was poured m  its place (see II 2 4) Half of this 
section of the gel was removed, after it had set
A sample of FVIII was run m  an agarose gel (see II 10 1) This 
electrophoresis strip was then cut out and placed across the 
antibody containing gel, m  the region cut out This gel was laid 
in a horizontal manner, and all the gaps were filled with molten 
agarose The sample was then electrophoresed into the gel, and 
the gel was fixed and then stained (see II 2 4)
II 10 3 POLYACRYLAMIDE GEL ELECTROPHORESIS (PAGE)
Stock solutions of 0 75 M T n s , pH 8 8, 0 25 M T n s ,  pH 6 8, 30% 
(w/v) acrylamide - 0 8% (w/v) bisacrylamide, 1% (w/v) ammonium
persulphate, and 10% (w/v) sodium dodecyl sulphate (SDS) were
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prepared
For the resolving gels the stock solutions were mixed with 
distilled water to give a gel concentration of 10%T ( T= total 
acrylamide concentration m  w/v), or 7 5%T, m  0 375 M T n s ,  pH 
8 8, containing 0 1% SDS The stacking gels were 4%T, m  0 125 M 
T n s ,  pH 6 8, containing 0 1% (w/v) SDS
Samples were dissolved m  10 mM T n s ,  pH 6 8, containing 8 M urea, 
2% (w/v) SDS, and 0 001% (w/v) bromophenol blue Samples were then 
incubated at 37°C for 30 m m ,  or boiled for 2 m m  with 50 pi 
EtSH/ml buffer The gels were then run in 0 025 M T n s  - 0 192 M 
glycme, pH 8 3, at 100 mA using the Bio Rad vertical 
electrophoresis system Gels were then stained or blotted
II 10 4 WESTERN BLOTTING
Gels were soaked in 25 mM T n s  - 192 mM glycme, pH 8 3 (blotting
buffer) for 1 hr Nitrocellulose paper (0 45 m, Schleicher and
Schuell) was then placed on the gel, and clamped m  the cassette
This was then blotted m  the Bio Rad Transblot apparatus overnight *
at 100 mA This was followed by 1 hr at 200 mA
The blots were then blocked m  PBS-BSA, containing 0 1% (w/v)
Tween, for 1 hr The monoclonal antibody was then diluted m  
blocking buffer, and incubated with the nitrocellulose for 1 hr 
at 37°C The blots were washed m  PBS-Tween for 1 hr Alkaline 
phosphatase-conjugated sheep anti-mouse IgG, was then added at a 
1/1000 dilution m  blocking buffer, and left for 1 hr at 37°C The 
blots were washed for 1 hr m  PBS-Tween and were incubated m  10 
mM T ns, pH 8 9 After 10 m m  substrate was added (0 5 M T ns, pH 
8 9, containing 4 mM MgC^, 0 12 mM nitro blue tetrazolium, 0 46 
mM 5-Bromo-4-chloro-3-mdolyl phosphate p-toluidme salt, and 
4%(v/v) N,N-Dimethylformahide) The blots were then washed m  
water and dried on tissue paper
II 10 5 DOT BLOTTING
This involved the direct application of protein to the 
nitrocellulose paper, rather than electroblottmg it from a gel
Samples were diluted m  PBS, and 2-5 ML were applied to 
nitrocellulose paper that had been soaked m  PBS and dried The 
samples were allowed to dry and the nitrocellulose was blocked,
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probed, and stained, as m  Western blotting (see II 10 2)
II 10 6 GEL STAINING
Two different stains were used for polyacrylamide gels
(a) Coomassie blue Gels were soaked m  0 5% Coomassie brilliant 
blue R250 in d e s t a m m g  solution for 1 hr They were then washed 
in d e s t a m m g  solution (45% (v/v) ethanol and 10% (v/v) glacial 
acetic acid) until the background was clear
(b) Silver staining For gels with low protein concentration a 
silver stain, based on the Bio Rad method was used Ultrapure 
water was used for all stages of the silver s t a m  Gels were 
soaked overnight m  40% (v/v) methanol and 10% (v/v) acetic acid 
Gels were then incubated m  oxidising solution (0 1% (w/v) 
potassium dichromate, containing 28 6 jjI concentrated nitric acid 
per 100 ml) for 10-15 m m  The gels were then washed for at least 
90 m m  in water After washing the gels were incubated m  0 2% 
(w/v) silver nitrate for 1 hr followed by washing for 2-3 m m  with 
water The gels were then soaked m  3 changes of developer (0 3 M 
sodium carbonate, containing 50 Ml formalm/100 ml) Development 
was stopped by pouring off the developer and adding stopping 
solution (5% (v/v) glacial acetic acid)
While silver staining is useful for detecting low levels of 
protein, certain proteins give a negative image, ie a clear band, 
with the silver s t a m  (Merril, 1984) In particular fibrinogen 
and its fragments give a clear band with silver staining These 
can only be visualised if the gel is allowed to over stam, giving 
a dark background
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II 11 AFFINITY CHROMATOGRAPHY
Monoclonal antibodies were coupled to CNBr-activated Sepharose, 
and were then used to isolate the antigen in a pure form The 
antigen could then be identified by electrophoresis, or relevant 
assay
II 11 1 COUPLING PROCEDURE
Purified antibody was dialysed against coupling buffer (0 1M 
NaHC03, pH 8 3, containing 0 5 M NaCl) and its volume was made
up to 5 ml/g gel CNBr-activated Sepharose was suspended m  1 mM
HC1 for 15 m m  The gel was then washed with 200 ml of 1 mM HC1
m  a scintered glass funnel, and dried by suction The gel was
then washed with with 100 ml of coupling buffer
The gel was suspended m  the antibody solution and mixed at room 
temperature for 1-2 hr The gel was dried by suction and the 
absorbance (280 nm) of the solution was checked to ensure that all 
the protein had bound The gel was washed in 100 ml of coupling 
buffer, and dried by suction and incubated m  0 1 M Tns-HCl, pH 
8 0, for 1 hr to block any remaining unreacted sites on the 
activated sepharose The gel was then washed in low pH buffer 
(0 1 M sodium acetate, pH 4 0, containing 0 5 M NaCl) followed by 
high pH buffer (0 1 M Tns-HCl, pH 8 0, containing 0 5 M NaCl) 3 
times The repeated changes m  pH are responsible for the elution 
of protein that is not strongly bound to the gel The coupled gel 
was stored at 4°C m  0 025 M Tris, pH 7 3, containing 0 15 M NaCl, 
and 0 02% (w/v) sodium azide
The concentration, m  mg/ml, of the purified antibody solution 
was calculated by multiplying the measured absorbance of the 
solution at 280 nm by 0 74 (Hudson and Hay, 1980) The antibody 
was diluted to 5 mg/ml gel 1 g dry gel swells to 3 5 ml
II 11 2 ELUTION FROM THE GEL
The antibody-coupled gel was suspended m  PBS, and poured into a 
10 ml syringe The sample was applied to the column m  the 
reverse direction and left for 15 m m  The column was then washed 
m  the forward direction with PBS until the eluted buffer showed 
no traces of protein The sample was then eluted from the column 
with elution buffer (0 2 M glycme-HCl, pH 2 5) by gravity flow,
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and 1 ml fractions were collected The pH of the fractions were 
raised to pH 7-8 with a Tns solution The remainder of the 
protein was eluted with elution buffer containing 10%(v/v)
dioxane Again the pH of the fractions were raised The fractions
containing protein were pooled, and dialysed against PBS
During the elution the presence of protein was detected using a 
micro Bradford assay The Bradford reagent (Bio Rad) was diluted 
1 4 with distilled water, and 200 pi was added into the wells of a 
96 well microtitre plate 10 pi of the eluted buffer was added to 
each well, and incubated for 5-60 m m  at room temperature A 
blue colour indicated the presence of protein
A second procedure was also used for FVIII, based on the method of 
Fass et al , (1982) Koate containing 0 25 M CaCl2 was applied to 
the antibody-linked column When all the unbound protein was 
eluted the column was washed with 1 column volume of 2 M NaCl 
This was followed by a wash with 1 column volume of histidine
buffer (10 mM histidine, 5 mM CaCl2, 1 mM PMSF, and 0 1 M NaCl,
pH 6 0) The protein bound to the antibodies was eluted with a 
1 1 mix of histidine buffer and ethylene glycol The eluted 
protein was pooled and dialysed against PBS overnight
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I I  12 CLINICAL STUDIES
II 12 1 PATIENT SELECTION
A sequential trial was established to test the clinical 
effectiveness of coumann The patients were divided into 3 broad 
groups, based on diagnosis chronic brucellosis (50%), cancer, 
mainly breast carcinoma and melanoma (30%), and the remainder had 
either chronic infections (including toxoplasmosis, mycoplasmosis 
and mononucleosis), or chronic fatigue syndrome, also known as 
myalgic myeloencephalopathy (ME) When the results from the trial 
were assessed, the number of patients had reached 2,137 Patients 
treated m  this study had given their informed consent and were 
treated at St Laurences Hospital, Dublin, now Beaumont Hospital, 
Dublin, The Missionary Hospital, Drogheda, and The James 
Connolly Memorial Hospital, Blanchardstown, Dublin
II 12 2 CLINICAL EVALUATION OF PATIENTS
All patients had regular medical examinations, with full blood 
counts (FBC) and liver function tests (LFTs) every 3 months This 
included determination of serum bilirubin (both total and direct), 
serum transaminases, both Alanine Aminotransferase (ALT/GPT) and 
Aspartate Aminotransferase (AST/GOT) and serum alkaline phosphat­
ase (AP) These tests were performed m  the hospital that the 
patient regularly attended
II 12 3 DOSE REGIMENS
The dose of coumann administered to each patient was adjusted to 
give the maximum clinical response, measured m  terms of an 
improvement m  the patients condition Doses ranged from 25mg/day 
for chronic infections, to 2 g/day for advanced renal cell 
carcinoma and glioma The majority of patients received 100 
mg/day for 1 month, followed by 50 mg/day for 2 years The 
coumann used m  the trial was donated by Schaper and Brummer (W 
Germany)
II 12 4 EVALUATION OF HEPATOTOXICITY
The role of coumann m  a case of hepatitis was assessed with a 
scheme used by Strieker and Spoelstra (1985) They used 3 
criteria viz the specificity of the clinicopathological (CP) 
pattern, the presence of a temporal relationship, and the ex­
clusion of other possible causes (see V 1 5)
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(l) The CP pattern is defined as the clinical, histological and 
biochemical data, along with any other data which may help to 
define the toxicity A highly specific CP pattern is one that is 
sufficiently unique, to enable it to be differentiated from other 
causes of hepatitis Examples of this are alcoholic cirrhosis, 
deposits of certain agents at the site of injury, toxic levels of 
the agent m  the blood, etc A specific CP is one that is 
frequently caused by drugs Its presence does not prove that it 
was caused by a drug, but it is a strong indicator of drug 
toxicity Examples of this are persistent rash, with hepatitis, 
or persistent fever, with hepatitis Both these could be caused 
by viruses, but if they persist after the appearance of the 
jaundice, they are more likely to be due to a drug reaction
(11) A temporal relationship implies that the hepatitis appears 
within 6 weeks of starting treatment with the suspect agent 
Certain drugs need up to several months before hepatitis appears 
The LFTs should return to normal promptly, after stopping the 
drug There should be a prompt recurrence of hepatitis, on 
retreatment
(111) Other possible causes, eg cancer and viral infections should 
be excluded
The model used by Strieker and Spoelstra (1985), uses different 
levels (A-G) to assess the role of a drug m  hepatitis
LEVEL A The presence of a highly specific CP pattern This 
indicates a definite case of hepatotoxicity 
LEVEL B The patient is rechallenged with the suspect drug 
A strong temporal relationship indicates a definite 
case of hepatotoxicity, and the absence of a 
temporal relationship indicates an unlikely/
possible relationship The absence of a clear 
temporal relationship suggests a possible/probable 
cause In level C-G there is no rechallenge of the 
patient
LEVEL C Mainly cholestatic, acute hepatic injury 
LEVEL D Mainly hepatocellular, acute hepatic injury 
LEVEL E Chronic intrahepatic cholestasis 
LEVEL F Vascular disorders
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LEVEL G Liver tumours
In level C and D the presence of any 2 of the 3 criteria indicates 
a probable cause (eg specific CP pattern and a clear temporal 
relationship) The presence of only 1 of the criteria indicates a 
possible cause
SECTION I I I
MONOCLONAL ANTIBODIES TO BLOOD 
COAGULATION FACTORS
IIII 1 1 BLOOD COAGULATION
Blood is the major transport system m  the body It is
responsible for the „ transportation of nutrients, and hormones to 
the cells, and the transport of waste away from the cells It
also serves to transport cellular components, le the erythrocytes 
which carry oxygen, leucocytes which fight infection, and 
platelets Any malfunction of this transport system can have very 
serious consequences A loss of blood, such as haemorrhage due 
to trauma, causes hypotension, which can eventually lead to
shock This hypotension leads to reduced perfusion of many 
organs, which can result in damage to sensitive tissue, and 
ultimately to fatal brain damage A blockage in the blood supply 
to a specific area, such as that due to a thrombus (a clot), or 
an embolism (a fragment of a thrombus), leads to ischaemia In 
the extremities this leads to necrosis, and even gangrene In the 
brain it leads to a stroke, the severity of which depends on the
location of the ischaemia In the heart the result is ischaemic
heart disease, which can lead to myocardial infarction
Due to the importance of maintaining adequate perfusion of all 
tissue, there are 3 mechanisms for regulating blood flow The 
first is the heart/nervous system This pumps the blood and 
regulates the pressure The second is the coagulation/haemostatic 
system which prevents blood loss from the system The third is 
the fibrinolytic system which removes any unwanted clots from the 
system
The coagulation system is found in the plasma It consists of a
number of proteins arranged in a cascade system which convert 
fibrinogen to fibrin, allowing it to polymerise, forming a clot 
These proteins are numbered with Roman numerals, which denote 
their order of discovery, and not their sequence m  the cascade
(Wright, 1962) There is no number VI Certain factors are 
usually refered to by their name eg fibnn(ogen) (FI), (pro)- 
Thrombin (FII), tissue thromboplastin (Fill), and calcium (FIV) 
The letter "a" after a number indicates an activated form of the 
protein
I I I  1 INTRODUCTION
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The coagulation system can be divided into 3 stages There are 2 
mitiation/amplification stages, followed by an activation/ coag­
ulation stage The latter involves the conversion of prothrombin 
to thrombin by FXa, in the presence of FVa, calcium, and
Platelet factor 3 (PF3) Thrombin then converts fibrinogen into 
fibrin which results in clot formation (see fig III 1 and below) 
These 3 stages form the cascade system (Macfarlane, 1964)
There are 2 initiation pathways The first is the extrinsic
system (Zur and Nemerson, 1981) Damaged tissue releases tissue
thromboplastin which m  the presence of FVII, and calcium,
activates FX The role of the extrinsic system m  coagulation is
uncertain, but it is thought that its activation produces small
amounts of thrombin rapidly This thrombin then activates FV,
and FVIII which are essential for the fuctioning of the intrinsic
system Kallikrem, which is produced at the early stages of the
intrinsic system, also activates FVII In this role the small
amounts of thrombin produced act to accelerate the intrinsic
system Unlike the intrinsic system PF3 is not required for
*activation of the extrinsic system This is because Fill has
phospholipids associated with it (see Fig III 2)
The second initiation system is the intrinsic system (Griffin, 
1981) This is activated by a 'foreign surface1 eg collagen, 
sebum, glass, and low pH This activates a small amount of 
Hageman factor (FXIIa) This converts prekallikrem (Fletcher 
factor) to kallikrem, which in turn convers FXII to FXII frag­
ments (FXIIf) FXIIf activates prekallikrem, and plasminogen 
proactivators Both FXIIa, and FXIIf activate FXI in the 
presence of Fitzgerald factor (high molecular weight kmmogen, a 
precursor of bradykmin) FXIa converts Christmas factor to FIXa 
FIXa activates FX in the presence of FVIIIa, PF3, and calcium 
(see Fig III 3) While m  vitro both the intrinsic, and 
extrinsic coagulation pathways are separate, m  vivo there is 
probably no distinction between the two
The heart of the coagulation system is the activation of thrombin 
Not only does thrombin convert fibrinogen to fibrm, it also 
activates FV and FVIII which are essential for clot formation 
FXIII, which is responsible for cross linking fibrm clots, is 
also activated by thrombin The complicated cascade system serves
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2 mam functions Firstly, there are a number of different control 
points which allows fine control of the system Secondly, the 
large number of steps enables the signal to be amplified In the 
intrinsic system there are 6 steps to the activation of FX If 
there is a 10 fold increase m  signal at each step, there will be 
a 1 million fold increase overall
The mechanism which controls blood loss (haemostasis) requires 3 
components viz, the coagulation system, platelets, and vascular 
smooth muscle If there is a small hole m  a vessel wall, 
platelets easily lodge m  it Clot formation then occurs which 
plugs the hole With larger holes, platelets adhere to the 
collagen at the edge of the wound von Willebrands Factor is 
necessary for this These platelets secrete factors that initiate 
platelet aggregation (ADP), as well as factors which cause a 
localised vasoconstriction, thereby reducing blood flow Platelet 
aggregation (involving vWF) is then followed by coagulation, which 
plugs the hole Factors released from platelets are essential for 
coagulation, eg PF3, FV, and PF4 (heparm neutralising factor) 
Thrombosthenm, released by the platelets, causes retraction of 
the fibrin strands This draws the edges of the wound together, 
and^ also increases the mechanical strength, of the clot 
Haemostasis is measured by the bleeding time In some disorders
the coagulation time can be normal, and yet the bleeding time is
prolonged (Williams et al , 1977)
Not only does FXIIa activate the intrinsic coagulation system, it 
also activates plasminogen activators in the plasma These then 
activate the fibrinolytic system by converting plasminogen to 
plasmm Plasmm breaks down both fibrinogen, and fibrm (see 
below), and thus removes unwanted clots(see Fig III 4) During 
clot formation, plasminogen becomes incorporated into the 
thrombus When plasminogen activators diffuse into the clot they 
convert the plasminogen to plasmm, which then proceeds to 
hydrolyse the thrombus Both coagulation, and fibrinolysis are 
subject to control by inhibitors of their respective systems
(Williams et al , 1977)
III 1 2 FIBRIN(OGEN) STRUCTURE
Fibrinogen is a globular protein with a molecular weight of
340,000 It is converted to its active form (fibrin) by the 
action of thrombin The ammo acid sequence for fibrinogen has
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been determined, as has its structure The structure, and 
function of fibnn(ogen) is reviewed by Doolittle (1981a, 1981b)
Fibrinogen consists of 3 different polypeptide chains The alpha 
(Aa) chain has 610 amino acids and a Mr of 67,000 The beta (B&) 
chain has 461 amino acids and a Mr of 56,000 The gamma (Y) chain 
has 411 ammo acids and a Mr of 47,000 (Doolittle, 1981b) 
Fibrinogen consists of 2 of each of these chains and thus , it is 
^a2^2^2 s^ee ^  Electron microscopy studies showed a
trmodular structure for fibrinogen (Hall and Slay ter, 1959) 
The dimensions of the nodules were calculated to be 500 nm for the 
central globule, 650 nm for the terminal globules, and 150 nm 
(thickness) for the connecting arms (see Fig III 6) The length 
of the complete molecule was calculated to be 4,750 nm There are 
29 disulphide bonds in the molecule
One Aa, B$, and Y chain are held together by 2 rings of disulphide 
bonds which are m  the N terminal region This is known as the N 
terminal DiSulphide Knot (NDSK) (Blomback et al , 1968) In the
NDSK region each chain has the following sequence cys-X-Y-Z-cys 
The first cys from the A chain is bound to the last cys m  theY 
chain The second cys in the AOt chain is bound to the first cys 
in the B3 chain, and the last cys m  the Bg chain is bound to the
first cys m  the y chain - this is the disulphide ring (see Fig
III 7) The first cys m  the Act chain is ammo acid 45, while in
the B B chain it is 76 and m  the y chain it is 19 The second 
disulphide ring occurs at cys 161 (Achain), 193 (bB chain), and 
135 (Y chain) The region between the 2 disulphide rings is 
coiled in an alpha helical structure
The C terminal region of the B B chain and the Y chains are each 
folded into separate globules The Aa chain is hydrophobic and 
remains in an uncoiled form These form the terminal globules 
(Doolittle, 1981a) Fibrinogen is a dimer, with the N terminal 
regions of the 3 chain monomer joined together by 3 disulphide 
bonds One of disulphide bonds joins the A& chains, and other 
two join the Y chains There are 2 different carbohydrate chains 
on each of the monomers (Gaffney, 1972) These 2 chains account 
for approximately 10,000 daltons (see Fig III 8)
III 1 3 FIBRIN(OGEN) FUNCTION-CLOT FORMATION
The function of fibrinogen is m  the formation of clots The first
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step is the conversion of fibrinigen to its active form - fibrin 
This is then followed by the polymerisation of the fibrin monomers 
into a clot, which is then stabilised
The enzyme responsible for activating the fibrinogen is thrombin 
This is a protease which cleaves off the terminal region of the 
and Bg chains These are called f ibnnopeptides A and B 
Fibnnopeptide A is 16- amino acids long, while fibnnopeptide B 
is 14 ammo acids long The resulting molecule is the fibrm 
monomer and is (Laurent anc* Blomback, 1958)
Fibrinogen has an overall charge of minus 26 The central globule 
has a charge of minus 8, while the terminal globules have a charge 
of minus 4 The connecting chains are neutral When the 
fibnnopeptides are removed the central globule loses its negative 
charges and becomes plus 5 (Doolittle, 1981a)
During activation by thrombm, the two f ibnnopeptides are 
released at different rates, with fibnnopeptide A being released 
before B The regions exposed by the f ibnnopeptides are 
responsible for the polymerisation of fibrinogen (Ferry, 1952, 
Laurent and Blomback, 1958) and The Aa chain region exposed by 
removal of fibnnopeptide A is attracted to a portion of the y  
chain carboxyl region by an electrostatic interaction This is 
then elongated to form a long polymer which is 2 molecules thick 
The region of the B chain exposed by removal of fibnnopeptides B 
is probably involved m  lateral polymerisation of the fibrm 
chains At this stage the clot is very fragile, as it is only 
held together by electrostatic bonds The polymer is strengthened 
by the action of factor XIII (FXIII), which is activated by 
thrombm This forms covalent bonds between suitably sited 
lysines and glutamines (Pisano et al , 1971) The initial cross 
linking occurs at the carboxy terminal region of the Y chains 
The Y chains lie m  an antiparallel manner and there are 2 cross 
links, 8 ammo acids apart (Chen and Doolittle, 1970) Cross 
linking also occurs between the Aa chains, but at a much slower 
rate (McKee et al , 1970) While the y cross linking only links 2 
fibrm monomers, each Aa chain is linked to at least 2 different 
AOt chains The glutamines involved m  the A^ chain cross linking 
are 38 ammo acids apart m  the middle of the Aa chain, while the 
lysmes are near the carboxy terminal The resulting cross-linked 
polymer is mechanically stronger and is resistant to enzymatic
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d i g e s t i o n
III 1 4 FIBRIN(OGEN) FUNCTION - CLOT LYSIS
Unwanted clots are digested by an enzyme called plasmin, which is 
the active form of plasminogen This acts on fibrin and 
fibrinogen at the same rate Plasmin succeeds in breaking the 
stabilised fibrin clots by attacking their weak point This is 
the alpha helical connectors between the globules At this point 
the clot is only 3 chains thick (le the Act, B$, and y chain) 
After breaking a few of these bonds the clot is split into a 
number of intermediate fragments, allowing the clot to be 
solubilised Plasmin continues to digest the clot until only 
small core fragments are left Stabilised clots are digested at a 
slower rate than unstabilised clots
Plasmin digestion of fibrm(ogen) has been the subject of many 
investigations, and was important in the determining of the 
structure of fibnn(ogen) (Harder, 1971) The initial action of 
plasmin is the formation of fragment X, which has a Mr of 250,000 
(Nieuwenhuizen and Gravesen, 1981) This fragment is formed by- 
the removal of two Mr 45,000 pieces from the carboxyl portion of 
the Aa chains The next fragment i*s the Y fragment, Mr 150,000 
This is formed by the removal of one D fragment, Mr 90,000 
(Haverkate et al , 1979), plus a small connector region, from the 
carboxy terminal of the X fragment The D fragment, consists of 
part of 1 Aa chain, 1 B$ chain (N terminal part), and part of 1 Y 
chain (N terminal part) The final fragment is fragment E, Mr
50,000 This consists of two N terminal fragments of the Aa 
chain, 2 fragments of BB, and 2 N terminal fragments of the Y 
chain The Y fragment is D2E, and there are 2 D fragments and 1 E 
fragment in each fibrinogen molecule (see Fig III 6) The 
molecular weight of the D fragment is different if calcium is used 
in its preparation (Haverkate and Timan, 1977) Thus, D(cate) 
has a Mr of 93,000, while the Mr of D(EGTA) is 80,000 D
fragments prepared in the presence of calcium have strong
anticoagulant activity, while those prepared in the presence of 
EGTA have no anticoagulant properties (Haverkate et al,, 1979) 
Plasmin digestion of fibrin yields a D2 dimer It is probably due 
to protection of one of the plasmin sites by the calcium, since m  
the presence of EGTA, D monomers are formed Fibrinogen has 3 
calcium binding sites, 2 of them are m  the carboxyl terminal of 
the Y chain, which is located m  the' D(cate) fragment
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(Nieuwenhuizen and Gravesen, 1981) Table III 1 summarises the 
structures of the fibrm(ogen) fragments (from Koppert et al , 
1986)
III 1 5 FIBRIN(OGEN) DISORDERS
Disorders of fibrinogen can either be congenital, or acquired The 
congenital disorders are classed as quantitative, le hypofibrin­
ogenaemia, or afibrinogenaemia (depending on severity), and qual­
itative, le dysfibrinogenaemia
With congenital afibrinogenaemia, there is no fibrinogen present, 
but in some cases levels of 5 mg/100 ml have been detected 
(normally 200-300 mg/100 ml) Patients suffer from internal
bleeding bouts, and prolonged bleeding after minor traumas The 
disorder is transmitted as an autosomal trait Treatment involves 
replacement therapy In hypofibrinogenaemia there is usually no 
bleeding bouts, but there can be prolonged bleeding after surgery 
(Williams et al , 1977, Bloom, 1981)
A large number of dysflbrmogenaemias have been identified In 
each case there is usually a modification to the fibnn(ogen) 
molecule, but in some cases there is an associated hypofibrin­
ogenaemia Dysfibrinogenaemia is usually due to a dominant auto­
somal trait, and they are usually named after the place in which 
they were first identified In a few cases the actual alteration 
has been identified Fibrinogen Detroit has an arginine, at 
position 19 of the Pa chain, replaced by a serine Fibrinogen 
Zurich has abnormal fibrin monomer aggregation, fibrinogen 
Bethesda I has defective fibrinopeptide release, and fibrinogen 
Oklahoma has defective fibrinogen cross-linking Patients often 
have prolonged coagulation time Treatment is not usually 
necessary (Bloom, 1981)
The acquired disorders of fibrinogen are known as defibrination 
syndromes This defibrination is due to disseminated vascular 
coagulation (DIC) There are 3 problems associated with DIC The 
first is consumption of coagulation factors which, along with the 
increase in production of fibrin degradation products, leads to 
prolonged bleeding Secondly, fibrin can be deposited m  
capillaries which would block blood flow, leading to ischaemia 
Thirdly, loose strands of fibrin deposited in blood vessels may 
not cause a blockage, but they can damage the red blood cells as
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they pass by The severity of the last two effects depends on the 
effectivness of the fibrinolytic system (Williams et al , 1977, 
Brozovic, 1981)
DIC only occurs m  conjunction with other serious disorders In
particular disorders of pregnancy such as toxaemia, or retained
dead foetus Other disorders which cause DIC are gram-negative
endotoxinaemia, gram-positive septicaemia, liver disease such as 
%cirrhosis, heatstroke, extensive burns, and certain malignant 
diseases Therapy usually involves continuous infusion of 
heparin This prevents coagulation, thereby preventing further 
depletion of coagulation factors This can be accompanied by 
replacement therapy In particular, cryoprecipitate is effective 
m  this as it provides both fibrinogen, and FVIII Platelets may 
also need to be administered If there is serious bleeding due to 
inhibition of coagulation by high levels of fibrin degradation 
products, a finnolysis inhibitor can be used Aminocaproic acid 
(EACA) can be used for this, but its use can be hazardous 
(Brozovic, 1981)
III 1 6 FIBRIN(OGEN) ASSAYS
There are 2 main fibrinogen assays The first involves the 
addition of thrombin to a plasma sample Thrombin acts directly 
on fibrinogen, and is not dependent on any other factors The 
thrombin time is the time taken for a clot to form, and this is a 
measure of the amount of fibrinogen present (Clauss, 1957) A 
variation on this is the gravimetric assay This involves 
removing the clot, drying it, and weighing it This gives a 
direct measure of the fibrinogen present The second method uses 
antibodies to fibrinogen m  an ELISA, or RIA This is especially 
useful for studying fibrm(ogen) degradation products
III 1 7 FACTOR VIII COMPLEX
The study of factor VIII (FVIII) deficiency disorders indicated 
that FVIII had 2 distinct properties - coagulation (thrombosis) 
and the prevention of blood loss (haemostasis) Subsequent studies 
indicated that FVIII consisted of 2 proteins, one which controls 
coagulation (FVIII) and the other which controls haemostasis (von 
Willebrands factor - vWF) The nomenclature of these proteins has 
often been the source of confusion The system used here is the 
most widely used at present (Hoyer, 1981)
FVIII C - the portion of the complex with procoagulant
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activity
FVIIIR/(vWF) - the portion of the molecule with haemostatic 
properties (von Willebrands factor)
FVIII CAg - the antigenic portion(s) of FVIII C 
FVIIIR Ag - the antigenic portion(s) of vWF 
FVIIIR RC - the portion of vWF that binds ristocetin 
resulting m  platelet aggregation 
For convenience, the term FVIII is used to refer to the complex
of FVIII C and vWF when neither property is being being referred 
to specifically
FVIII C and vWF are both seperate and distinct proteins, but they 
do interact with each other The FVIII complex has a molecular 
weight of 1-20x10^, with FVIII C comprising about 1% of the total 
The 2 proteins can be dissociated with high ionic strength 
buffers, with 0 25 M calcium being used generally While the 2 
are seperate, immobilised polyclonal antisera to FVIII will remove 
both FVIII CAg and FVIIIR Ag from plasma This is not due to the 
antisera binding to FVIII CAg since the FVIII CAg can be eluted 
from the column using calcium On the other hand immobilised 
antibodies to FVIII CAg only remove this antigen, and do not
deplete plasma of FVIIIR Ag This is thought to be due to
destabilisation of the complex on binding the antibodies Under 
normal conditions the concentrations of both FVIII C and vWF 
fluctuate together, but in certain diseased states, eg haemo­
philia, their concentrations can vary independently of each 
other Thus, while the 2 proteins are seperate from each other, 
they also interact strongly together (Hoyer, 1981)
III 1 8 FVIII C - STRUCTURE
In 1984 Vehar et al , Toole et al , Gitschier et al , and Wood et
al , reported the successful cloning of the FVIII C gene, and the
subsequent determination of its amino acid sequence
The gene is located on the X chromosome, and it consists of 186
kbp (kilo base pairs), and is about 0 1% of the X chromosome
There are 26 exons ranging in size from 69 bp to 3,106 bp, the 
latter is thought to be the largest known exon The introns range 
m  si2e from 207 bp to 32 4 kbp The completed mRNA is 96 kbp 
Due to its large size it is estimated that transcription would 
take about 3 hr at a rate of 15 neucleotides per second
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IThe mature protein is a single polypeptide chain containing 2,332 
amino acids, and it has a calculated molecular weight of 264,763 
The apparent molecular weight on SDS-PAGE is 330,000, which is m  
agreement with the calculated molecular weight allowing for 
glcosylation SDS-PAGE yields a number of bands for FVIII C 
Vehar et al , (1984) report 2 major protein pools The first has a 
Mr of 90,000-210,000, and the second has a Mr of 70,000-80,000 
Fay et al , (1982) reported a Mr of 72,000 band under non-reducing 
conditions, and a Mr of 100,000 band under reducing conditions
Vehar et al , (1984) found that the tryptic sequences from the Mr 
90,000-210,000 pool of peptides indicated that they were all 
derived from the N terminal of the parent molecule Similarly the 
Mr 70,000-80,000 pool were all found to be derived from the 
carboxy-terminal of the parent molecule The difference m  
apparent Mr between the reduced and non-reduced forms indicates 
intrachain disulphide bonds (see Fig III 9)
Molecular cloning data indicated that there were 2 repeating
homologous regions m  FVIII C The first is the A domain which is
approximately 330 amino acids long The second is the C domain 
which is 150 ammo acids long There is also a B domain of 980
ammo acids There are 3 A domains, 2 C domains, and only one B
domain (see Fig III 9) The C domains are at the carboxy- terminal 
end
Thrombin, which is responsible for activating FVIII C, cleaves
the molecule into 2 fragments The Mr 90,000 fragment contains
the Al and A2 domains, and the Mr 80,000 consists of A3-C1-C2 
The Mr 80,000 can be further cleaved to a Mr 73,000 fragment The 
Mr 90,000 fragment is cleaved to Mr 50,000 and Mr 43,000 fragments 
on prolonged exposure to thrombin The Mr 50,000 fragment can be 
further cleaved to an Mr 30,000 and an Mr 20,000 fragment (see Fig 
III 9)
The A domains were found to be approximately 30% homologous with
the A domains of ceruloplasmin which consists of 3 A domains, but
is lacking in B, and C domains Both ceruloplasmin and FVIII C 
bind metals Ceruloplasmin binds 6 copper ions, while calcium 
ions are bound by FVIII C (Mikaelsson et al , 1983) The ammo 
acids responsible for some of the copper binding sites m
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ceruloplasmin are conserved in the A1 and A3 domains of FVIII C, 
indicating that there is probably a similar binding mechanism 
involved There are also a number of similarities between FVIII C 
and FV (Kane and Davie, 1988) In each case they act in
conjunction with another vitamin K-dependent protein (FIXa m  the 
case of FVIII C, and FXa in the case of FV) m  the presence of 
calcium and phospholipid The proteins they act on (prothrombin 
in the case of FV, and FX m  the case of FVIII C) are also vitamin 
K-dependent proteins FVIII C and FV are single chain poly­
peptides with molecular weights greater than 300,000, and they are 
both activated by thrombin to give 2 polypeptides - Mr 90,000 and
Mr 80,000 in the case of FVIII C, and fragments D and E m  the
case of FV)
III 1 9 FVIII C - FUNCTION
FVIII C acts as a cofactor m  the activation of FX by FIXa Both
calcium and phospholipid are necessary for the reaction FVIII C
on its own has no effect, it only acts as a catalyst Activation
of FVIII C to Mr 80,000 and Mr 90,000 by thrombin is necessary for
activity This is thought to occur at Arg(372)-Ser(373) Ware et
*al , (1988) used a monoclonal antibody which inhibited coagulat­
ion, and identified its binding site as residues 338-362 on the Mr
90,000 fragment This would indicate that the Mr90,000 fragment 
is FVIIIa But, if the mechanism of activity of FVIII C is 
similar to that of FV, then both fragments would be necessary for 
activity, as is the case of FV Prolonged exposure of FVIII C to 
thrombin inactivates it Activated protein C, and FXa also 
inactivate FVIII This cleavage is thought to occur at Arg(336)- 
Met(337)
III 1 10 von WILLEBRANDS FACTOR - STRUCTURE
Like FVIII C, the structure of vWF was determined by molecular
cloning (Sadler et al , 1985, Lynch et al , 1985, Verweij et al ,
1985) and by protein sequencing (Titani et al , 1986) The cDNA 
was 8 9 kbp long, and it encodes for a single polypeptide chain of
2,813 amino acids, with a Mr of 309,000 The mature vWF has a Mr
of 225,000, and is 2,050 ammo acids long During maturation the 
22 amino acid signal peptide, and a 741 amino acid peptide are 
cleaved off This peptide is called von Willebrands antigen II 
(vWAg II) (Fay et al , 1986)
The vWF precursor protein consists of 4 homologous domains There 
are 3 A domains, each of about 311 amino acids There are 2 B 
domains, and 3 C domains, which are quite short There are 4 D 
domains, which are 350-400 amino acids long vWAg II consists of 
the first 2 D domains from the N terminal The lead sequence of 
the N terminal of the mature protein is part of a D domain, called 
D* (Girina et al , 1987) (see Fig III 10)
The mature vWF is a single chain polypeptide chain with 2,050 
amino acids, and 22 probable glycosylation sites with 18 7% 
carbohydrate resulting m  a molecular weight of 270-280,000 
(Chopek et al , 1986, Titani et al , 1986) On SDS-agarose gels
under non-reducing conditions, vWF forms a series of multimers 
which have a range of molecular weights up to Mr 12x10^ (Hoyer, 
1981) On SDS- PAGE gels, under reducing conditions there is a 
single band of Mr 240,000 (Shapiro et al , 1973, Fowler et al ,
1985) The basic unit of the multimers is probably a dimer of the 
single polypeptide chain Two of the polypeptide chains are held 
together by strong disulphide bonds at the carboxy-terminals 
These dimers are held together m  a linear polymer (Fowler et al , 
1985, Chopek et al , 1986) Research indicates that the monomer 
is the active form of vWF The multimers probably enable 
localised high concentrations of the vWF to occur
III 1 11 vWF - FUNCTION
While the major function of vWF is in the aggregation of 
platelets, it has a number of functional sites, such as platelet 
binding, collagen binding, FVIII CAg binding, which enable it to 
carry out its function (reviewed by Girma et al , 1987)
The binding of vWF to platelets is mediated by 2 membrane bound 
glycoproteins In the presence of ristocetin, vWF binds to 
glycoprotein lb (Gplb), which leads to aggregation This has been 
confirmed by the elimination of binding in the presence of a MoAb 
to Gplb MoAbs which prevent aggregation bind to a Mr 46,000 
fragment on vWF between residues 449 and 728 (Fujimura et al ,
1986) This has been shown to be the Gplb binding site Gplb is 
involved in platelet - vessel wall interactions
vWF also binds to platelets m  the presence of thrombin or ADP 
This binding was found to involve glycoprotein Ilb-IIIa
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(GpIIb-IIIa) This was confirmed by MoAbs to GpIIb-IIIa The 
postulated binding site of GpIIb-IIIa is at residues 1,744 to 
1,746 (Titani et al , 1986)
At high shear rates, such as those found m  much of the 
circulatory system, vWF is necessary for platelet adhesion to 
vessel walls This is due to the binding of vWF to collagen m  
the vessel walls Using MoAbs the binding sites for type III 
collagen were localised to ammo acids 542-622, and 948-998 The 
former is also part of the Gplb binding region These 2 peptides
correspond to the Al and A3 domains These 2 regions have a
homologous sequence at 567-621, and 969-992, which is probably 
the collagen binding site (Roth et al , 1986)
Again, using MoAbs, it has been shown that vWF binds to cultured 
endothelial and smooth muscles cells, which does not involve 
collagen The binding site involved is unknown, except that it is 
on an region of molecular weight 80,000 on the carboxy terminal 
region (deGroot and Sixma, 1986) The portion of vWF that binds 
FVIII C was found to be located on an N terminal fragment with a 
molecular weight of 34,000, between residues 1 and 910 (Takahashi 
et al , 1987) A Mr 80,000 fragment from FVIII C is also involved 
vWF has been found to bind to heparm, the site for this is the
same as that for Gplb These binding sites are shown m  Fig
III 11
III 1 12 FVIII COMPLEX - DISORDERS
Congenital disorders of FVIII C are called haemophilia This term 
is used to refer to two different disorders Haemophilia A (here 
referred to as haemophilia) is due to a deficiency of FVIII C, 
while haemophilia B (Christmas disease) is due to a deficiency of 
FIX
Haemophilia is due to a sex-linked trait, since the gene is found 
on the X chromosome The disease usually only affects male 
offspring of carrier females Females are only affected if they 
are homozygous offspring of a carrier, and a haemophiliac The 
incidence of haemophilia is 1 per 10,000 m  males It appears 
that the gene also occurs by mutation at a rate of 1 per 300,000 
This is thought to be the origin of haemophilia m  the European 
royal families The mutation apparently occurred m  Queen Victoria 
who gave birth to 2 carriers, and 1 haemophiliac There was no
48
previous incidence of haemophilia m  her family
Haemophilia can be categorised into 3 types The first type, 
severe haemophilia, has no detectable FVIII CAg, nor FVIII C 
(less than 1% of normal) A few of these patients have low 
FVIII CAg levels, but no FVIII C This group of patients have no 
FVIII due to an absence of the gene Those with low levels of 
FVIII CAg could have a mutation that prevents activity of the 
molecule The other 2 groups, moderate, and mild haemophilia, 
have variable FVIII CAg levels, which usually reflect the FVIII C 
levels FVIIIR Ag levels are usually normal (Hoyer, 1981)
In the plasma of some haemophiliacs material that antigenically 
cross reacted with antihaemophilic factor, was identified with 
human antibodies These patients were referred to as CRM+ The 
problem with the use of heterologous serum for these studies is 
that the most antigenic portion of the FVIII complex is FVIIIR Ag 
Thus, in many cases these CRH+ patients have no FVIII CAg, but 
normal vWF (Hoyer, 1981) Moabs against FVIII CAg are needed for 
accurate studies Studies have shown that at least 85% of 
carriers have low FVIII C levels, and normal FVIIIR Ag levels 
This is due to the absence of one of the FVIII C genes
The clinical manifestations of haemophilia depend on its severity 
The most common means for identifying haemophiliacs, especially 
the mild, or moderate cases, is by prolonged bleeding after 
dental extractions Other problems are haematomata (bleeding into 
the tissue), peripheral neuropathies (due to pressure on a nerve 
from intramuscular bleeding), and haemarthroses (bleeding into 
soft tissue surrounding a joint) Patients with mild, or severe 
haemophilia rarely suffer from haemarthroses Patients with 
severe haemophilia often suffer from permanent disability, and 
disfigurement from haemarthroses The main treatment for haemo­
philia is care in the prevention of injury that could result m  a 
bleeding bout In cases of severe bleeding, such as in 
haemarthroses, replacement therapy can be used FVIII concen­
trates are also given prior to surgery (Williams et al , 1977, 
Bloom, 1981)
Acquired haemophilia is due to the production of IgG to FVIII C 
This can occur m  patients undergoing replacement therapy, or 
spontaneously in healthy patients The IgG produced can be weak
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(type II), producing only mild1 inhibition, or it can be strong 
(type I), depending on the epitope the antibodies are directed to 
(Gawryl and Hoyer, 1982) The reason for the occurrence of these 
antibodies is unknown Treatment involves replacement therapy 
Patients with strong inhibitors can often require many plasma 
volumes to stop the bleeding Sometimes sufficient FVIII cannot 
be infused to overcome the inhibition, m  which case exchange 
plasmapheresis may be helpful But, even this only removes the 
circulating IgG (60-75%), and FVIII concentrates may be needed to 
supplement plasmapheresis Since the anti-FVIII antibodies are 
often species specific, bovine, or porcine FVIII may be useful, 
but these can only be used once or twice as they are very 
antigenic Another possibility is infusion of vitamin K-dependent 
factor concentrates These appear to initiate coagulation without 
FVIII Immunosuppressive therapy has been used for long term 
maintenance of patients with FVIII inhibitors (Williams et al , 
1977, Brozovic, 1981)
von Willebrand's disease (vWD) is due to a congenital deficiency 
of FVIIIR The disease is not sex-linked (Bloom, 1981) There 
are 3 types of vWD In type I vWD both FVIII CAg and FVIIIR Ag 
are reduced, but the levels are similar The bleeding time is 
prolonged, and there are often associated bleeding episodes In 
type II vWD there is only a slight reduction m  FVIII CAg and vWF, 
but a larger decrease in FVIIIR RC In severe vWD (type III)
there is a marked reduction of both FVIII CAg and FVIIIR Ag This 
is a homozygous form of the disease and is very rare (Takahashi et 
al , 1984) In type I vWD the multimer pattern of vWF in agarose 
electorphoresis is unchanged from the normal but it is reduced in 
quantity In type II vWD there is an absence of the large 
multimers of vWF usually present In vWD Ila only small multimers 
are present Type lib is similar to type Ila except that there 
are intermediate forms of the multimers present also Type lie is 
also similar to type Ila, but there are aberrant triplet 
structures present m  the multimers (Ruggen and Zimmerman, 1981, 
Ruggen et al , 1982, Fulcher et al , 1983) In type II vWD the
patients platelet-rich plasma (PRP) has reduced aggregation when 
ristocetin is added But m  type IIB vWD, patient's PRP has 
increased reactivity to ristocetin The reduction in FVIII CAg
levels is secondary to the vWD It is probable that vWF 
stabilises FVIII C, or protects it from proteases Thus, while 
the abnormal FVIIIR may not cause platelet aggregation, it 'still
appears to bind, and protect FVIII C Treatment involves 
replacement therapy, and prognosis is usually good (Bloom, 1981)
There is also an acquired form of vWD, known as von Willebrand's 
Syndrome (vWS) This is due to the production of inhibitor 
antibodies directed against vWF (Fricke et al , 1985) In some 
patients the antibodies also inhibit the FVIII C molecule as well
III 1 13 FVIII COMPLEX - ASSAYS
FVIII assays are divided into 2 types The first measure FVIII C, 
and the second measure FVIIIR The FVIII C activity of 1 ml of 
plasma from a large donor pool (normal plasma) is defined as 1 
International Unit (IU) Similarly, the FVIIIR Ag, and the 
FVIIIR RC activity of 1 ml of normal plasma is 1 IU The levels 
of FVIII CAg m  plasma have been estimated at 50 ng/ml, le 50 
ng/IU Similarly, the concentration of FVIIIR Ag in normal 
plasma has estimated to be between 5 and 10 Pg/ml (Hoyer, 1981)
The assays used for FVIII C are functional assays since antisera 
to FVIII only recognise FVIIIR Ag Also, since the concentration 
of FVIII CAg is so low, it would be difficult to measure The 
activated wpartial thromboplastin time (APTT) is the main assay 
used (Williams et al , 1977) This uses FVIII-deflcient plasma 
from haemophiliacs to provide all the essential coagulation 
factors The plasma is stored m  a chelating agent to prevent 
coagulation The reagent that activates the plasma is kaolin (a 
"foreign surface"), and phospholipid (similar to PF3) Once the 
system has been activated, calcium is added to allow coagulation 
to occur The time taken for coagulation to occur is directly 
proportional to the amount of FVIII C present A new chromogenic 
assay for FVIII C has been developed This uses a synthetic 
peptide which is hydrolysed by FVIIIa This forms a chromogenic 
substrate The absorbance is proportional to the FVIII C 
concentration
vWF is measured by the addition of ristocetin to test plasma, and 
the rate of platelet aggregation is measured by a platelet 
aggregometer (Williams et al , 1977) This is proportional to the 
vWF concentration ELISA assays using sera against FVIII are also 
used to measure directly vWF concentration So too does rocket 
immunoelectrophoresis (Zimmerman et al , 1975) In "normal" 
patients the vWF level will be the same as the FVIII C level, le 1
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IU/ml Platelet aggregation, APTT, ELISA, and the bleeding time 
are used together in the diagnosis, and characterisation of 
bleeding disorders
III 1 14 SYNTHESIS OF BLOOD FACTORS
Fibrinogen has been shown to be synthesised m  liver parenchymal 
cells (Hamashima et al , 1964) It is probably stored in
reticuloendothelial cells (Williams et al , 1977) von Willebrand 
Factor is synthesised m  endothelial cells (Jaffe et al , 1973, 
Levine et al , 1982) The site of synthesis of FVIII CAg has been 
difficult to detect, but using hybridisation probes it has been 
been possible to detect FVIII mRNA, indicating a site of 
production Wion et al , (1985) located the mRNA in hepatocytes, 
lymph nodes, and spleen, pancreas and kidney cells FVIII CAg 
was also detected m  m  hepatocytes using an immuno-gold stain 
(Zelechowska, 1985)
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TABLES AND FIGURES
TABLE III 1
This table shows the ammo acids present in fibrm(ogen) and 
their plasmin degradation fragments The figures represent
the numbers of the start and end ammo acids The»N-terminal ammo acid on each chain is no 1
1 11 FRAGMENT !
Ammo acid sequence
Aa chain B^  chain Y chain
| Fibrinogen | (1-610) 2 (1-461) 2 (1-410) 2
| Fibrm monomer | (17-610) 2 (15-461) 2 (1-410) 2
1 x 1 (1-208) 2 (1-461) 2 (1-410) 2
1 Y | 1-208/1-78 1-461/54-122 1-410/1-!58 |
| D(cate) | 111-197 134-461 86-410
1 D(EGTA) | 111-197 134-461 86-303
1 E I (1-78) 2 (54-122) 2 (1-58) 2 I| NDSK(fbg) | (1-51) 2 (1-118) 2 (1-78) 2 1| NDSK(fb) 1 (17-51) 2 (15-118) 2 (1-78) 2 1[ flbrmopeptide A| 1-16 ....
| fibrmopeptide B| .... 1-14
X, Y, and E plasmm degradation products of fibrinogen
D(cate) plasmm degradation product D of fibrinogen
prepared m  the presence of calcium 
D(EGTA) Plasmm degradation product D of fibrinogen,
prepared m  the presence of EGTA 
NDSK N-terminal disulphide Knot of fibrinogen
(fbg) and fibrin (fb)
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F i g  I I I . 2 THE EXTRINSIC PATHWAY
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Fig III.3 THE INTRINSIC PATHWAY
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FIG III.5 Showing the structure of the fibrinogen molecule, and 
the molecular weights of its1 chains (Doolittle, 1981a)
, ----------------------  170,000  [
f--------------------------------------------- 340,000  f
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FIG III 6 Showing the structure of fibrinogen and ltjs plasmm 
degradation products The figures in parentheses are 
the molecular weights of the fragments (Doolittle, 1981a)
FIBRINOGEN (340,U00;
(45,U00; v
Y
FRAGMENT D 
(90,000)
FRAGMENT Y (.150,OUO) 
\y (1U,000)
FRAGMENT E ( 5 0 , 0 0 0 )
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FIG III 7 Showing the structure of the disulphide bonds m  the N-
termmal disulphide knot (Doolittle, 1981a) The numbers
in parentheses represent the position of the amino acids
m  the fibrinogen chains
(161) (165)
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FIG III 8 This figure shows the structure of one half of the fibrinogen molecule The 
molecule is a dimer, with each half consisting of 1 Aa chain (grey), 1 B£ chain (white), 
and 1 y chain (black) The carbohydrate residue is indicated by a hexagon The thrombin 
cleavage sites are indicated by arrows rhe structure of the disulphide rings is given 
m  Fig III 7 (Doolittle, 1981a)
itsf thrombin degradation fragments The figures-represent the positions
of the ammo acids on the molecule Also shown are the molecular weights
of the fragments (Vehar et al, 1984)
FIG  I I I  9 Show ing  t h e  h o m o lo g o u s  r e g i o n s  i n  t h e  F V I I I .C  m o l e c u l e  and
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FIG  I I I  10 Show ing  t h e  h o m o lo g o u s  r e g i o n s  i n  t h e  p r e c u r s o r  vWF
m o l e c u l e  (,Girma e t  a l  , 1987)
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FIG III.11 Showing the homologous regions of the mature vWf molecule 
and its' functional binding sites (Girma et al 1987)
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I l l  2 RESULTS
III 2 1 PURIFICATION OF FVIII
Ethanol cryoprecipitation of 800 ml of plasma yielded a partially 
purified FVIII concentrate of 1 77 IU/ml PEG precipitation of 
this FVIII fraction gave 4 ml of a high purity preparation of 8 
IU/ml These FVIII C levels were assayed by the APTT assay This 
represented only 6% of the FVIII C activity of the starting 
plasma 65% of the FVIII C activity remained in the plasma A 
second batch of 450 ml, produced 4 ml of a high purity FVIII 
preparation of 10 IU/ml This represented 8 8% of the total 
FVIII, and 21 5% remained m  the plasma (see Table III 2)
Fig III 12 shows agarose electrophoresis of the different FVIII 
fractions As can be seen there is no noticeable difference 
between normal and FVIII-deficient plasma The cryoethanol 
precipitate (I) shows a decrease m  the number of proteins present 
especially those of low molecular weight (at the top of the gel) 
There are two major contaminants present, one of high molecular 
weight, and the other of low molecular weight The high purity 
fractions (HI and H2) have a further decrease m  the low molecular 
weight fractions There is a total absence of the major low 
molecular weight band, but there is still some of the major high 
molecular weight band present The PEG 1 precipitate (F) shows 
only one band of high molecular weight (other than the protein 
remaining at the sample application point), while the remaining 
supernatant after PEG precipitation (R) shows only one small 
molecular weight band The increase m  the staining m  the high 
purity FVIII, as compared to the partially purified form, is 
probably due to the increased protein concentration The high 
purity fractions are 8 2 and 10 IU/ml while the-partially purified 
form is only 1 77 IU/ml
The presence of FVIII in both the cryoethanol precipitate and the 
high purity FVIII was confirmed by Laurell rocket immunoassay (see 
Fig III 13 and III 14) No FVIII was detected m  the first PEG 
precipitate The presence of FVIII in the FVIII deficient plasma 
is due to vWF The commercial polyclonal antibodies detect the 
vWF portion of the FVIII complex, which is usually present m  
haemophilia, instead of the FVIII CAg portion
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Fig III 15 shows agarose electrophoresis of both the high purity 
FVIII and FVIII-deficient plasma One of the lanes containing the 
high purity FVIII was cut out and used in crossed Immuno­
electrophoresis This was then electrophoresed m  a perpendicular 
direction into a gel containing anti-vWF and a second gel 
containing anti-human serum Only one peak is formed This is m  
the anti-vWF gel, and it corresponds to the main peak m  the 
single dimension electrophresis This indicates that the major 
protein m  the high purity sample is FVIII and that any other 
contaminating protein is only present In small quantities In the 
single dimension electrophoresis there is a second protein band 
which travels m  the opposite direction to FVIII This is 
probably the immunoglobulin fraction, as this normally travels to 
the cathode This fraction will not form a peak m  the anti-human 
serum gel as it will run towards the cathode, le away from the
gel, m  the crossed Immunoelectrophoresis
To further purify FVIII chromatography a Sepharose Cl 6B column 
was used Both PEG precipitated cryoprecipitate, and koate were 
used The profiles obtained from both of these were similar (see 
Fig III 16 and III 17) 4 protein peaks were obtained in each
case The first, Kl, was the void volume peak and corresponded 
to the major FVIIIR Ag peak The second, K2, probably contained 
fibrinogen The FVIIIR Ag peak trails off slowly This was 
probably due to fragments of vWF, which were not part of the FVIII
complex, due to proteolysis
III 2 2 PURIFICATION OF FIBRINOGEN FRAGMENTS/CHAINS 
After production of the fibrinogen fragments m  the presence of 
EGTA the mixture was applied to a Sepharose column Instead of 
obtaining the 3 expected peaks, corresponding to the X, Y, and 
combined D and E fragments, only 2 peaks were obtained These 
corresponded to the combined X, and Y fractions, and the 
combined D, and E fractions The reason for the incomplete 
separation of the X and Y fragments was due to the size of the 
column Nieuwenhuizen and Gravesen (1981) use a 230cm column, 
this is compared to a 76 cm column used here The molecular 
weights of the X and Y fragments are too similar to be separated 
on a column of 76 cm
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After fibrinogen was split into its chains the mixture was applied 
to a CM-cellulose column The chains were eluted with a linear 
gradient of sodium acetate Fig III 18 shows the profiles of the 
eluted protein and of the gradient There was only 1 peak obtained 
instead of the expected 3 The reason for this is unknown
III 2 3 MONOCLONAL ANTIBODY PRODUCTION
8 fusions were performed using Koate as the antigen There was no 
growth m  5 of the fusions One of the fusions produced clones, 
but these subsequently stopped producing antibody All the clones 
obtained were from 2 fusions There was a total of 1,344 clones 
from these fusions 306 of these were positive by ELISA using 
Koate as the antigen A total of 26 of these remained positive and 
were expanded into flasks 5 of these were cloned out, and 
further characterised (see Table III 3)
In fusion AHF2, 28% of the clones were positive, and 14% survived 
the first expansion 6% remained positive, and 2 6% survived and 
grew in flasks In fusion AHF3 only 19% of the clones were 
positive, 12% survived the first expansion, 3 25% were positive 
after the second screening, and 1 4% survived to grow m  flasks 
The percentage of positives from AHF2 that survived was almost 
twice that of AHF3
III 2 4 ANTIBODY ISOTYPING
Antibodies were typed using a commercial kit Table III 4 shows 
the results of the isotyping of the antibodies AHF1 1 had very 
weak binding by both anti-IgA and IgM It was bound strongest by 
anti-IgGl, IgG2a and IgG2b It was bound very weakly by 
anti-IgG3 This would indicate that the antibody is an IgG, and 
is a mixture of Gl, G2a and G2b subclasses Anti-IgG2a bound 
strongly to AHF2 la, while the binding by anti- IgM, IgGl, IgG2b, 
and IgG2b were weaker It had virtually no activity with anti- 
IgG3 and IgGA Thus, it is probably an IgG 2a Meanwhile AHF2 lb, 
which was cloned from the same clone as AHF2 lb and was bound 
strongly by IgGl AHF2 2 was bound strongest by IgGl, but it 
also showed binding by IgG2a This is probably a mixture of IgGl 
(mainly) and IgG2a AHF2 3 was bound strongest by IgG2b and 
weaker by IgGl This is also a mixture, mainly IgG2b but also 
some IgGl AHF2 4 was bound strongest by IgGl, with some binding 
by IgG2a Again this is probably a mixture of IgGl with some IgG2a
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also present All antibodies were bound much stronger by the
anti-k chain antibody rather than by the anti-X chain antibodies 
Table III 5 summarises the isotypes of the antibodies The 
isotype which gave the highest absorbance was taken as the 
isotype
III 2 5 PURIFICATION OF ANTIBODY
Antibodies that were grown as ascitic tumours were purified by 
ammonium sulphate precipitation A solution of 10-15 mg of 
purified antibody/ml was usually obtained Titres were determined 
by ELISA against immobilised Koate, and the results are shown m  
Table III 6 A second batch of AHF1 1 was prepared and its
activity is summarised m  Table III 7
The titre was defined as the concentration of antibody that
produced an absorbance equal to half it's maximum absorbance, m
ELISA This would be on the linear portion of the
concentration-response curve The maximum dilution was defined as
the lowest concentration that gave the maximum absorbance This
would be on the plateau of the concentration-response curve For
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the second batch of AHF1 1 the titre was 100 ng/ml, and the 
maximum dilution was 1 Mg/ml The titre for the first batch of 
AHF1 1 was 2 jjg/ml, for AHF2 la, 2 pg/ml, and that for AHF2 lb was
approximately 200 ng/ml The maximum dilutions were 20pg/ml for
all 3 antibodies The activity profile of AHF1 1 was a bell 
shaped curve At concentrations of 1 mg/ml and above there was no 
activity of the antibody detectable (see Fig III 19)
III 2 6 STABILITY STUDIES ON ANTIBODIES
Samples of some antibodies were stored at a concentration of 200 
pg/ml in 0 1 M Tns, pH 8, at 4°C These were tested for activity 
during storage These results are summarised in Table III 8
After 6 weeks the binding of all 3 antibodies had dropped, but it 
was higher in subsequent weeks This was probably due to the ELISA 
rather than to the antibodies It could have been caused by a 
decrease in the activity of the batch of enzyme-labelled second 
antibody used, or due to reduced binding of Koate to the 96 well 
plates for that assay By week 16 there was a drop m  binding by 
all 3 antibodies This can be seen as a drop in the absorbance at 
an antibody concentration of 20 pg/ml Thus, after 16 weeks the 
absorbance for a 20 jjg/ml antibody solution for AHF1 1 was reduced
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form 0 3 to 0 18, while the value for AHF2 la was reduced from 
0 98 to 0 36, and the value for AHF2 lb was reduced from 1 27 to 
0 69 After this initial drop the antibodies remained stable for 
at least 39 weeks
III 2 7 SCREENING OF ANTIBODIES BY ELISA
Antibodies were screened by a number of different ELISA assays 
Table III 9 compares the binding of different concentrations of 
AHF1 1 and AHF2 lb to different fractions of Koate by ELISA
AHF1 1 preferentially binds to the void volume fraction obtained 
following chromatography of Koate on a Sepharose column (Kl) It 
has much weaker binding to the first fraction after the void 
volume (K2) AHF2 lb bound strongly to both fractions but it 
showed stronger binding to the K2 fraction
Table III 10 compares the binding of 6 antibodies to different 
proteins, immobilised on a 96 well plate The binding was
determined by ELISA AHF1 1 bound to Koate (K0), and it's Kl 
fraction It did not bind to BSA and only very weakly to the 
Koate K2 fraction It also bound to Fibrinogen obtained from 
Sigma All the other antibodies bound strongly to Koate (KO),
fibrinogen and Koate fraction K2 They showed weaker binding to
Koate fraction Kl, and they showed no binding to BSA
To further characterize the antibodies their ability to bind to 
vWF was determined by ELISA Normal plasma or Koate were added to 
plates coated with commercial anti-FVIII and allowed to bind, 
similar to the ELISA for vWF After washing the plates the were 
then probed with either labelled anti-vWF antibody (see II 2 3), 
or else AHF1 1 or AHF2 lb were then added to the wells and then 
probed with labelled anti-mouse Ig (see section II 8 1) When 
normal plasma was added to the wells the immobilised anti-vWF 
antibodies only bound FVIII This coated the plate with pure 
FVIII only The binding of FVIII was confirmed after probing with 
the labelled anti-vWF, as the absorbances after probing were off 
scale Binding of AHF1 1 to the FVIII on the plate was not 
detected by probing with labelled anti-mouse Ig (see Table 
III 11) However, AHF2 lb bound to the FVIII if Koate was used to 
coat the plate, but not if normal plasma was used
III 2 8 SCREENING OF ANTIBODIES BY COAGULATION ASSAY
AHF1 1, AHF2 la, and AHF2 lb were tested for their effect on the
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activated partial thromboplastin time (APTT) Unpurified ascitic 
fluid containing these antibodies was used The results are 
summarised m  Table III 12
AHF1 1 had only a slight effect on the APTT AHF2 la, and 
AHF2 lb both slightly decreased the APTT This was probably due 
to contaminating calcium ions rather than to any effect of the 
antibody The commercial anti-FVIII antibody had only a slight 
effect This was because it is anti-FVIIIR Ag and not anti- 
FVIII CAg
III 2 9 AFFINITY CHROMATOGRAPHY
Purified AHF1 1 was coupled to a CNBr-activated Sepharose column 
and this was then used to isolate FVIII Initially 20 ml of 
normal plasma was applied to a column of about 2 ml, containing 
approximately 7 mg of antibody The protein eluted with glycine, 
pH 2 5 was assayed by APTT assay The protein eluted had no 
procoagulant activity at all However, electrophoresis under both 
reducing and non-reducing conditions showed one band, with Mr
79,500 and 61,900, respectively The plasma applied to the column 
could not be assayed for APTT because it contained heparin as an 
anticoagulant
To try and elute active FVIII from the column a different method 
was used Koate was applied to the column m  0 25 M CaCl2 This 
dissociates the FVIII C from the vWF, which should improve 
binding of FVIII to the column The FVIII was eluted from the 
column using ethylene glycol-histidine buffer The applied 
sample, the protein washed off the column (le did not bind to the 
immobilised antibody) and the eluted protein, which had bound to 
the immobilised antibody, were assayed for FVIII activity (see 
Table III 13) While no active FVIII could be detected m  the 
protein that was eluted from the column with ethylene 
glycol-his tidme, there was a loss of activity m  the Koate after 
passage through the column, compared with the sample applied to 
the column Since the APTT assay requires calcium free plasma for 
the assay there is a problem comparing samples of different 
dilutions, since their calcium levels are different Thus, the 
only valid comparison is between the applied Koate and the column 
washings when both are diluted at 1/50 For the 1/20 and 1/10 
dilution of the washing there is no FVIII concentration 
calculated This is because the high calcium concentration would
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interfere with the results and any readings from a standard curve 
would be macccurate
III 2 10 ELECTROPHORESIS
Koate run on a 7 5% SDS-PAGE system under non-reducing conditions 
produced 2 bands when stained with Coomassie blue (see Fig 
III 20) The first band was at the very top of the gel and 
consists of fibrinogen and vWF The second band had an apparent 
approximate molecular weight of 60-70,000 The precise molecular 
weight of this second band was difficult to determine for two 
reasons Firstly, it produced a "V" shaped band in the gel making 
it difficult to compare it with the markers Secondly, the 
markers stained very faintly with Coomassie blue which also made 
any comparisons difficult When Koate was run under reducing 
conditions three bands were detected when stained with Coomassie 
blue (see Fig III 20) One of these had a molecular weight of 
approximately 66,000 and the other two had molecular weights of 
around 50,000 These probably correspond to the fibrinogen chains 
rather than to the FVIII, since FVIII under reducing conditions 
produces a very faint, diffuse band which is difficult to detect 
even with silver staining (see Fig III 21)
A sample of protein, prepared by affinity chromatography of normal 
plasma on a Sepharose column with immobilised AHF1 1 antibody, was 
electrophoresed on 10% (w/v) polyacrylamide gel Under non-
reducmg conditions only one band with a molecular weight of
60,000 was detected when silver stained Under reducing conditions 
there was also only one band detected, but with a molecular 
weight of 75,800 (see Fig III 21) Under reducing conditions the 
band was much fainter than under non-reducing conditions, even 
though the same amount of protein was added to each lane
Fibrinogen run on a 7 5% (w/v) polyacrylamide gel under
non-reducing conditions, and stained with Coomassie blue stained 
produced a single large molecular weight band at the top of the 
gel Under the same conditions the first plasmm digest pool 
produces two bands corresponding to fragment X and fragment D 
The latter appears as a dimer The second plasmm digest pool
also produces two bands one corresponding to fragment D, the
other, a very faint band corresponds to fragment E (see Fig 
III 22)
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Fig III 23 shows the fibrinogen chains, and fragment E when 
stained with a silver stain They produce a negative image, which 
can only be seen if the rest of the gel is allowed to overstam
III 2 11 DOT BLOTTING
Dot blotting was used to screen the antibodies against different 
FVIII preparations (see Fig III 24) AHF1 1 showed only very weak 
binding to FVIII deficient plasma, normal plasma and serum It 
had slightly higher binding to Koate The reason for this lack of 
binding was probably due to the low level of FVIII CAg present m  
the dots There was about 100 pg of FVIII present m  the normal 
plasma applied to the nitrocellulose, while the Koate would have 
about 500 pg This is at the limit of sensitivity for dot 
blotting
AHF2 lb, AHF2 2, AHF2 3 and AHF2 4 all bound to normal plasma, 
FVIII deficient plasma and to Koate None of them bound to normal 
serum This would indicate that none of them bound to FVIII CAg, 
and that they bound to a protein that was consumed during 
coagulation - probably fibrinogen These results are summarised m  
Table III 14
III 2 12 WESTERN BLOTTING
Fig III 25 compares the binding of AHF2 2, AHF2 3 and AHF2 4 to 
different fibrinogen preparations The lane with reduced 
fibrinogen (2) shows only 1 band with an apparent molecular weight 
of 55,000 when stained with AHF2 3 and AHF3 4 This band 
corresponds to the chain of fibrinogen AHF2 2 bound to none 
of the chains
All 3 antibodies bound to 3 bands m  the lane containing the 
pooled D and E fragments (1) There was a major band at Mr
109,000 and 2 smaller bands at Mr 98,700 and Mr 94,600 These
probably constitute the heterogenous population of D fragments 
AHF2 2 also bound to a band at Mr 72,000 AHF2 3 also bound to
this band, but the binding was very weak AHF2 3 also bound to a
band with Mr 48,000 This corresponded to the E fragment of 
fibrinogen Thus, AHF2 3 bound to both D and E fragments, 
AHF2 2 bound to the D fragment and a Mr 72,000 band, and AHF 2 4 
only bound to the D fragment
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Fig III 26 shows the binding of AHF2 1 to the fibrinogen
preparations The lane containing the reduced fibrinogen molecule 
had 2 bands which corresponded to molecular weights 64,400 and
60,500 These bands correspond to the heterogenous population of 
Aa chains The lane containing the plasmin degradation fragments
of fibrinogen show 2 bands with molecular weights 61,700 and and 
48,100 This latter band corresponds to the E fragment
Fig III 27 shows a Western blot of fibrinogen, and its 
degradation products on 7%(w/v) SDS-PAGE AHF2 lb bound to
fibrinogen, and the X, Y, D and E fragments AHF2 3 bound to 
fibrinogen, and the X, Y and D fragments
Fig III 28 shows the binding of AHF1 1 to different preparations 
of FVIII Lane 1 of the blot on the left shows binding of AHF1 1 
to two different bands m  Koate under non-reducing conditions 
These bands have apparent molecular weights of 61,900 and 103,300 
Under reducing conditions there is only 1 band m  the Koate
preparation with Mr 79,500 (lane 2) Lane 3 and 4 contain the
protein eluted with glycine, pH 2 5, from AHF1 1 immobilised on
CNBr-activated Sepharose after the application of normal plasma to
the column Lane 3, which was run under reducing conditions shows 
a very faint band at Mr 79,500 Lane 4, which was run under 
non-reducing conditions shows 1 band with Mr 61,900
Fig III 28 also shows the binding of AHF1 1 to different
preparations of FVIII In lane 1 of the middle blot there are 2 
bands of Mr 88,000 and Mr 79,900 when Koate, run on a reducing 
gel, was used In lane 2, containing Koate run under non- 
reducmg conditions, there are 3 bands with Mr 75,000, Mr 112,000, 
and Mr 121,900 The blot on the right shows absence of binding of 
the second antibody to Koate run under either non-reducing or 
reducing conditions and is a negative control These results are 
summarised m  Table III 15
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TABLES AND FIGURES
TABLE III 2
This table shows the concentration of FVIII m  the different 
fractions during purification of FVIII
| % OF STARTING | 
I ACTIVITY |
FVIII CONC | 
(IU/ml) |
I FRACTION | RUN 1 I RUN 2*| RUN 1 RUN 2
| starting plasma | 100 1 1 0 62 1 0 || cryoethanol ppt | 35 6 1 ND 1 1 77 ND || remaining plasma | 64 5 1 21 | 0 4 0 21 |
| PEG ppt 1 1 2 | 1 24 | 0 62 0 23 |
| high purity 1 6 | 8 8 | 8 2 10 || PEG supernatant I 0 2 1 ND | 0 16 ND |
Run 1 800 ml plasma
Run 2 450 ml plasma
* During run 2 the starting plasma's FVIII level was not 
determined For calculation purposes it was assumed to be 
normal plasma le 1 IU/ml
Cryoethanol ppt The fraction after cryoethanol precipitation 
Remaining plasma plasma after cryoethanol precipitation 
PEG ppt 1 The pellet from the first PEG precipitation 
High purity The pellet from the second PEG precipitation 
PEG supernatant the supernatant after the second PEG 
precipation
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TABLE III 3
This table shows the number of clones produced m  each 
fusion, the number of clones that were positive to Koate by 
ELISA, and their survival during expansion
FUSION| NO OF | NO +ive| EXP | NO +ive| EXP | EXP | CONT
NAME | CLONES I CLONES 1 1 |I CLONES | 2 1 3 1AHF2 | 576 1 163 | 80 1 33 | 17 I 15 I1 24AHF3 | 768 1 143 | 90 1 25 I 11 I 11 1 2
EXP 1 The number of positive clones that grew after
expansion into a 24 well plate 
EXP 2 The number of positive clones that grew after
expansion into a 6 well plate (or into 3 wells of a 
24 well plate)
EXP 3 The number of positive clones that grew after
expansion into a flask 
CONT The number of positive clones that were contaminated
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TABLE III 4
Shows the binding of antiisotype antibodies to the 
monoclonal antibodies A negative control which contained 
PBS-Tween and no monoclonal antibody was used for each 
isotype These negative controls were used as blanks
ISOTYPE AHF1 1 AHF2 la AHF2 lb
IgA 0 07 I 0 09 0 10 0 07 1 0 06 | 0 06
IgM 0 08 | 0 15 0 18 0 05 | 0 03 | 0 07
IgGl 0 16 | 0 34 0 53 0 29 1 0 28 I 0 24IgG2a 0 17 | 0 58 0 17 0 21 | 0 17 1 0 15IgG2b 0 14 | 0 15 0 17 0 09 1 0 35 | 0 10IgG3 0 01 | 0 01 0 04 0 01 | 0 02 | 0 02k% 0 19 | 0 52 0 49 0 29 | 0 33 | 0 27A 0 08 | 0 10 0 11 0 03 | 0 03 | 0 03
AHF2 2 AHF2 3 AHF2 4
TABLE I I I  5
This Table shows the isotypes of cloned antibodies
| ANTIBODY I ISOTYPE | LIGHT CHAIN [
| AHF1 1 | IgGl/IgG2a 1 k 1| AHF2 la I IgG2a 1 k 1| AHF2 lb 1 IgGl 1 k |
| AHF2 2 1 IgGl 1 k 1| AHF2 3 1 IgG2b 1 k 1! AHF2 4 1 IkGI 1 k |
TABLE III 6
This table shows the absorbance for 100 jul of purified 
ascites at different concentrations m  an ELISA assay using 
plates coated with Koate A negative control using no first 
antibody was used as the blank
ANTIBODY
| CONCENTRATION | AHF1 1 I AHF2 la AHF2 lb |
| 20 jjg/ml | 0 30 | 0 98 1 27 |
1 2 jjg/ml | 0 10 | 0 37 1 09 |
| 200 ng/ml j 0 04 | 0 09 0 44 |
| 20 ng/ml | 0 1 o 0 09 |1 2 ng/ml ! 0 1 o 0 I
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TABLE III 7
Shows the concentration and binding (measured by absorbance 
m  an ELISA on plates coated with koate) of AHF1 1 A 
negative control which had no first antibody was used as the 
blank
| CONCENTRATION 1 ABSORBANCE |
| 10 mg/ml 1 o 014 |
| 1 mg/ml 1 0 067 |
| 100 Pg/ml 1 0 325 |
| 10 jJg/ml 1 0 455 |
| 1 JJ g/ml 1 0 424 || 100 ng/ml 1 o 275 |
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TABLE III 8
This table shows the binding (absorbance by ELISA on plates 
coated with Koate) of 3 antibody preparations at intervals 
during storage The antibodies were stored at a 
concentration of 200 Mg/ml at 4°C in Tris, pH 8 0 Negative 
controls (wells containing second antibody only) were used 
as blanks m  the assay
| TIME CONC | ANTIBODY
1 (weeks) (PK/ml) 1 AHF1 1 | AHF2 la | AHF2 lb |
200 | ND | ND | ND |
1 o 20 | 0 30 | 0 98 | 1 27 |
2 1 0 10 1 0 37 | 1 09 |
200 | 0 15 I 0 64 | 0 74 |
1 6 20 | 0 09 | 0 31 | 0 76 |
2 I 0 03 | 0 19 | 0 84 |
200 | 0 30 | 0 77 | 0 49 |
1 16 20 | 0 18 | 0 36 | 0 69 |
2 I ND | 0 11 I 0 55 |
200 | 0 34 | 0 91 | 0 51 |
1 26 20 | 0 22 | 0 84 | 0 80 |
2 I ND | 0 53 | 0 65 |
200 | 0 31 | 0 77 | 0 72 |
| 39 20 | 0 18 | 0 55 | 0 90 |
2 I ND | 0 35 | 0 75 |
ND= not determined
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TABLE I I I  9
Shows the binding of 2 antibodies (unpurified ascites) m  
ELISA against the 2 Koate fractions The Koate fractions 
were prepared by chromatography on Sepharose The K1 
fraction is the void volume fraction, and the K2 fraction is 
the first fraction after the void volume A negative 
control containing no first antibody was used as the blank
| DILUTION 
1 (X103)
AHF1 1 AHF2 lb |
K1 1 K2 Kl | K2 |
1 o 1 0 16 | 0 06 0 42 | 0 65 |
| 1 0 15 | 0 04 0 37 | 0 74 |
1 2 0 13 | 0 04 0 39 | 0 69 |
1 * 0 07 | 0 02 0 35 | 0 60 |
1 8 0 04 | 0 01 0 28 | 0 50 |
1 16 0 02 | 0 01 0 19 | 0 32 |
| 32 0 01 | 0 0 0 13 | 0 21 |
| 64 0 01 | 0 0 0 07 | 0 14 |
| 128 0 0 | 0 0 0 03 | 0 07 |
I 256 0 0 | 0 0 0 02 | 0 05 |
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TABLE III 10
This table shows the binding (measured as absorbance) of 6 
antibodies to different proteins by ELISA K0 is Koate, K1 
is the void volume fraction eluted after Koate was applied 
to a Sepharose column,and K2 is the first fraction following 
K1 during chromatography Fib is commercially purified 
fibrinogen, and BSA is commercially purified Bovine serum 
albumin A negative control, containing no first antibody 
was used as the blank
1 1 I ANTIBODY |
ANTIGEN
K0 1 K1 K2 | FIB BSA |
| AHF1 1 | 0 50 0 20 0 09 | 0 14 0 01 |
| AHF2 la | 0 55 0 24 0 24 | 0 29 0 01 |
| AHF2 lb | 0 90 0 37 0 70 | 1 03 0 01 |
| AHF2 2a j 0 95 0 39 0 71 | 1 04 0 01 |
| AHF2 3a | 0 87 0 22 0 61 | 0 87 0 00 |
I AHF2 4a | 0 70 0 17 0 47 | 0 74 0 01 |
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TABLE III 11
Shows the binding of antibodies to FVIIIR Ag isolated from 
different preparations using plates coated with 
anti-FVIIIR Ag Binding was determined using ELISA 
Peroxidase-labelled anti-FVIII antisera m  ELISA gave
readings that were too high to read for both the normal 
plasma and Koate A negative control using no first
antibody was used as the blank
I SAMPLE | AHF1 1 j AHF2 lb  |
1 NP | 0 02 | 0 06 |
1 NP (1/2) | 0 02 | 0 06 |
1 K0 1 0 05 1 0 27 [
1 KO (1/2) | 0 02 | 0 09 |
| DP j 0 02 | 0 04 |
1 s | 0 0 I 0 04 |
NP— Normal plasma DP« FVIII deficient plasma
S= Normal human Serum K0=* Koate
Figures m  parentheses are the dilution factors
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TABLE III 12
This table shows the effect of antibodies on the activated 
partial thromboplastin time (APTT), expressed as the change 
in the coagulation time Neat ascitic fluid was mixed 1 1 
with normal plasma diluted 1 in 10, and incubated for 3 hr 
at 37°C prior to the assay A control containing PBS only 
was used in each case
I ANTIBODY SIGMA | VERIFY |
| AHF1 1 + 55 | + 4 5  |
| AHF1 1 * + 30 1 ND |
| AHF2 la " 3 5  | ND |
| AHF2 lb - 5 5 1 ND |
I COMMERCIAL + 15 | ND |
* Purified antibody at a concentration of 0 1 mg/ml was 
mixed with normal plasma m  a ratio of 14, and 
incubated at 37°C for 4 hr prior to the assay Samples 
were then diluted 1 m  20 for the assay
SIGMA Normal plasma obtained from Sigma 
VERIFY Normal plasma obtained from Warner Lambert 
COMMERCIAL Anti-FVIII antibody obtained from Serotec 
ND Not determined
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TABLE III 13
This table shows the coagulation time in an activatd partial 
thromboplastin time (APTT) assay for the applied sample, the 
protein washed off the column and the eluted protein The 
column was CNBr-activated Sepharose (2 ml volume) containing 
approximately 7 mg of coupled antibody (AHF1 1)
I SAMPLE
DILUTION
FACTOR
COAGULATION 
TIME (SECS)
FVIII | 
C0NC (IU/ml) |
| Koate 50 75 0 84 |
| Washings 50 132 5 0 022 |
| Washings 20 58 ND |
| Washings 10 10 ND |
| Eluate 1 150 < 0 01 |
| Def plasma 1 150 < 0 01 |
Koate the applied Koate sample in 0 25 M CaCl2 
Washings the protein that did not bind to the column 
Eluate the protein eluted from the column with ethylene 
glycol-histidine buffer This protein bound to the 
imobilised antibody 
Def Plasma FVIII-deflcient plasma 
ND Not determined
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TABLE III 14
This table shows the binding of 5 antibodies to Koate, 
plasma, FVIII deficient plasma and normal serum by dot 
blotting Binding is rated as strong (+++), medium (++), 
weak (+), very weak/uncertain (+/-), and no binding (0) as 
compared to a control which had no first antibody
I ANTIBODY II KOATE
NORMAL
PLASMA
DEF
PLASMA SERUM |
| AHF1 1 | + + +/- +/- 1| AHF2 lb | +++ +++ +*H- 0 |
| AHF2 2 | +-H- +++ +++ 0 |
| AHF2 3 1 ++ ++ ++ 0 I! AHF2 4 | ++ ++ +4- 0 1
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TABLE I I I  15
This table shows the molecular weights of bands on western 
blots with 5 different antibodies 4 different preparations 
were used fibrinogen D+E fragments, fibrinogen chains, 
Koate reduced, and Koate unreduced All samples were run 
on SDS-PAGE (10%) and blotted onto nitrocellulose The blots 
were probed with alkaline phosphatase-labelled anti-mouse 
antibodies
1 MOLECULAR WEIGHT OF BANDS
1 FIBRINOGEN | KOATE I
1 ANTIBODY 1 D+E CHAINS 1 REDUCED 1 UNRED 1
1 88,000 1 121,000 11 AHF1 1 1 ND ND 1 
1
79,000 1 
!
112,000 1 
75,000 1
I AHF2 1 1 61,700 
1 48,100
64,400 1 
60,500 1
ND 1 
1
ND 1
1 109,000 1 11 AHF2 2 1 98,700 
1 94,600 
i 72,000
..... 1
1
1
ND 1 
1 
1
ND 1
1 109,000 1 11 98,700 1 11 AHF2 3 1 94,600 
1 72,000 
1 48,000
55,000 1 
1 
1
ND 1 
1 
1
ND 1
1 109,000 1 11 AHF2 4 1 98,700 
1 94,600
55,000 1
...... 1
ND 1 
1
ND 1
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TABLE III 16
This table summarises the binding of 5 monoclonal 
antibodies The table shows the antigen as well as the 
chain, and the amino acid residues they may bind to
1 ANTIBODY 1 1I ANTIGEN | CHAIN
| RESIDUE 
I NUMBERS
| SEQUENCE | 
I LENGTH |
| AHF1 1 1 1 | FVIII C |
1 1
light 1(1690-2332
1
1 642 |
| AHF2 1 1 1| fibrinogeni 
1 1
Aa 1| 1-78 
1
1 78 |
| AHF2 2 1 1 | Fibrinogeni
1 I
frag D I
1
1 —  I
| AHF2 3 1 1 | Fibrinogeni 
1 1
B(3 1| 54-122 
1.
1 68 |
| AHF2 4 1 1 | Fibrinogeni
1 1
B3
1| 134-461 
I
1 327 |
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FIG III.12
Shows samples after electrophoresis in a non-denaturing 1% (w/v)
agarose gel.
N: Normal plasma D: FVIII-deficient plasma
I: Partially purified FVIII (cryoethanol precipitate)
HI: Highly purified FVIII (8.2 IU/ml)
H2: Highly purified FVIII (10 IU/ml)
F: First PEG precipitate
R: remainder after PEG precipitation steps
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FIG III.13
Shows sample analysed by Laurell rocket electrophoresis using 
anti-vWF antisera in the gel.
Lane 1+2: Cryoethanol precipitate dissolved in Tris (1/4
dilution)
Lane 3: High purity FVIII after PEG precipitation (1/20) 
Lane 4: High purity FVIII after PEG precipitation (1/10)
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1 2  3 4
FIG 14
Shows samples analysed by Laurell rocket electrophoresis on a gel 
containing anti-vWF antisera
Lane 1 High purity FVIII, undluted
Lane 2 High purity FVIII, 1/10 dilution
Lane 3 High purity FVIII, 1/5
Lane 4 First PEG precipitate
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FIG III.15
Shows sample analysed by crossed immunoelectrophoresis. The first 
dimension was on a non-denaturing 1% (w/v) agarose gel. The
second dimension was into a gel containing anti-vWF antiserum in 
the first layer, and anti-human-serum anti-sera in the second 
layer.
D: FVIII-deficient plasma 
H: High purity FVIII
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FIG III.16 Showing the absorbances at 280nm and at 490nm in a FVIlIR ELiSA tor the 
different tractions after the elution of 1 bottle of highly purified cryoprecipitate
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FIG 111.17 Showing the absorbance at 28unm and 
the absorbance at 490nm in a FVIIIR ELISA for the 
different fractions after elution of 1 bottle of 
Koate from a sepharose Cl 6B column.
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FIG III.18 Showing the absorbance at 280nm of the different fractions of carboxymethylated
ABSORBANCE 
(280nm)
10,000  1 ,000  100 10 1 0 1 
ANTIBODY CONCENTRATION (jjg/ml)
FIG III 19 This figure shows the absorbance values for 
different concentrations of AHF1 1 The values were obtained 
from an ELISA assay using plates coated with Koate at 405nm
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FIG III.20
This figure shows the results of samples run on a 7. 
SDS-polyacrylamide gel, and stained with Coomassie blue.
1: Koate under non-reducing conditions 
2: Koate under reducing conditions 
3: Molecular weight markers (too faint to see)
(w/v)
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FIG III.21
Thios figure shows the results of electrophoresis on a 10% (w/v) 
SDS-Polyacrylamide gel, stained with a silver stain.
1: Molecular weight markers (the figures are the molecular 
weights in thousands)
2: Koate under reducing conditions 
3: Koate under non-reducing conditions
1 2
FIG III 22
This figure shows the results of samples electrophresed on a 7 5% 
(w/v) SDS-Polyacrylamide gel under non-reducing conditions, 
stained with Coomassie blue
1 D+E pool from plasmm digest of fibrinogen
2 X+Y pool from plasmm digest of fibrinogen
3 Fibrinogen
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FIG III 23
This figure shows the results of electrophoresis on a 10% (w/v)
SDS-Polyacrylamide gel, stained with a silver stain
1 Molecular weight markers (figures are the
molecular weights m  *000 1 s)
2 D+E pool of plasmm digest of fibrinogen
3 Fibrinogen under reducing conditions
All of the fibrinogen fragments, and chains produce a negative
image with silver staining, le they appear as clear bands, and can 
only be seen if the background is dark
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FIG III.24
This figure shows dot blots probed with different antibodies. The 
were then probed with an anti-mouse IgG labelled with alkaline 
phosphatase. The arrangement of the dots is the same on all the 
blots. The arrangement is shown for AHF2:3.
P: normal plasma
D: FVIII-deficient plasma
S: Normal serum
K: Koate
-ive: Control with no first antibody.
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FIG III 25
This figure compares the binding of 3 different antibodies to 
different preparations of fibrinogen m  a Western blot The
original SDS-PAGE was on a 10% (w/v) gel The figures are the
molecular weights of the markers m  '000*s and they indicate 
their position on the gel
1 D+E pool of the plasmin digest of fibrinogen
2 Fibrinogen under reducing conditions
101
FIG III 26
This figure shows binding of AHF2 1 to two different preparations 
of fibrinogen in a Western blot The sample were electrophoresed
on a 10% (w/v) SDS-PAGE system first The figures on the right
are the positions and molecular weights ( m  '000's) of the 
markers
1 D+E pools of the plasmm digest of fibrinogen
2 Fibrinogen under reducing conditions
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AHF2 1 AHF2 3
FIG III 27
This figure shows the binding of 2 antibodies to different 
fibrinogen preparations on a Western blot after electrophoresis on 
a 7 5% (w/v) SDS-PAGE system Samples were probed with alkaline 
phosphatase-labelled anti-mouse Ig The blot containing no first
antibody, l e negative control, (not shown) was clear
1 D+E plasmm digest pool of fibrinogen
2 X+Y plasmm digest pool of fibrinogen
3 Fibrinogen under non-reducing conditions
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FIG III 28
This figure shows the binding of AHF1 1 to different Koate 
preparations m  a Western blot Samples were electrophoresed on a 
10% (w/v) SDS-PAGE system The blots were probed with alkaline 
phosphatase-labelled anti-mouse IgG The figures on the right 
indicate the positions and molecular weights (m '000's) of the 
markers
1 Koate under non-reducing conditions
2 Koate under reducing conditions
3 Protein isolated from plasma after elution from a
column with immobilised AHF1 1- reducing conditions
4 Protein isolated from plasma after elution from a
column with immobilised AHF1 1- non-reducing
conditions
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Ill 3 DISCUSSION
FVIII was purified from plasma and different FVIII concentrates 
This purified FVIII was used to immunise mice for the production 
of monoclonal antibodies From these fusions 5 antibodies were 
cloned and characterised
III 3 1 PURIFICATION OF FVIII
Newman et al , (1971) reported a yield of 62% on their purificat­
ion of FVIII In the system used here the final yield was between
6 and 9% In run 1 the major problem was a low yield during the 
cryoethanol precipitation Only 35% of the FVIII was precipitated 
out Newman reported that the major factor m  obtaining a high 
yield from plasma was the ethanol concentration In run 2 there 
was a 79% yield of FVIII based on a theoretical FVIII 
concentration of 1 IU/ml m  the starting plasma During run 2, 
5 8%(v/v) ethanol was used while m  run 1 2 8%(v/v) ethanol was 
used Thus, increasing the ethanol concentration improved the 
yield of FVIII
The second major loss of FVIII occured during PEG precipitation 
The supernatant remaining after both PEG precipitations had very 
little FVIII activity (0 2% m  run 1) The first PEG precipitate 
showed between 1 and 2% of the starting activity Fig III 13 and 
III 14 confirm this by the absence of FVIIIR Ag m  a Laurell
rocket assay Thus, since the FVIII activity was not m  the first
PEG precipitate nor m  the supernatant, it must have been m  the 
second PEG precipitate Since only 6-9 % of the FVIII pro­
coagulant activity was present m  this second precipitate the 
remainder must have been FVIII that had lost its coagulation 
activity Agarose electrophresis (Fig III 12) showed a strongly 
staining band m  the high purity FVIII preparation This was 
identified as FVIIIR Ag by crossed Immunoelectrophoresis (Fig 
III 15), indicating that there was a high level of FVIII present, 
a large percentage of which was no longer active
There are at least two reasons for the loss of activity of FVIII 
Firstly, FVIII is very susceptible to proteolysis which inactiv­
ates it This may be prevented to some extent by using a protease 
inhibitor m  the separation procedure The second possibility is 
the formation of aggregates on storage as reported by Newman et
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al , (1971) and Fulcher et al , 1983) Agarose electrophoresis of 
the FVIII preparations (Fig III 12) shows a band at the sample 
application well that stains heavily in Coomassie blue This 
indicates that there are some proteins with molecular weights so 
large that they could not run into an agarose gel FVIII will 
electrophorese on an agarose gel The results of an ELISA assay 
(see Table III 11) also suggest that aggregate formation occurs 
It was found that AHF2 1 bound to FVIIIR Ag bound to immobilised 
anti-FVIII antibody However, this only occured if Koate was used 
as the source of FVIII Since AHF2 1 was found to be an anti- 
fibrinogen antibody, this would indicate that on storage, FVIIIR 
and fibrinogen formed a complex Newman et al , (1971) recommend 
altering many of the conditions of the purification eg ethanol 
concentration, pH, and PEG concentration if the plasma has been 
stored for more than 3 months These modifications cater for the 
alterations of the physiochemical properties of FVIII after it
aggregates The mam problem with purifying FVIII was obtaining
suitable sources of FVIII It proved to be very difficult to 
obtain fresh plasma for the purification procedure, due to the 
high demand for plasma Thus, "old" plasma had to be used despite 
the difficulties associated with this
As can be seen from Fig III 12, cryoethanol precipitation removed 
many of the low molecular weight proteins from plasma The two 
major contaminating proteins appear to be fibrinogen and albumin 
The first PEG precipitation appears to remove the fibrinogen, 
while the second PEG precipitation appears to precipitate the 
FVIII leaving the albumin in the supernatant The major contam­
inants m  the FVIII fraction appear to be immunoglobulins (these 
run m  the opposite direction to the other serum proteins) and
fibrinogen The higher levels of contaminants m  the higher
purity fraction was due to the concentration difference between it 
and the low purity FVIII The intermediate purity FVIII for run 1 
had a volume of about 100 ml, while the high purity fraction had 
a volume of about 4 ml, le it was 25 times more concentrated
Crossed Immunoelectrophoresis (Fig III 15) showed only 1 peak, 
representing FVIIIR There was no evidence of any other 
contaminants other than immunoglobulins Both PEG precipitated 
cryoprecipitate, and Koate, produced similar profiles when their 
absorbances were analysed at 280nm, following chromatography on a 
Sepharose column (see Fig III 16 and III 17) Both profiles show
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4 major peaks FVIII, which was found m  the first peak, was the 
smallest of these peaks The largest peak was probably 
fibrinogen This would indicate that cryoethanol precipitation of 
frozen plasma gave a higher purity than commercially available 
FVIII cryoprecipitate, since it only had only one band m
electrophoresis
III 3 2 MONOCLONAL ANTIBODY PRODUCTION
Successs m  the production of monoclonal antibodies can be
difficult to achieve There are many factors involved, and 
usually it is very difficult to isolate a particular reason for an 
unsuccessful fusion There is evidence to indicate that one of 
the most important variables is the operator An other major
problem is mycoplasma contamination This can cause a loss of 
antibody producing abilty in clones, inhibit growth of clones,
and also prevent successful fusions (Carroll and O'Kennedy, 1988)
8 fusions were performed, but 5 of these produced no viable 
clones The specific cause(s) for this are not known One fusion 
produced 5 positive clones which subsequently ceased to produce 
antibody There are 2 possible reasons for this The first is 
overgrowth by non-producing clones This was unlikely as all the 
clones were cloned twice Westerwoudt (1986) suggests that 
cessation of antibody production is seldom due to overgrowth by 
non-secreting cells, but is probably due to loss of the ability 
to produce antibody Since the newly formed hybridomas have double 
the normal amount of chromosomes, they shed half of their 
chromosomes before they stabilise It is probably a 50 50 chance 
whether they loose the chromosome responsible for producing the 
antibody or the chromosome responsible for growth m  culture 
Fusion AHF2 had a higher percentage of positive clones compared 
with AHF3 This difference was probably due to differences m  the 
immune response of the mice used for the 2 fusions
III 3 3 ANTIBODY ISOTYPE ANALYSIS
Isotype analysis indicated that none of the clones produced had 
only 1 particular isotype In particular AHF2 la and AHF2 lb were 
both from the second cloning of the same clone which was 
monoclonal, and yet AHF2 la is predominantly an IgG2a, while 
AHF2 lb is predommatly an IgGl
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The reason for these differences is due to the ability of a clone 
to change the isotype of its antibodies The constant region loci 
are arranged m  the following order
(51) u - 6 - y3- yr  Y2b~ Y2a~ e - a O')
This switching of isotypes can occur spontaneously m  culture 
The highest frequency of changes is to to their nearest neighbour 
on the 3’ end, but even larger shifts are possible (Kipps, 1985) 
Thus, shortly after cloning some of the cells m  AHF2 la probably 
changed the isotype of their secreted antibody from IgGl to IgG2a 
The frequency of this shift was estimated at 10"  ^by Kipps (1985) 
The reason that there is a mixture of isotypes m  most of the 
clones is that they were not screened for isotype during cloning 
It is possible to have clones that only produce one particular 
isotype if they are repeatedly cloned and screened for a 
particular isotype Only those with a single isotype would be 
expanded, and further cloned
III 3 4 ANTIBODY STABILITY
Table III 6 shows the binding of 3 antibodies to Koate at differnt 
concentrations Both AHF1 1 and AHF2 la have titres of 2 Pg/ml, 
even though they are against different antigens AHF2 lb has a 
titre closer to 200 ng/ml This would suggest that the change in 
isotype from IgGl to IgG2a also produced a lower titre Also the 
maximum absorbance that was obtained m  ELISA is reduced for 
AHF2 la Thus, the ability of the IgG2a to bind to the antigen is 
less than that of the IgGl
The binding of AHF1 1 to Koate m  ELISA was found to be repesented
by a bell shaped curve (Table III 7) Thus, at concentrations 
that are either above or below the optimum (1-10 pg/ml) there is a
reduction m  binding At low concentrations this occurs due to a
lack of antibody At higher concentrations this is probably due 
to stenc hindrance by other antibodies Thus, if the ratio of 
antibody to antigen is too high the antibody cannot bind properly 
This could be due to many antibody molecules partially binding, 
le only one "arm" of the antibody can bind The second "arm" 
cannot bind because all the antigen sites are occupied Since 
these antibodies are not properly bound they are probably washed 
off during the ELISA
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AHF1 1 and both AHF2 1 antibodies were stable on storage at 4°C 
After 9 months storage at a concentration of 200 jjg/ml there was 
only a slight reduction m  binding which occured during the first 
3-4 months of storage
III 3 5 ANTIBODY CHARACTERIZATION AHF1 1
AHF1 1 was found to be predominantly an IgG2a with a k light 
chain ELISA indicated that it preferentially bound to the void 
volume fraction (Kl) of Koate following Sepharose chromatography 
(see Table III 9) It did not bind to BSA and bound only slightly 
to fibrinogen and to the second Sepharose fraction (K2) of Koate 
(see Table III 10) This data would indicate that it bound to a 
large molecular weight component of Koate with a molecular weight 
of at least 4x10^ (this is the exclusion limit of Sepharose 6B) 
The obvious candidate for this was FVIII, as its molecular weight 
is several millions (Hoyer, 1981)
Western blotting using Koate as the antigen and AHF1 1 as the 
probe, showed that under non-reducing conditions AHF1 1 binds to 3 
bands of molecular weights 121,000, 112,000 and 75,000 Some
Koate preparations show bands at 103,000 and 61,900 Fay et al , 
(1982) report a molecular weight of 72,000 for FVIII Vehar et: 
al , (1984) report two pools of protein when FVIII is run under
non-reducing conditions One has a molecular weight of 80,000 
while the other has a range of proteins from 90,000 to 210,000 
This latter pool contains a number of bands, including single 
bands at 120,000 and 100,000 While the intact molecule has a 
molecular weight of 330,000, if thrombin is present m  the 
preparation the Mr 90,000, and Mr 80,000 bands are formed due to 
proteolysis During prolonged exposure to thrombin the Mr 90,000 
fragment is converted to Mr 50,000 and Mr 43,000 fragments The 
Mr 80,000 is similarly converted to a Mr 73,000 fragment (see Fig 
III 9) Thus, AHF1 1 probably binds to the thrombin degradation 
product of the Mr 80,000 fragment of FVIII Lollar et al , (1988) 
report a conversion of a Mr 76,000 band to a Mr 69,000 band after 
exposure of porcine FVIII to thrombin The Mr 61,900 fragment 
seen here is probably due to proteolysis of the FVIII, either by 
thrombin or some other proteasa
Under reducing conditions AHFl 1 was found to bind to two bands 
with molecular weights of 79,900 and 88,000 The larger apparent
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molecular weight during electrophoresis under reducing conditions, 
indicates the presence of internal disulphide bonds m  the 
protein Fay et al , (1982) found that FVIII forms a single band
with an apparent molecular weight of 100,000 under reducing
conditions
The Mr 90,000 fragment (heavy chain) is the N-terminal fragment of 
FVIII and the Mr 80,000 fragment (light chain) is the C-termmal 
fragment of FVIII Thus, it appears that AHF1 1 binds to the 
light chain only Since it also binds to the degraded form of the 
light chain its epitope must be on a region of 640 amino acids 
This region is between amino acids numbers 1,690 and 2,332
To confirm that the antibody AHF1 1 bound to FVIII CAg it was 
coupled to CNBr-activated Sepharose, and used to isolate its 
specific antigen The protein that was isolated had the same 
characteristics on SDS-PAGE, under both reducing and non-reducing 
conditions, as the FVIII m  Koate, and as the void volume 
fraction from Koate (Kl) However, this protein had no pro-
coagulant activity This is not surprising when glycine, pH 2 5
was used to elute it, as FVIII is very unstable below pH 6 
(Hoyer, 1981) When ethylene glycol-histidme, pH 6, was used 
to elute the FVIII there was still no activity This could be due 
to inactivation of the FVIII by thrombin or other proteases 
Certainly, western blotting of Koate showed a high proportion of 
low molecular weight le Mr 60,000-70,000 m  some preparations 
This is usually associated with inactivation of the protein The 
loss of procoagulant activity after passing Koate through the 
column (from 0 84 IU/ml to 0 02 IU/ml) is too large to be due to 
dilution, and thus, probably represents removal of FVIII C from 
the Koate due to binding to the immobilised antibody (see Table 
III 13)
ELISA was used to examine the possibility that AHF1 1 was binding 
to vWF rather than to FVIII CAg This would account for the 
absence of activity m  the protein fraction binding to immobilised 
AHFl 1 and eluted from the affinity column Plates coated with 
anti-vWF antibody showed no binding of AHFl 1 Similarly, plates 
coated with AHFl 1, showed no binding of vWF Also, the 
molecular weight of vWF, under non-reducing conditions, is so 
large (usually greater than 10 )^ that it has to be run on agarose 
Under reducing conditions it has an apparent molecular weight of
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195, 000-240, 000 (Hoyer, 1981) The Western blots show that 
AHF1 1 does not bind to a protein of this molecular weight
ELISA indicated that AHF1 1 had weak binding to both the K2 
fraction from Sepharose column chromatography, and to fibrinogen 
This could be due to a similar epitope on both proteins It is 
more likely that FVIII was a contaminant in both fibrinogen 
preparations Fig III 16 and III 17 show that the majority of vWF 
is in the K1 peak, but there is also some present in the K2 peak 
The molecular weights of monomeric FVIII C and vWF are 330,000 and
240,000 respectively These would coelute with fibrinogen which 
has a molecular weight of 340,000 There is also evidence that 
fibrinogen and FVIII form a complex (Fulcher et al , 1983) This 
was also found with AHF2 1 which binds to fibrinogen, and also 
binds strongly to K1 SDS-PAGE of the protein fraction isolated 
by affinity chromatography of normal plasma produced only 1 single 
band This band corresponded to FVIII There was no evidence of 
fibrinogen m  the eluted protein This would indicate that AHF1 1 
did not bind to any other proteins m  plasma
Inhibition studies on plasma coagulation show that AHF1 1 had very 
little effect on the coagulation time (3-5 sec increase m
coagulation time) This is to be expected as the FVIII C site was
localised to residues 338-362 on the heavy chain (Ware et al , 
1988) Binding of AHF1 1 to FVIII C may be hindered if the intact 
FVIII complex is used This is because the binding site for vWF to 
FVIII C is at residues 1,670 and 1,684 on FVIII C, which is 
adjacent to the binding site for AHF1 1 at residues 1,690 to
2,332 If AHF1 1 binds at the N-terminal of this fragment, its
binding to the complex would be inhibited due to masking of the 
epitope If it binds to the C-terminal of light chain it would be 
less likely that the epitope would be masked
III 3 6 ANTIBODY CHARACTERIZATION AHF2 1
Two different versions of AHF2 1 were cloned out One of these 
(AHF2 la) was an IgG2a with a k light chain, the other (AHF2 lb) 
was an IgGl with a k light chain Both these antibodies were 
stable on storage at a concentration of 200 pg/ml, at 4°C, for at 
least 9 months
Both antibodies bound to the K1 fraction, and the K2 fraction of 
Koate, and to fibrinogen Neither of them bound to BSA This
111
would indicate that they bound to fibrinogen, especially since 
they always gave a higher maximum absorbance than AHFl 1 (1 2 v’s 
0 3) Dot blotting showed that AHF2 1 did not bind to serum 
indicating that the only plasma proteins that it bound to were 
those that were consumed during coagulation
Western blot analysis using reduced fibrinogen on SDS-PAGE shows 
two bands of molecular weights 64,400 and 60,500 These correspond 
to the fibrinogen A & chain which has a molecular weight of 67,000 
(Doolittle, 1981) However, this consists of a population of
mixed molecular weights due to proteolysis of the chain
Western blotting from SDS-PAGE, using the pooled D and E 
fragments, showed that AHF2 1 bound to 2 bands of molecular
weights 61,700 and 48,000 The reported molecular weight of the D
fragment is between 80,000 and 90,000, while that of the E 
fragment is 50,000 Thus, it would appear that AHF2 1 binds to
the E fragment, as well as a Mr 61,700 band the identity of which 
is unknown Western blotting of fibrinogen and its early degrad­
ation products on 7 5% (w/v) SDS-PAGE show binding to fibrinogen, 
and the X, Y, D and E fragments
Since AHF2 1 binds to both the E fragment and the A a chain its
epitope can be narrowed to a region of 78 ammo acids This is the
portion of the A a chain that is present m  fragment E (see Table 
III 1) These ammo acids are Aa (1-78) Binding to X and Y 
would be expected since they contain both the D and E fragments 
Binding to the D fragment could be due to a similar epitope on 
both fragments, or due to pieces of the E fragment remaining on 
the D fragment during digestion
III 3 7 ANTIBODY CHARACTERIZATION AHF2 2
AHF2 2 was found to be an IgGl with a k light chain It was found 
to bind strongly to Koate fraction K2 and fibrinogen It 
demonstrated weaker binding to Kl, and it did not bind to BSA 
Dot blotting showed that AHF2 2 did not bind to serum, indicating 
that it must bind to a protein that is consumed during 
coagulation Since it also binds to FVIII deficient plasma, it
cannot bind to FVIII Thus, it was probably an anti-fibrinogen
antibody
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Western blotting of reduced fibrinogen on SDS-PAGE showed no 
binding of AHF2 2 to any of the chains This would indicate that 
AHF2 2 only recognises the native protein Thus, its binding 
site probably incorporates more than 1 of the chains
Western blotting of the plasmm degradation products D and E of 
fibrinogen after SDS-PAGE show 4 bands when probed with AHF2 2 
These bands have molecular weights of 109,000, 98,700, 94,600,
and 72,000 The 3 larger molecular weight bands are probably D 
fragments, which are a heterogenous group of polypeptides 
(Haverkate et al , 1979) Western blotting of fibrinogen and its 
early degradation producs on 7 5% (w/v) SDS-PAGE shows binding by 
AHF2 2 to bands that correspond to fibrinogen, and fibrinogen 
fragments X, Y and D
Thus, AHF2 2 binds to the D fragment of fibrinogen Binding to X 
and Y fragments would be expected since they both contain the D 
fragment It only recognises the native protein
III 3 8 ANTIBODY CHARACTERIZATION AHF2 3
AHF2 3 was found to be an IgG2b with a k light chain It was 
found to bind strongly to fibrinogen and the K2 fraction from 
Koate It had weaker binding to Kl, and did not bind to BSA Dot 
blotting showed that it bound to normal plasma and FVIII deficient 
plasma Thus, it appeared to bind to fibrinogen
Western blotting of reduced fibrinogen on SDS-PAGE showed that 
AHF2 3 bound to 1 fragment of molecular weight 55,000 This is 
obviously the Bf3 chain which has a reported molecular weight of
56.000 (Doolittle, 1981a)
Western blotting with the plasmin degradation fragments of 
fibrinogen showed that it bound to 5 fragments These had 
molecular weights of 109,000, 98,700, 94,600, 72,000, and
48.000 The 3 high molecular weight fragments are probably the D 
fragments, while the low molecular weight fragment is probably the 
E fragment
Since AHF2 3 binds to the E fragment and to the Bg chain its 
epitope must be in a region of 68 ammo acids (see Table III 1) 
Thus, its epitope is located at Bg (54-122)
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Some of the antibodies bind to both the D and E fragments This 
could be due to a similar epitope on both fragments It could also 
be due to pieces of the E fragment remaining attatched to the D 
fragment during digestion
III 3 9 ANTIBODY CHARACTERIZATION AHF2 4
AHF2 4 was found to be an IgGl with a k light chain It bound 
strongly to fibrinogen and Koate fraction K2 in ELISA It bound 
weakly to fraction K1 and did not bind to BSA Dot blotting 
showed that it bound to normal plasma and FVIII deficient plasma 
It did not bind to serum Thus, it was probably directed against 
fibrinogen
Western blotting of reduced fibrinogen on SDS-PAGE with AHF2 4 
showed binding to one band with a molecular weight of 55,000 
This band corresponds to the Bg chain
Western blot analysis of the plasmm degradation products of 
fibrinogen on SDS-PAGE showed binding to 3 bands with molecular 
weights of 109,000, 98,700 and 94,600 These probably make up the 
D fragments of fibrinogen
Since AHF2 4 binds to the Bg chain of the D fragment the epitope 
must be a 327 ammo acid fragment located at B 8(134-461)
III 3 10 CONCLUSION
Table III 16 summarises the details of the 5 antibodies that were 
characterised There are many uses for these antibodies The two 
mam applications for monoclonal antibodies to blood factors are 
m  analysis and purification
In recent years there has been a growing awareness of the hazards 
of using replacement therapy for factor deficient disorders, 
especially haemophilia The most recently identified risk is from 
HIV infected plasma This problem has reached crisis point as 
many patients are at risk from infected plasma (Fnedland and 
Klem, 1987) Haemophiliacs are a very high risk group due to the 
necessity of receiving multiple blood transfusions A recent 
survey showed that all commercially available FVIII deficient 
plasma (usually obtained from haemophiliacs) was HIV positive 
(Jones et al , 1985) One solution to this problem is to use
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genetically engineered FVIII While this has been produced and is 
due for routine use m  the next few years, indications are that 
it will be much more expensive than the FVIII concentrates 
currently m  use In addition, patients with FVIII inhibitors 
have to be treated with animal FVIII preparations
These problems can be overcome by using either human or animal 
FVIII concentrates The risk of infection with these preparations 
can be eliminated by using heat treated concentrates which are 
then affinity purified This results m  a very high purity FVIII 
preparation with minimum risk of infection (Ronneberger, 1986)
It also eliminates many of the other unwanted proteins found m  
FVIII concentrates These contaminating proteins can cause risks 
as the recipient may produce antibodies against them This can 
then result m  the patient developing a second, acquired factor 
deficiency A commercial concentrate such as Koate is almost 90% 
fibrinogen Suitable monoclonal antibodies could remove inactive 
FVIII as well as other contaminants, which would greatly reduce 
the amount of protein that has to be administered to achieve the 
same results
The problem with using AHF1 1 for affinity purifying FVIII is that 
it binds to the light chain rather than to the heavy chain which 
contains the active site But, AHF1 1 will still remove the 
complete FVIII C molecule, which is probably the best way to 
administer it A more frequently used method for the affinity 
purification of FVIII is to use an anti-vWF antibody Since it 
removes vWF it will also remove FVIII C This has the added 
advantage that vWF stabilises FVIII C, and protects it from 
proteolysis However, when a pure source of FVIII is necessary the 
use of an anti-FVIII CAg antibody is faster and less expensive for 
isolation
A second use for AHF1 1 is m  the assay of FVIII C levels The 
problem that must be overcome with any assay for FVIII C is that 
it's levels m  normal plasma are estimated to be between 50 and 
200 ng/ml (Hoyer, 1981, Bloom, 1983) If a 100 jjl sample is used 
for the assay, a very sensitive assay would be necessary This 
would be at the limit of sensitivity for conventional ELISA This 
can be overcome by using RadioImmunoAssay (RIA) or some other 
amplification immunoassay system These assays would not replace 
the coagulation assay, since this measures the amount of active
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FVIII present, which is the important value However, they can
be used to determine if a FVIII deficiency is quantitative or 
qualitative It may also have a function m  carrier detection, 
since carriers of haemophilia appear to have a lower level of 
FVIII C than the normal population (Hoyer, 1981)
AHF1 1 would also be very useful in studying the fuctions of 
FVIII Many of the active sites on FVIII and vWF were located by 
using monoclonal antibodies eg the localisation of the coagulation 
site (Ware et al , 1988) and the localisation of the vWF binding
site on FVIII C (Foster et al , 1988)
There is no major role for anti-fibrinogen antibodies in the
purification of fibrinogen This is because fibrinogen is present 
m  high concentrations m  plasma and it is relatively easy to 
purify The mam use for these antibodies is m  assaying plasma 
levels of fibrinogen and fibrm degradation products Kruskal et 
al , (1987) showed that there was a difference between the levels 
of fibrm degradation products m  patients with stable angina and 
those with unstable angina and^  acute myocardial infarction There 
results show that m  the latter there is an increase m  the fibrm 
degradation products indicating a fibrinolytic process They 
suggest that this fibrinolysis may be involved in the conversion 
of unstable angina to acute myocardial infarction, and that 
anti-fibrinolytic agents may prevent this conversion Thus, 
routine screening of patients with angma for level of fibrinogen 
and fibrin degradation products would enable a differential 
diagnosis of stable and unstable angma, and might possibly 
prevent the development of acute myocardial infarction by early 
treatment with anti-fibrinolytic agents To be effective for this 
the antibodies would have to be specific for either the D monomer 
(derived from fibrinogen) or the D dimer (derived from cross- 
linked fibrin)
Fibrm specific antibodies also have a potential use m  locating 
fibrm deposits m  the vascular network Once detected, 
fibrinolytic therapy can be commenced, thereby reducing the risk 
of a stroke Brown et al , (1988) showed that solid tumours 
convert fibrinogen to fibrm which is necessary for their growth 
and proliferation Labelled monoclonal antibodies to fibrm could 
also be used to detect these tumours m  vivo There is also a 
possible role for anti-FVIII CAg antibodies m  tumour detection
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Cancer of FVIII CAg producing cells such as hepatocytes and spleen 
cells (Wion et al , 1985), could also be detected with labelled 
anti-FVIII CAg antibodies
Further work necessary for the total characterization of these 
antibodies would involve the use of enzyme digests of FVIII C to 
determine specifically the binding site of AHF1 1 It would also 
be necessary to develop a suitable elution system to affinity
purify active FVIII These require a large amount of relatively
pure, and fresh FVIII, or large amounts of fresh plasma Both of 
these are expensive, and difficult to obtain Further work on the 
anti-fibrinogen antibodies is necessary to determine whether or 
not they are specific for fibrin or fibrinogen degradation 
products
The antibodies will also be used m  the development of an
adsorptive stripping voltametnc system for the study and analysis 
of FVIII and fibrinogen (Smyth et al , 1988, Rodriguez-Flores et 
al , 1988a, 1988b) One of the benefits of this system is that it 
is thought that an immunoassay using an adsorptive stripping 
voltametnc technique as the amplification step would be more
s^nsitve than ELISA and RIA
{
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SECTION IV 
PRODUCTION OF ANTIBODIES 
TO DIAZEPAM
IV 1
]
INTRODUCTION
IV 1 1 HAPTENS
The ability of the immune system to respond to antigens depends on 
their 'antigenicity' The antigenicity of a substance depends on 
a number of different properties, one of the most important being 
its size Molecules-with a molecular weight of 1,000, or less, 
are poor antigens (Erlanger, 1980), and they are called haptens 
Haptens are usually conjugated to carrier proteins before 
immunisation If the carrier protein is sufficiently antigenic 
some of the antibodies will be directed against the hapten portion 
of the conjugate since it should form the major epitope Examples 
of commonly used haptens are peptide hormones, neurotransmitters, 
and drugs Often when antibodies to specific portions of a
molecule are required it is easier to isolate the fragment, 
conjugate it to a carrier, and use this as the antigen
IV 1 2 CONJUGATION REACTIONS
The nature of the coupling reaction depends on available reactive 
groups on the protein and on the hapten There are 5 major 
reactive groups on proteins E-ammo groups (lysine residues) , 
a-ammo groups, phenolic hydroxyl groups (tyrosine residues), 
sulfhydryl groups (cysteme residues) , and imidazole groups 
(histidine residues) It is important to choose a reactive group 
on the protein that is present m  sufficient quantity In BSA 
there are 59 e -ammo groups, 7 sulfhydryl groups and only 1 
cc-amino group Thus, the e-ammo groups would be better suited 
to conjugate formation than the sulfhydryl groups (Erlanger, 
1973)
The mam criterion m  choosing a conjugation reaction will be the 
available reactive groups on the hapten The 3 mam reactive 
groups on haptens that are used for conjugation are carboxyl
groups, ammo groups, and hydroxyl groups (Erlanger, 1973) 
When there are no suitable reactive groups on a hapten they have 
to be inserted chemically
Landsteiner (1945) considered that 10 haptenic groups per molecule 
of BSA was optimal for antibody formation while Dixon (1982) 
considered an 18 to 1 molar ratio of hapten to protein to be
optimum Another consideration is the orientation and
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confonnation of the hapten Since antibodies are very specific
for the antigen, eg antidigoxm antibodies can distinguish between 
digoxin (OH group on C12) and digitoxin (H on C12) (Butler, 
1973), the part of the molecule that the antibody has access to 
must be carefully selected Sometimes a spacer arm (a chain of
carbon atoms) between the hapten and the carrier can improve the 
antigenicity of the hapten, and the subsequent specificity of the 
antibodies, by improving access to the molecule
IV 1 3 DIAZEPAM
Pharmacologically diazepam (Valium) is a tranquillizer (also 
termed antineurotic or anxiolytic drugs) Chemically, it is a 
benzodiazepine Benzodiazepines are the "classic" tranquillizers, 
thus, many other compounds with similar effects to diazepam are 
refered to as benzodiazepines even though their chemical structure 
would not justify this Hence the term "benzodiazepine" is used to
refer to a class of compounds rather than to a chemical structure
\
The true benzodiazepine consists of a fused bicyclic nucleus (see 
fig IV 1) This nucleus consists of a benzene ring and a* 1 
membered, partially unsaturated heterocyclic ring, with 2 nitrogen 
atoms in the 1,4 positions (1,4-benzodiazepmes) There is also 
an aromatic ring (usually phenyl) substituted m  the 5 position 
Compounds with only one nitrogen, m  either the 1 or 4 position, 
are technically benzazepmes but have similar properties to the 
benzodiazepines Fig IV 2 shows the structures of the benzodiaze­
pines used for immunisation, and characterisation studies
Hypnotics, sedatives and tranquillizers are very closely related 
groups of drugs Hypnotics act by producing sleep directly, while 
sedatives relax the patient which will enable them to fall asleep 
Tranqillisers are used to produce a calming effect m  patients 
that are anxious or tense Benzodiazepines' anticonvulsant 
activity is used m  the prophylactic treatment of epilepsy They 
also have central muscle relaxant effects which are used to treat 
status epilepticus and tetanus (Pharmaceutical Codex) Benzo­
diazepines also have strong behavioral effects, they have a 
calming effect in anxious states, and they have sedative effects 
As tranquillizers, the benzodiazepines have no anti-psychotic 
activity
I
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The toxicity of benzodiazepines is very low The major problem 
associated with the chronic use of diazepam is the strong 
psychological dependence that can develop, and the withdrawal 
symptoms that can follow the cessation of long term therapy (Nutt, 
1986) There are also a few very rare cases of hepatotoxicity to 
diazepam Certain severely disturbed patients become aggressive 
when administered diazepam (Pharmaceutical Codex) In acute 
exposure to diazepam, as in an overdose, there is little risk to 
the patient as a lot of diazepam has to be consumed before any 
serious problems arise
IV 1 4 GABAergic NERVES
Within the nervous system nerves do not make electrical contact 
with each other, instead there is a small gap, the synaptic 
junction, between each nerve fibre Chemicals called neuro- 
transmitters are used to transmit signals across the synaptic 
junction Neurotransmitters bind to specific receptors on both 
the pre- and postsynaptic membranes If the binding of the neuro- 
transmitter to its receptor causes a depolarization, resulting m  
an action potential, the presynaptic nerve is known as as 
excitatory nerve Conversely, if a hyperpolanzation is caused, 
stabilising the membrane, then the presynaptic nerve is termed an 
inhibitory nerve A postsynaptic nerve would usually have a 
number of different afferent (incoming) nerves Some of these may 
be inhibitory and others may be excitatory The transmission of 
an action potential m  the postsynaptic nerve depends on the sum 
of the depolarizing and hyperpolanzmg signals Adrenalin and 
acetylcholine are both excitatory neurotransmitters The amino 
acid, y -Ammobutync acid (GABA) is an inhibitory neurotrans­
mitter
Chemicals that bind to a receptor and mimic the response due to 
binding of the neurotransmitter are termed agonists Binding of 
agonist produces a response m  the neuron Antagonists bind to the 
receptor but they have no effect other than preventing an agonist 
from binding Partial agonists bind to a receptor and initially 
cause a response which is short lived Subsequently they remain 
bound to the receptor and act as antagonists
Localisation studies indicated that GABAergic nerves are found m  
Purkinje fibres of the cerebellum, pyramidal cells of the cerebral
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cortex and hippocampus, and the olfactory bulb GABA is the major 
inhibitory neurotransmitter in the brain with about 30% of the 
synapses being GABAergic (Haefely, 1983) GABA has two different 
receptors The main one is coupled to a chloride channel m  the 
membrane (Bowery, 1982) Activation of these receptors increases 
the influx of chloride ions through the membrane of the cell In 
most neurons this flow of chloride ions is inwards, causing a 
hyperpolarisation In certain neurons there is an efflux of 
chloride ions causing a depolarisation This depolarisation is 
inhibitory because it reduces the amplitude of the action 
potential since it starts from a smaller potential (Haefely,
1983) The second type of receptor is linked to a calcium channel 
where it decreases the permeability to calcium thus causing an 
inhibition (Bowery, 1982)
Receptor studies have confirmed the differences in the 2 GABA 
receptors The chloride channel-linked receptors are inhibited by 
bicucullme, while the calcium channel-linked receptors are 
bicuculline-insensitive The bicucullme-insensitive receptors 
bind only a few of the GABA analogues In particular they bind 
baclofen, while the bicucullme-sensitive receptors do not The 
bicucullme-sensitive, chloride channel-linked receptors were 
termed GABAa while the bicucullme-insensitive, calcium channel- 
linked receptors were called GABAb (Bowery, 1982)
IV 1 5 GABA AND BENZODIAZEPINES
In 1967 Schmidt et al , showed that diazepam enhanced presynaptic 
inhibition Haefely et al , (1975) and Costa et al , (1975) showed 
that this was probably due to an enhancement of GABAergic 
inhibition Subsequently it was found that GABAergic neurons 
throughout the bram responded to benzodiazepines GABAergic 
neurons m  the spmal cord, the dorsal column nuclei,- the 
cerebellar cortex and the hippocampal pyramidal cells all showed 
enhanced activity in the presence of benzodiazepines This 
response was also found to the application of exogenous GABA 
(Haefely, 1983)
Adenosine, which is a putative inhibitory neurotransmitter found 
m  purinergic nerves was also found to be effected by 
benzodiazepines The uptake of adenosine into cells appears to be 
inhibited This effectively increases the concentration of 
adenosine at purmergic synapses and thereby increasing the
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inhibition due to the adenosine Certain benzodiazepine 
antagonists also act as weak adenosine antagonists (Phillis and 
O' Regan, 1988)
GABAergic nerves provide a control of the activity of neurons 
They prevent neurons from becoming overstimulated Thus, in 
certain pathological states such as epilepsy or anxiety, part of 
the GABAergic system does not function properly Benzodiazepines 
act by increasing the activity of the GABAergic nerves thereby 
overcoming the defect The role of adenosine is probably 
secondary to that of GABA
IV 1 6 THE BENZODIAZEPINE RECEPTORS
Braestrup and Squires (1977) and Mohler and Okada (1977) 
identified high affinity binding sites m  the brain for
-3JH-diazepam These binding sites were considered to be specific 
receptors Subsequently, there was a search for an endogenous 
ligand for the benzodiazepine receptor based on the idea that the 
existence of a receptor also indicates the existence of an 
endogenous ligand
Using %-flumtrazepam, which covalently binds to the benzodiaze­
pine receptor m  the presence of uv light, it has been possible 
to localise and purify the benzodiazepine receptor (Mohler et al , 
1980, Sigel et al , 1983) This established a direct relationship 
between the GABA and benzodiazepine receptors
Various ligands with affinity for the benzodiazepine receptor were 
synthesised CL 218872, a tnazolopyridazme, and ethyl-g-carbo- 
lme-3-carboxylate (g-CCE) both displaced 3H-flunitrazepam from 
the receptor with a high potency These compounds differed from 
the benzodiazepines m  many respects g-CCE has effects directly 
opposite to those of the benzodiazepines g-CCE not only antagon­
ises the anticonvulsant effects of diazepam, it also has procon- 
vulsant effects when bicuculline is used to induce seizures g-CCE 
antagonises the anxiolytic actions of diazepam and also has 
anxiogenic activity In cultured mouse spinal cord cells diazepam 
produces an increase in the opening of chloride channels by GABA, 
while g-CCE produces a decrease
Initially it was thought that since g-CCE opposes the actions of 
diazepam it must be an "antagonist" and diazepam an "agonist11 for
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the benzodiazepine receptor However, the problem with this is 
that both produce a response on binding to the receptor So the 
question arose as to which was the agonist and which was the 
antagonist The difficulty was overcome by considering diazepam 
to be an agonist and B -CCE an "inverse agonist" Other 
g-carboline derivatives had similar effects on the benzodiazepine 
receptor In particular methyl- B- carbolme-3-carboxylate (MCC) 
and methyl 6,7-dimethoxy-4- ethyl-g-carboline-3-carboxylate (DMCM) 
both induced seizures when injected into mice Ro 15-1788 (an 
lmidazodiazepme) has no intrinsic activity at the benzodiazepine 
receptor, but antagonises the anticonvulsant activity of the 
benzodiazepines and the convulsant activity of both MCC and DMCM 
Thus, it is a true antagonist
The concept of inverse agonists has caused problems m  the world 
of pharmacology One way of conceptualising is to use the model 
proposed by Ehlert (1986) He uses a two state model for the 
benzodiazepine-GABA receptor complex similar to that proposed by 
Chin and Rosenberg, (1983) The open state is associated with an 
open chloride channel, and the closed state is associated with a 
closed chloride channel Both GABA and diazepam have a higher 
affinity for the open state GABA enhances the binding of
diazepam, which m  turn enhances the binding of GABA This is
positive cooperativity The binding of GABA to the open state
causes the chloride channel to remain open Benzodiazepines have 
no effect on their own, as their affinity for the open channel is 
low in the absence of GABA The ligands with a higher affinity 
for the closed state allosterically inhibit the binding of GABA 
This is termed negative cooperativity An antagonist, such as Ro 
15-1788 (Fluazepil) would have equal affmty for both the open and 
closed states and act by blocking both the positive and negative 
cooperativity
Recent work has indicated that there may be 2 distinct receptor 
types for benzodiazepines, with different biological distrib­
utions The second class of receptors is mainly distributed
outside the CNS, although a few localised areas m  the CNS also
have these binding sites Ro 5-4864 does not bind to the CNS 
benzodiazepine receptor, but it has a high affinity for the
peripheral receptor Ro 15-1788 has a high affinity for the CNS 
receptors, but does not bind to the peripheral receptors At 
present there is no known function attributed to these peripheral
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receptors, and thus, they may be acceptors rather than receptors 
(Haefely, 1983)
After the success m  locating endogenous ligands for the opiate 
receptor, many researchers tried to locate an endogenous ligand 
for the benzodiazepine receptor Many compounds were isolated and 
a lot of interest was focused on 6-carbolmes Those that had the 
highest affinity for the benzodiazepine receptors were unlikely to 
occur m  the CNS, and those that were likely to occur in the CNS 
had only weak affinity for the receptor (Haefely, 1983) The 
most likely candidate for endogenous receptor is a polypeptide 
called Diazepam Binding Inhibitor (DBI), described by Guidotti et 
al , (1983) The binding site was localised to an 18 amino acid 
fragment called ODN (Ferrero et al , 1984) This peptide has an
anxiogenic effect Endogenous ligands may play an important role 
m  modulating GABA neurons and thereby enhancing anxiety Benzo­
diazepines may act by both antagonising the actions of ODN and 
enhancing the actions of GABA (Cooper, 1985)
IV 1 7 ANTIBODIES TO DIAZEPAM
*
The work presented here involved synthesising diazepam conjugates 
to be used m  the production of antibodies to diazepam
Antibodies to diazepam have a number of useful functions The
most important is for use m  assaying diazepam levels m  
biological fluids Diazepam is reputed to be one of the most 
prescribed drugs m  the world (Nutt, 1986) In one survey it was 
the fifth most common drug found m  the urine of Los Angeles
County probationers (Budd and Walkm, 1980) HPLC and GLC 
techniques, while very sensitive, are costly and time consuming 
Both these problems can be overcome by using immunoassays These 
can be m  the form of Enzyme Multiplied Immunoassay (EMIT) (Budd 
and Walkm, 1980) or ELISA These techniques require little 
specialised equipment, are very sensitive, can easily assay a
large number of samples, and lend themselves to automation Radio 
ImmunoAssay (RIA) (Dixon, 1982) and voltametnc analysis of 
diazepam are other useful roles for antisera to diazepam Another 
use for antibodies to diazepam is m  the production of 
antndiotypic antibodies (Briles and Kearney, 1985) These 
antibodies bind to the recognition site of the anti-diazepam 
antibodies Since there is a limit to the number of possible 
conformations of proteins that will bind the same compound, the 
binding site on an anti-diazepam antibody must be similar to the
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binding site on the diazepam receptor Thus, an antndiotypic 
antibody would probably recognise the benzodiazepine receptor and 
could then be used for studying the receptor
Diazepam is a much abused drug and consequently there are many 
cases of overdose Antibodies have been shown to be very 
effective m  reducing the plasma levels of many drugs m  overdose 
situations eg with digoxm overdose (Butler, et al , 1973) They 
can often be better than using a receptor antagonist which may 
precipitate a life threatening withdrawl
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FIG IV 1 Showing the general structure of benzodiazepines, and 
numbering system of the ring structure The R groups 
the usual site for functional groups
the
indicate
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FIG IV.2 Showing the structures of some benzodiazepines
CH.
Diazepam (Ro 5-2807)
Ro 7-3551
Ro 5-2180
Ro 20-9749
N NHCOCH,
NH,
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Ro 20-9748
FIG IV 3 Showing the synthesis of the diazepam derivative used for 
conjugation to BSA
CH.
Ro 7-355
MeOH
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IV 2 RESULTS
A diazepam-BSA conjugate was synthesised and used for producing 
antibody-rich ascites fluid in mice This ascites fluid was 
purified and the binding of the antibodies to benzodiazepines 
studied
IV 2 1 CONJUGATE SYNTHESIS
The proposed synthetic pathway for the diazepam hapten is shown m  
Fig IV 3 This inserts a -NH2 group onto the 5-phenyl group of
the basic benzodiazepine molecule A 4-hydroxyphenyl derivative 
(Ro 7-3351) was used, as this directs the £-ammoacetanilide 
group to the 3-phenyl position This ammo group was then used 
for a dia?o coupling to BSA
When the method of Earley et al , (1979) was used only 31 mg of 
crystals were obtained when 400 mg of Ro 7-3551 were used This 
was a very low yield, representing between 5% and 10% yield Its 
IR spectrum (Fig IV 4) contains a broad band from 1660 to 1690 
/cm This is the expected band for 2 C=0 bonds There was
insufficient product to proceed with the next stage of the 
reaction
Fryers revised method was then used This combined the synthesis 
of Ro 20-9749 and Ro 20-9748 500 mg of Ro 7-3351 was used and
1 25 g of crystals were obtained, which corresponded to impure Ro 
20-9749 This was then converted to Ro 20-9748 by removal of one 
of the C=0 groups and was purified using Flonsil chromatography 
Crystallization from THF/ethanol gave 40 mg, and recrystallization 
gave 24 mg This was a very low yield (about 5%) The melting 
point was 254-257°C, which is lower than the expected 265-268°C 
The IR spectrum (Fig IV 5) shows a broad band at 3350-3450/cm 
which would be expected for the 2 -NH2 groups, and a narrow band 
at 1670/cm which would be expected for a single C=0 group The 
yield from this reaction was too low for synthesis of the 
conjugate
At this stage a sample of pure Ro 20-9748 was made available by 
Hoffman La Roche and was used for the conjugate synthesis 20 mg 
of this was coupled to 200 mg of BSA Attempts were made to couple 
Ro 20-9748 to fibrinogen by the same method, but m  each case an
msolube complex was formed Similarly, an attempt to couple Ro 
20-9748 to Keyhole Limpet hemocyamn (KLH) failed due to the 
inability to dissolve the KLH in the coupling buffer (pH 9) 
Consequently the diazepam-BSA conjugate was used for both immun­
isation and screening
XV 2 2 ASCITES PRODUCTION
A number of mice were immunised and were tapped to remove their 
ascitic fluid Eventually the surviving mice were killed and 
their ascitic fluid was collected The ascitic fluid was pooled 
and purified by ammonium sulphate precipitation
A total of 15 ml of ascitic fluid was obtained, with a total 
protein content of 387 mg (micro Bradford assay) The purified 
ascitic fluid had a total protein content of 69 mg and a 
concentration of 15 mg/ml The binding of the antisera to the 
diazepam conjugate was studied by ELISA (see Table IV 1)
The maximum binding for pure IgG was at 15 Pg/ml and the titre was 
between 1 5 Pg/ml and 150 ng/ml The maximum binding for the 
crude ascites was at a 1/100 dilution, and the titre was at 
1/10,000
IV 2 3 CHARACTERISATION OF POLYCLONAL ANTIBODIES
To look at the role of binding of the antibody to BSA m  the 
ELISA, ascitic fluid diluted m  PBS-Tween was compared to that 
diluted in PBS-BSA (1% w/v)-Tween (see Table IV 2)
As can be seen from Table IV 2 the titre of the ascitic fluid 
diluted m  PBS-Tween was between 1/50,000 and 1/100,000 However, 
the titre of the ascites when BSA was used in the diluent was 
between 1/5,000 and 1/10,000 This 10 fold drop m  titre when BSA 
was used m  the diluent was due to the removal of anti-BSA 
antibodies
For further studies it was necessary to purify the antibodies 
further This was achieved by using 2 CNBr-activated columns The 
first had BSA coupled to it and the second had the BSA- conjugate 
coupled to it The purified antibody was passed through the first 
column which removed anti-BSA antibodies Unbound antibody from 
this was then passed through the second column which bound the 
anti-diazepam antibodies These were eluted from the column with
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glycine buffer pH 2 9 (see section II 11)
A total of 4 mg of purified antibody was applied to the column and 
0 97 mg was eluted This represented a 25% yield The eluted 
antibody had a low titre (absorbance of 0 37 at 130 pg/ml) This 
purified antibody was used to examine binding to different 
diazepam derivatives
Derivatives of diazepam were dissolved in DMSQ and used m  a 
competitive ELISA to determine their ability to compete with the 
diazepam-BSA conjugate for binding to the antibodies The amount 
of antibody that bound was determined by ELISA (see Table IV 3)
Table IV 3 summarises the results of the competitive ELISA 
Conjugate, BSA, and different benzodiazepines were added to a 
microtitre plated coated with conjugate These competed with the 
immobilised conjugate for binding of the antibody It was found 
that the conjugate completly eliminated binding of the antibody to 
the immobilised conjugate, while BSA eliminated most of the 
binding Binding to Ro 20-9748 could not be determined as it came 
out of solution when the DMSO solution was diluted m  PBS-Tween 
Ro 5-2180 and Ro 5-3453 had no effect on the binding of the 
antibodies to the immobilised conjugate Ro 5-2807 reduced the 
binding of the antibody to the immobilised conjugate by a small 
amount at 300 jjg/ml, but not at the lower concentrations Ro 
7-3351 reduced binding to the immobilised antibody at all 
concentrations
IV 2 4 MONOCLONAL ANTIBODY PRODUCTION
The diazepam conjugate was used to immunise mice for use in the 
production of monoclonal antibodies 14 fusions were performed 
with spleens from mice immunised with the diazepam conjugate In 
8 of these fusions there was no growth of clones In one of these 
the lack of growth was probably due to a poor batch of serum that 
was found to have poor growth stimulating effects 1 fusion 
produced approximately 500 clones all of which were negative, and 
remained negative on repeated screening while the positive control 
gave a strong positive result 1 fusion produced clones but these 
died soon after
4 fusions produced positive clones 2 of these together produced 
6 positive clones which on repeated screening were reduced to only
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2 1 of these ceased to produce antibody and the other one was
frozen down On thawing, this clone failed to produce antibody 
1 fusion produced 12 positive clones on the first screening On 
the second screening there were only 2 positive clones which 
became contaminated 1 fusion produced 172 positive clones on the 
first screening On a second and third screening there were only 
14 positive clones All 14 clones failed to expand into larger 
wells
I
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TABLES AND FIGURES
TABLE IV 1
This table compares the absorbance values (405 nm) for 
different concentrations of crude ascitic fluid and the 
purified antibody, using diazepam-BSA conjugate as the 
antigen in ELISA The second antibody was a (3-galactosidase- 
lmked anti-mouse antibody
1 PURE IrG I ASCITES FLUID
I CONC | ABS I DILUTION | ABS |
| 1 5 mg/ml | ND 1 1° 1 1 9 || 150 Mg/ml | ND 1 100 | 1 9 |
I 15 ng/ml | 1 93 | 1000 | 1 77 |
1 1 5 Pg/ml | 1 24 | 10000 | 0 86 |
| 150 ng/ml 1 0 27 ! 100000 | 0 14 !
TABLE IV 2
This table compares the absorbance readings from ELISA (405 
nm) for ascitic fluid diluted m  PBS-Tween with that diluted 
in PBS-Tween containing l%(w/v) BSA
| DILUTION 
I FACTOR
ABSORBANCE VALUES |
PBS-TWEEN | PBS-BSA-TWEEN |
| 100 1 70 | 1 30 |
| 500 1 68 | 1 13 |
| 1 000 1 58 | 0 91 |
| 5 000 1 37 | 0 46 |
| 10 000 1 19 | 0 29 |
| 50 000 0 57 | 0 10 |
I 100 000 0 39 | 0 07 |
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TABLE IV 3
This table shows the absorbance values (405 run) for the 
binding of antibody to diazepam-BSA conjugate m  the 
presence of benzodiazepine derivatives, BSA, or diazepam-BSA 
conjugate The values were determined by ELISA Drugs were 
dissolved in DMSO and made up m  PBS-Tween and used at 3 
different concentrations The control well contained DMSO 
and PBS-Tween without any drug BSA and the conjugate were 
made up m  PBS-Tween only
| DRUG/ 
J ANTIGEN
I ABSORBANCE VALUES
I 300 Ms/ml | 30 Mg/ml 1 3 P s/ml|
| Ro 20-9748 1 1 ND 1 ND || Ro 5-2180 | 0 17 | 0 16 1 0 11 |
| Ro 5-3453 | 0 15 | 0 13 1 0 12 |
| Ro 5-2807 | 0 12 | 0 10 1 0 10 |
| Ro 7-3351 | 0 15 | 0 09 | 0 08 |
| Conjugate | 0 00 | 0 00 | 0 00 |
| BSA | 0 08 | 0 05 | 0 03 |
I Control I 0 19 | 0 11 1 0 10 |
ND= not determined
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FIG IV. 4 Showing the IR spectrum (prepared in Nujol) of Ro 20-9748, prepared as m  text. 
The figures represent the frequency (cm

IV 3 DISCUSSION
The production of diazepam derivatives for conjugation to BSA was 
quite successful, especially when the modified procedure was used, 
except for the low yield The final product had an IR indicating 
that it was probably Ro 20-9648 This IR agreed with that of Ro
20-9748 that was provided by Dr Fryer from Hoffman La Roche The 
mp was lower than that of Ro 23-9748 but this was probably a 
reflection on the purity of the compound The good agreement of 
the IR spectra is a stronger indication of identity than agreement 
of melting points
The production of polyclonal antibodies m  rabbits, sheep, goats 
etc is a commonly used technique The major drawback is the 
expense of keeping these animals, especially since a large number 
have to be used, as not all animals will produce high titre 
antiserum The use of mice for the production of antiserum 
reduces this expense Since mice produce very little antiserum a 
modification is necessary to obtain sufficient antibody This 
involves producing the antibodies m  ascitic fluid This method 
produced 69 mg of IgG with a working dilution of between 1 5 g^/ml 
to 150 ng/ml Thus, this technique can produce a reasonable yield 
of polyclonal antibody The major disadvantage is that not all 
mice respond Also, some of the mice die during the tapping 
procedure It is therefore essential that a sufficient number of 
mice be used to allow for this
Another solution to the production of antibodies is to produce 
monoclonal antibodies This method can give excellent results,
but it is not always successful In this case 14 fusions yielded
no clones In section III 3 the problems associated with 
monoclonal antibody production are dicussed
Another problem m  the production of antibodies to conjugates is
that a high percentage of antibodies will be directed against the
carrier protein The ascitic fluid had a 10-fold decrease m
titre when BSA was used m  the diluent In fact, even m  the 
affinity purified antibody most of the binding was eliminated by 
competition with BSA This indicates a high level anti-BSA
antibodies Monoclonal antibodies can overcome this problem If 
clones are screened against a conjugate with a different carrier
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protein, or are diluted m  a solution of the carrier protein, 
anti-carrier clones can be eliminated The final number of stable 
clones directed against the hapten will be small, but if 
sufficient cells are used m  the fusion this would not be a 
problem In previous fusions (see III 2 2) only about 8% of 
positive clones are stable With this success rate 12 positive 
clones to the conjugate would be necessary to obtain 1 stable 
positive clone If the number of antibodies against the carrier 
is 10-times greater than those against the hapten, then 120 
positive clones against the conjugate would be needed to produce 1 
clone that was positive against the drug portion
De Bias et al , (1985) produced monoclonal antibodies to benzo­
diazepines They used 3-Hemisuccmyloxy-clonazepam-BSA as the 
antigen The 4 monoclonal antibodies produced had high affinities 
for Ro 5-4864, which is a peripheral receptor ligand They also 
had higher affinities for derivatives with a methyl group in the 1 
position, and a NO2 or Cl m  the 7 position The phenyl ring at
position 5 was essential for binding, but addition of a Cl group
to its 4 position did not effect binding
The characterisation studies on the polyclonal antibodies 
indicated that even after affinity chromatography to remove
anti-BSA antibodies they are still responsible for the major part 
of the binding of the antiserum to the conjugate Ro 5-2180, Ro 
5-3453 and Ro 5-2807 (diazepam) are all very similar in structure 
Ro 5-2180 and diazepam only differ m  the substituent on the N(l) 
position of the heterocyclic ring In diazepam it is a methyl 
group, and m  Ro 5-2180 it is hydrogen Neither of these had any 
effect on the binding of the antibodies indicating that the methyl 
group on the N(l) is not essential for the binding to the drug 
Ro 5-3453 is similar to diazepam except it has a -NO2 group on the 
7 position of the heterocyclic ring instead of the Cl This
indicates that the Cl at position 7 is not important for binding 
Ro 7-3551 is also similar to diazepam, but it has a hydroxyl 
group at the 4 position of the 5 phenyl ring This does reduce 
binding of the antibody, indicating that this hydroxyl group is an 
important factor m  the binding of the antibodies
r
Thus, the major epitope on the hapten is at the 5- phenyl 
position The hapten has a hydroxyl group on this phenyl group 
This hydroxyl group is necessary to direct the incoming
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conjugating group (£-ammoacetanilide) to the 3-position To 
reduce the antibodies produced to this site it would be necessary 
to try and remove the hydroxyl group In fact the ammophenylazo- 
1 inker arm is probably also involved m  the binding This
illustrates one of the problems of the use of conjugates, namely
the production of antibodies to the conjugate rather than to the 
hapten Thus, the polyclonal antibodies produced are more likely 
to bind to BSA or to Ro 7-3351, than to Ro 5-2807 (diazepam)
While the production of specific antibodies to diazepam was not 
achieved, the methodology for the production of polyclonal 
antibodies m  ascitic fluid was successfully developed To ensure 
the production of antibodies directed against diazepam, and not 
the conjugate, the monoclonal antibody technique is necessary 
This technique enables a clone of cells to be selected, based on
the ability of the secreted antibody to bind to a specific region
of the antigen As well as their uses in immunoassay systems, 
antibodies to benzodiazepines have an important role to play m  
the production of anti-idiotypic antibodies These anti-idiotypic 
antibodies can be used to mimic the actions of the original drug 
as either an agonist or antagonist They can also be used to 
isolate the benzodiazepine receptor, and to locate and identify 
specific cell types m  the CNS
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SECTION V 
COUMARIN AN IN VITRO STUDY 
OF ITS EFFECTS ON CELL GROWTH
INTRODUCTION
V 1 1 HISTORICAL
Coumann is a member of a class of compounds called benzopyrones 
These consist of fused benzene and alpha-pyrone rings (see fig
V 1) Coumann occurs naturally m  plants and derives its name 
from the plant Coumarouna odorata Coumann often exists as an 
odourless complex with sugars and acids, and is released by the 
action of acids , enzymes or uv radiation Thus, the smell of 
coumann m  hay only develops after drying the grass In 1820 
Vogel purified coumann from the tonka bean (Dipteryx odorata), 
and Perkin synthesised it m  1868 Plants containing coumann have 
been used m  folk medicine for such ailments as burns, leprosy, 
rheumatic disease and as antispasmodics
V 1 2 CHEMICAL PROPERTIES
Coumann has a melting point of 70 6°C and a boiling point of 303 
°C It has a molecular weight of 146 1 and it has a fragrant 
odour It is freely soluble m  ethanol, chloroform and ether, and 
it is soluble m  water at 0 25 g/ 100ml at 25°C
Coumann is widely used m  the perfume industry, due to its strong 
fragrant odour (Meuly, 1978) and it is also used as a sweetener 
and fixative m  many perfumes It also used to enhance the 
fragrance of natural oils such as lavender, citrus and rosemary 
Coumann is often used m  combination with vanillin m  soaps and 
detergents In some countries where there are less strict 
controls on food additives, coumann is found with vanillin m  
confectionary Many tobaccos use coumann as a flavour/odour 
enhancer Coumann is also very effective m  masking unpleasant 
odours, and is used in many industrial products, eg paints, 
plastics, rubbers etc It is especially effective against iodo­
form, phenolic and quinoline odours Coumann is also used m  
electroplating to reduce the porosity and increase the brightness 
of nickel, zinc and cadmium deposits
While coumann has many synthetic and natural derivatives only a 
few have any economic importance 3,4-Dihydro coumann has a 
similar odour to coumann and it is used m  perfumes Unlike
t
coumann, it is permitted m  foodstuffs and is used with vanilla,
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butter, rum and caramel It is synthetised by hydrogenation of 
coumann and it is also a metabolite 6-Methylcoumarm is also 
used as a flavour enhancer 7-Hydroxycoumarm (umbelliferone) has
a blue fluorescence m  solution and is used in sun screens and as 
a fluorescent bnghtener The most important of the derivatives 
is 4-hydroxycoumarm This is a metabolite of coumarm found m  
spoiled hay, and is also the precursor of dicoumarol and warfarin 
which, are vitamin K antagonists Warfarin is also used as a 
rodenticide (Meuly, 1978)
V 1 3 METABOLISM
The major phase I metabolic route of coumarm m  animals is 
hydroxylation (Kaighen and Williams, 1961, Schilling et al, 1969) 
While hydroxylation can occur at all tne possible ring positions, 
there are two major hydroxylation pathways that yield either 
7-Hydroxy coumarm (7-OHC), or 3-Hydroxycoumarm (3-OHC) The
3-OHC is further metabolised by non-enzymatic ring splitting to 
o-Hydroxyphenyllactic acid (OHPLA) and o-Hydroxyphenylacetic acid 
(OHPAA) (see fig V 2) The major phase II metabolite is a 
glucuronide conjugate (Ritschel et al , 1977), which forms about 
60% of the metabolites of coumarm m  man (Moran et al , 1987)
There are species differences m  the metabolites that are formed,
but these are of a quantitative nature, rather than of a 
qualitative nature In primates (man and baboons) the major 
metabolite is 7-OHC (68-92%) (Schilling et al, 1969), with a small 
amount of OHPAA also formed In rats the major metabolite is 
OHPAA (12-27%), with small amounts of 3-OHC (1-2%) and very 
little 7-OHC (Kaighen and Williams, 1961) In rabbits the major 
metabolites are OHPAA (18-22%), 3-OHC (18-23%) and 7-OHC (10-16%), 
there are also trace amounts of 4-, 5-, 6-, and 8- Hydroxy-
coumann (Kaighen and Williams, 1961) (see Fig V 3) In mice
there is a difference m  metabolism m  different strains The 
activity of coumarm- 7-hydroxylase m  DBA/2J mice is much higher 
than that in C3H/HeJ mice (Wood and Conney, 1974) The coumarm 
hydroxylases are part of the microsomal enzyme system and are 
inducible enzymes The activity of coumarm-7-hydroxylase is much 
higher m  human microsomes, than m  rodent microsomes The 
coumarm-3-hydroxylase activity is very high m  rodent micro­
somes, and is absent m  human microsomes (Cohen, 1979)
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V 1 4 PHARMACOKINETICS
Ritschel et al , (1977) found that coumarm and 7 -hydroxycoumarm- 
glucuromde (7-OHCG) had distributions that were best fitted by 
open, two compartment models The biological half-life for 
coumarm was 1 0 2  hr for the intravenous ( i v ) route, and 0 8 hr 
for the oral (po) route The biological half-life for 7-OHCG was 
1 47 hr (iv), and 1 15 hr (po) 7-OHC was found to be best fitted 
by an open one compartment model Only 3 4% of the coumarm was 
present m  the plasma as coumarm, the rest was converted to 
7-OHC The 7-OHC was rapidly converted to its glucuronide 
conjugate (7-OHCG)- peak concentrations occured m  less than 0 5 
hr after iv administration of coumarm The levels of 7-OHC were 
never more than 2 2% of the 7-OHCG levels after iv administration 
There was no significant difference m  the biological half life 
between oral, and intravenous administration of coumarm
This data indicated that coumarm was rapidly absorbed from the 
gut and and was metabolised by a first-pass effect (to the extent 
of 97%) to 7-OHC This in turn was rapidly converted to its 
glucuronide form There was evidence that the glucuronidation 
also occured m  the gut and other tissues Further work by 
Ritschel and Hoffmann (1981) and by Ritschel (1984), compared the 
pharmacokinetics of oral coumarm and an oral, slow release 
preparation They found that on repeated dosage with the slow 
release preparation, higher plasma levels could be obtained 
Waller and Chasseaud (1981) found that the pharmacokinetics of 
coumarm in baboons was similar to that m  humans
The levels of 7-OHCG m  the plasma indicated that all the coumarm 
was absorbed from the gut Its volume of distribution during the 
beta phase was 1 7 times the body weight This indicates that
coumarm is taken up by tissue Evidence indicates that coumarm 
is, m  fact, widely distributed to both soft and deep tissues 
7-OHCG is excreted by active tubular secretion, with approximately 
90% of the dose of coumarm being excreted in this way This is 
different in other animals - In rats 32-38% is excreted m  the 
faeces, while m  rabbits 80-90% is excreted m  the urme (see fig 
V 3) (Cohen, 1979)
To explain the rapid metabolism of coumarm into 7-OHC, coumarm 
is often considered to be a pro-drug, which is converted into an
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active form, 7-OHC Work on high protein lymphoedema (HPLO) 
showed that 7-OHC had no effect on macrophages, while coumarm 
was active This cast doubt on the pro-drug theory But, the 
short half-life of coumarm, and its low bioavailability would 
suggest that it was unlikely to be the active compound This was 
also supported by research on the metabolism of coumarm Since 
the major metabolic route m  rats is via 3-OHC, not 7-OHC, and 
since coumarm is effective against HPLO in rats, then either
3-OHC is an active form of the drug as well as 7-OHC, or else 
coumarm is the active substance Further studies on HPLO showed 
that 7-OHC is effective in many forms of HPLO, indicating that 
possibly the pro-drug theory is correct Casley-Smith (1985) 
showed that the effects of coumarm on HPLO remained 2 weeks after 
its administration This was thought to indicate that cells can 
store coumarm, but pharmacokinetic data shows that coumarm is 
rapidly excreted, 80 % of the dose was eliminated withm 24 hr, 
and thus, it is unlikely to be stored It is more likely that 
coumarm acts by initiating a sequence of events eg altering 
cellular metabolism, or activating a second messenger via a 
receptor system This sequence then continue after the coumarm 
has been excreted
V 1 5 TOXICITY
Over the last thirty years coumarm has been m  the centre of a 
dispute over toxicity This arose from a ban on the use of 
coumarm in foodstuffs by the FDA m  1954, after preliminary data
showed that coumarm was hepatotoxic in the rat Since then there
have been conflicting claims over its carcinogenicity,
mutagenicity, and hepatotoxicity Unfortunately it is easier to 
have a drug declared toxic than it is to have it declared safe 
again Part of the problem is that chemically, coumarm, as a 
benzopyrone, is sometimes confused with the benzopyrenes The
benzopyrenes consist of 5 fused benzene rings, and are potent 
carcinogens Another group of chemicals, which are often confused 
with coumarm, are the dicoumarols These are formed from two
4-hydroxycoumarm molecules Coumarm, unlike the dicoumarols, 
has no anticoagulant properties (see below)
In acute studies the LD50 of coumarm m  the rat ranged from 290 
mg/kg (Hazleton et al , 1956) to 680 mg/kg (Jenner et al , 1964)
In mice the LD50 ranged from 196 mg/kg m  Hakka mice (Kitaguwa and 
Iwaki, 1963) to 780 mg/kg m  DBA/2J mice (Endel and Seidel,
1978) The LD50 for CH3/HeJ mice was 420 mg/kg (Endel and Seidel,
1978) (see Fig V 4) Fontaine et al ,(1967) found that the LD50 of
3-OHC m  mice was 1 8 g/kg, while 3 2 g/kg of 7-OHC in a similar 
study had no effect This shows that 7-OHC, the major metabolite 
m  humans, is a lot less toxic than 3-OHC, the major metabolite 
m  rodents This was further supported by Feuer et al , (1966) 
who showed that OHPAA (a product of ring fission of 3-OHC) causes
liver damage at doses, which are lower than the dose of coumarm
needed to cause damage It also takes coumarm 3 days longer to 
cause these effects
In a 2 year study Bar and Griepentrog (1967), and Griepentrog 
(1973) found liver damage and cholangiocarcmoraa with 5,400 ppm in 
the diet of rats With 2,500 ppm there was delayed growth and with
1,000 ppm there was no effect In a similar study Hagan et al , 
(1967) found that with 5,000 ppm m  their diet, rats had liver
damage with cholangiofibrosis after 2 years With 2,500 ppm m
their diet they had slightly fatty livers, with a reduction m  
growth Brune and Deutschwenzel (1985) found similar liver 
disorders with 5,400 ppm m  rats^ diet after 2 years They also 
found biochemical changes m  the dose range 1,800-5,400 ppm They 
rated 600 ppm as the no effect level (see Fig V 5) Feuer et al, 
(1966) found that coumarm (20mg/kg/day, for 7 days) inhibited 
hepatic glucose-6-phosphatase Ueno and Hirono (1981) found that 
0 5% coumarm in the diet of golden hamsters had no effect after 2 
years Seidel and Kreuser (1979) found that after 32 weeks, 1 8 
g/kg/day had no effect on DBA/2j mice, and caused only slight 
changes in liver enzyme levels m  CH3/Hej mice Evans et al , 
(1979) found that after 2 years, 22 5 mg/kg/day had no effect on
baboons, and 67 5 mg/kg/day had only a slight effect on the liver
(dilation of hepatocytes) (see Fig V 5)
There is a certain amount of contradiction between the data on 
both chronic and acute toxicity Part of the discrepancy lies m  
the dose regimens used Doses that cause death during gastric 
lavage tend to be lower than those that cause death m  food This 
can be due, in part, to the actual gastric lavage procedure 
itself, as well as the carrier used Thus, Hazleton et al , (1956) 
report an oral LD50 f°r coumarm, m  rats, of 290 mg, using 
propylene glycol as the carrier and the LD50, using corn oil as 
the carrier, was 520 mg (see Fig V 4) Another problem is that 
- using a compound such as coumarm, which has a strong odour, in
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food, may effect the eating pattern of the animals - hence it is 
difficult to estimate accurately the dose consumed When higher 
concentrations are used in the food the animals may well eat less, 
and thus they consume a lower dose of coumarm This is apparent 
m  some of the chronic studies where there is a reduction m  
growth in the animals at high dose levels, often accompanied by a 
reduction in food consumption during the first few months of the 
study Thus, Endel and Seidel (1978) found that the oral LD50 for
coumarm, m  corn oil, in DBA/2j mice, was 780 mg/kg, while 2
g/kg/day in their food, for 32 weeks, had no effect (Seidel and 
Kreuser, 1979) This latter study should be classed as a
sub-chronic study, rather than as an acute study Another 
problem is in converting dietary doses to doses of mg/kg/day 
Casley-Smith (1986) uses the ratio 1,000 ppm, equivalent to 100 
mg/kg/day Evans et al , (1979) uses 1,000 ppm, equivalent to 50 
mg/kg/day Schafer and Brummer use 1,000 ppm equivalent to 20 
mg/animal/day m  their literature review Allowing for an adult 
rat to be between 300 g to 500 g, this latter conversion gives 
40-60 mg/kg/day Thus, the method used by Evans and that used by 
Schafer and Brummer give similar figures, which are half those of 
Casley-Smith
The relevance of LD50 data m  acute toxicity studies is 
questionable Sodium chloride has an oral LD50 in rats, of 3 7 
g/kg, while 7-OHC coumarm has an LD50 of 3 2 g/kg, and yet salt 
is non-toxic At best acute toxicity studies can give an estimate 
of the therapeutic ratio - the ratio of the ED50 (effective dose 
in 50% of the test animals) to the LD50 (lethal dose m  50% of the 
animals) There is a 10 fold difference between the highest dose
used clinically (1,200 mg/day, le 20 mg/kg - for a "normal" 60 kg 
male) and the lowest dose that caused death (196 mg/kg m  mice) 
It must be remembered that this figure only applies to massive, 
single exposure to coumarm m  mice This therapeutic ratio gives 
an idea of the safety margin between the dose that is used 
clinically and the amount that would have to be ingested 
accidentally to cause death With a conservative estimate, 12 g 
of coumarm has to be consumed as a single dose (in a 60 kg male), 
before death would be remotely likely This makes coumarm
relatively safe
Of greater benefit m  clinical applications are the chronic 
toxicity studies In the baboon 22 5 mg/kg had»no effect on the
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liver, after 2 years (Evans et al , 1979) This is comparable to 
the maximum dose used to treat humans, and even then they would 
only be kept on this dose for a short period of time In the same 
study, baboons showed signs of liver enlargement (due to dilation 
of the endoplasmic reticulum) at 67 5 mg/kg, which Evans et al , 
considered to be the start of hepatotoxicity This dose is lower 
than the dose that caused toxicity m  rats - 1,800 ppm for 2 years 
(equivalent to 90 mg/kg/day) Both these doses cause slight 
changes m  the liver and are probably just below the dose that 
causes more serious liver damage In baboons the no effect dose 
was 22 5 mg/kg/day, while m  rats it was 30 mg/kg/day
Some authors discount the changes seen at the 67 5 mg/kg level, eg 
Cohen (1979), and maintain that this is not evidence of frank 
hepatotoxicity, as is seen in rats While the toxicity is 
different, Zimmerman (1978) considers dilation of the endoplasmic 
reticulum to be the ultrastructure equivalent of balooning degen­
eration These changes are also the first signs of carbontetra- 
chlonde poisoning While Zimmerman does not consider these 
changes to be of clinical relevance, they must not be ignored 
The fact that the chronic toxicity studies are different than the 
acute studies is not unusual, since the toxic effects seen in 
both are often caused by different mechanisms Cohen also points 
out that the changes seen m  the rat and the baboon are different 
This could be due to 2 factors The first possibility is that the 
toxicity seen is different Since the metabolism is different in 
each animal it is quite likely that the toxicity observed will be 
different, especially since the metabolites are suspected to be 
the toxic agents Thus, the depression of glucose-6-phosphatase 
(G-6-P) activity m  rat livers could be the toxic effect due to 
3-OHC (and/or its ring fission products), and the ultrastructure 
changes seen m  baboons could be due to the toxic effect of 7-OHC 
Hence, while rats are not good models for the toxicity of coumarm 
in humans, neither are they good models for the toxicity of 
coumarm m  baboons A second possibility is that the effect seen 
is the same, and that if higher doses were given to the baboon 
changes m  G-6-P activity would be seen This is possible since 
biochemical changes did not occur m  the rat below a dose of 1,800 
ppm (equivalent to 90 mg/kg/day) (Brune and Deutschwenzel, 1985)
which is above the highest dose given to baboons However, Feuer 
et al , (1966) found that this effect on G-6-P in rats occured at 
low doses m  a short period of time (20mg/kg/day, for 7 days), and
146
thus, it would have been expected to occur in baboons at the dose 
levels they received The data from the baboon study is the most 
appropriate to use for extrapolation to human therapy, as the
pharmacokinetic profile of baboons is very similar to that m
humans
Bar and Ggnepentrog (1967) and Griepentrog (1973) found evidence 
of biliary carcinomas m  rats given coumarin in their food at a 
dose of 5,000 and 6,000 ppm, for 2 years This resulted m  the 
NIOSH registry of toxic effects of chemical substances citing
coumarin as carcinogenic Hagan et al , (1967) found that rats 
given 5,000 ppm m  their diet for 2 years developed cholangioflb- 
rosis (proliferation of the bile ducts) Since Bar and
Griepentrog were the only workers to find these carcinomas the 
question is whether their diagnosis of cholangiocarcmoma was 
correct, or would cholangiofibrosis be a more accurate diagnosis? 
Another important question is whether cholangiofibrosis is a 
neoplastic or pre-neoplastic lesion The original slides were 
examined by Evans and Conning and they found no evidence of 
carcinoma (Cohen, 1979) There was no evidence of metastases 
either It is generally considered that these lesions were chol- 
angiofibrosis, misdiagnosed as cholangiocarcmoma Evans et al , 
went on to show that cholangiofibrosis is not a prequisite for
hepatocellular carcinoma and that it is not part of a carcinogenic 
process (personal communication) The NIOSH registry also cites 
coumarin as being neoplastic, le producing tumours not clearly 
defined as carcinogenic They cite the work of Roe and Salmon 
(1955) m  this However, this is erroneous In their paper Roe 
and Salmon state that coumarm showed no evidence of initiating 
tumours
Ames tests performed on coumarm and its metabolites indicated 
that they were not mutagenic (HRC, 1978) Other tests for 
mutagenisis gave similar results, eg the micronucleus test 
(Sterner and Korn, 1981) In fact coumarm has been shown to 
have anti-mutagenic effects (Ohta e t al , 1983) Grigg (1979) 
found that coumarm inhibited excision repair m  bacteria 
Coumarm was found to be non-teratogenic (Preuss-Ueberschar et 
al , 1984) and also it had no phototoxic effects (Kaidbey and 
Kligman, 1981, Prosser et al , 1988)
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A number of human studies have been performed using coumarm 
(Cerlek, 1977, Zanker et al , 1984, Marshall et al , 1987a) and
all showed no adverse effects or evidence of liver dysfunction 
Faurshou (1982) reported one patient who developed an unpred- 
ictable hepatotoxicity to coumarm In section VI, there is a 
report on a clinical trial of coumarm The trial consisted of 
2,163 patients with an incidence of 0 23% definite and 0 13% 
possible/probable hepatotoxicity This was an idiosyncratic type 
of hepatotoxicity and did not show up in other clinical trials due 
to the low incidence This toxicity is different to that found in 
rats
The LE>50s i*1 all species of animals is well above the clinically 
used dose m  man The dose used clinically has been found to be 
non-toxic m  2 year chronic studies m  both rats and baboons 
There is no evidence of teratogenic, mutagenic or carcinogenic 
activity by coumarm There is a very low incidence of 
idiosyncratic hepatotoxicity m  human studies, but these are well 
withm acceptable limits for clinical use Thus, despite early 
fears about the safety of coumarm all the current evidence 
indicates that coumarm is safe for clinical use
V 1 6 PHARMACOLOGY
In 1936 Szent-Gyorgyi and Rusznyak showed that an extract of 
lemons, which they called "citrm", had vitamin C like activity, 
and it also increased the permeability and fragility of capillar­
ies Further work found no vitamin C activity m  the extract, 
which was probably due to a contamination of the sample This 
activity was also found m  paprika, and thus, the active 
ingredient was called vitamin P Subsequently, the active agents 
from these extracts were identified as flavones, and the name 
vitamin P was dropped m  favour of bioflavenoids Pharmacologic­
ally the benzopyrones can be classed as bioflavenoids, along with 
other compounds such as rutin, eriodictyol, quercetm, and 
hesperetm
The role of the bioflavenoids m  normal physiology is contro­
versial It is estimated that the average western diet contains 
approximately 1 g of flavenoids (Middleton, 1984) This is
probably sufficient to exert a physiological effect It is
postulated that the flavenoids play a role m  maintaining the
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capillary bed They have been shown to have a weak vaso­
constrictor action on the capillaries and also to decrease 
capillary permeability and fragility (Casley-Sraith et al , 1975) 
The existence of a capillary defect that responds to bioflavenoids 
is questionable but it is thought that diabetic retinopathy may be 
one such defect
Coumarin has been shown to reduce oedema by activating macrophages 
(see below) , as well as acting on the rest of the immune system 
(see below), and it also has effects on the growth of tumour 
cells (see below) Coumarin inhibits the release of histamine 
from the mast cells and also has a mild adrenergic activity 
(Middleton, 1984), probably due to its inhibition of cathecol-o- 
methyltransferase This enzyme metabolises noradrenaline and 
thereby acts to terminate the adrenergic signal This may possibly 
account for coumarin’s reported spasmolytic activity (Kitagawa and 
Iwaki, 1963) Parente et al , (1979) and Koh (1979) showed that 
coumarin had anti-inflammatory activity Ritschel et al , (1982,
1984) and Kitagawa and Iwaki,(1963) showed that coumarin had anti­
pyretic effects on endotoxin-induced fever m  rabbits Coumarin
♦itself has little effect as an antibacterial or antifungal agent 
(Feuer, 1974), but some of its derivatives have eg dicoumarol 
and novobiocin
Coumanns are perhaps most famous for their anticoagulant 
activity This was first noticed by Schofield m  sweet clover 
disease in cattle This was later found to be due to the 
formation of dicoumarol in hay when it spoiled Dicoumarol is a 
potent anticoagulant and it was this effect which resulted in the 
death of the cattle These drugs inhibit synthesis of prothrombin 
and other coagulatipn proteins, by antagonising vitamin K 
Coumarin has no anticoagulant activity itself (Feuer, 1974)
V 1 7 HIGH PROTEIN LYMPHOEDEMA
Oedema is the swelling of tissue due to an increase m  
interstitial fluid The lymphatic system drains the interstitial 
fluid, but during oedema the system cannot cope with the excess 
fluid, resulting m  oedema This failure to drain the 
interstitial fluid can be due to a blockage m  the lymphatic 
vessels, or too much fluid entering the tissues The mam role of 
the lymphatics is to remove proteins and other macromolecules from 
the tissues These macromolecules cannot enter the blood, because
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their concentration is usually higher in the blood than m  the
tissue Also, being so large, they cannot easily enter through
the close junctions
In low protein oedemas there is an increase m  fluid m  the 
tissues, which cannot be removed quickly enough by the lymph­
atics This can easily be treated by diuretics, which increase 
fluid loss through the urine (diuresis) The second type of 
oedema is high protein lymphoedema, and it is due to an 
accumulation of protein m  the tissues Diuretics will remove the 
fluid, and decrease the oedema But, when they are stopped, the 
osmotic pressure of the protein draws the fluid back into the
tissue, causing oedema This increase m  macromolecules in the
tissues can be due to an increase m  permeability of the
capillaries (due to inflammation, or trauma), a deficiency m  the
lymphatics, or a loss in tone m  the tissues, resulting m  less
fluid being carried to the lymphatics
Foldi-Borcsok et al , (1971) found that coumarin was effective m  
treating oedemas due to thermal damage, surgically-produced 
lymphostatic oedema, and oedema due to mtraperitoneal and 
subcutaneous injection of protein Clodius and Piller (1978) 
found that 82% of patients, with postmastectomy lymphoedema of the 
arm responded to treatment with coumarin The response was slow - 
0 5 cm reduction in circumference m  10 months (as against 1 cm 
increase in circumference per year m  untreated patients), but 
better than can be obtained with other drugs
Coumarin exerts this reduction in lymphoedema by a number of 
different effects Coumarin has been shown to increase lymph flow
(Pflug and Taylor, 1975) which would help dram the tissue The
relevance of this is uncertain, since m  oedema the lymphatics 
would usually be maximally stimulated, and thus further 
stimulation would be ineffective Piller (1976c) showed that 
coumarin had no effect on thermally-induced oedema if the rats 
were pretreated with silica, which selectively kills macrophages 
Piller (1978) showed that coumarm increased the number of 
macrophages migrating to subcutaneously implanted coverslips, but 
also increased the percentage that were stimulated (Piller and 
Clodius, 1979) Piller (1977) showed that coumarm increased 
proteolysis m  rats with high protein lymphoedema Bolton and 
Casley-Smith (1975) showed that coumarm increased macrophage
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proteolysis in vitro Piller and Casley-Sraith (1975) and Piller 
(1976a) showed that coumarin increases phagocytosis by the macro­
phages, le it stimulates the reticuloendothelial system (RES) A 
number of authors have shown that coumarin increases vascular 
permeability, and thus, the leakage of protein, eg Casley-Smith 
and Window, (1976)
During oedema, eg after a burn, there is leakage of protein out of 
the vascular system, which draws fluid with it, causing the 
swelling When coumarin is administered a large percentage of it 
is protein-bound, especially to globulins and albumin (O'Reilly, 
1971, Garten and Wosilait, 1971) Its initial effect is to 
increase the leakage of protein from the blood to the tissue This 
leakage of protein allows the bound coumarin to get to the site of 
oedema Coumarin also increases the number of macrophages at the 
site of oedema and acts to activate them The coumarin, which is 
bound to the proteins, may act as a hapten making the proteins 
more antigenic, and thereby facilitating phagocytosis It is also 
thought that altered proteins, are more chemotactic for macro­
phages than native proteins This activation of macrophages 
results in an increase m  proteolysis, and the resulting protein 
fragments leave the cells by diffusion, or reverse phagocytosis 
These peptides are then removed by the vascular system because 
their size, and their concentration gradient (which, unlike that 
of proteins, is directed from the tissue) allow diffusion into the 
blood Once the protein is cleared from the tissue, the assoc­
iated fluid will be quickly absorbed As well as the increase in 
intracellular proteolysis, there is an increase in extracellular 
proteolysis due to the leakage of acid lysosomal proteases during 
phagocytosis Coumarin also increases the activity of neutral 
proteases (Piller, 1976b) In the case of pre-existing lymphoed­
ema there is usually a substantial amount of fibrosis at the site 
of the oedema Coumarin has been found to stimulate the breakdown 
of fibrotic tissue (Piller and Clodius, 1976)
Thus, by controlled proteolysis coumarin can slowly reduce the 
protein levels at the site of injury, and thereby reduce the 
oedema The effects of coumarin are limited to the site of the 
injury, since that is where the drug goes when it is protein-bound 
and that is where the macrophages are Because coumarin increases 
the natural protease activity of cells, and since its effects are 
limited to the site of oedema, its actions are termed "controlled
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p r o t e o l y s i s " .
V.1.8 IMMUNE SYSTEM
As well as its effect on macrophages (see above), coumarin also 
has other effects on the immune system. Marshall and Hollings­
worth (1987) found that coumarin augmented the response of 
peripheral blood lymphocytes to phytohaemagglutinin rn vitro, but 
not to Concanavalin-A,-nor to pokeweed mitogen. Zanker et al. ,
(1984) found that coumarin moderately increased natural killer 
activity in vitro when the effector:target ratio was 1:30, but it 
decreased NK activity when the ratio was 1:10. Marshall et al., 
(1987b) found no change in the peripheral blood leucocyte count or 
the differential count in patients treated with coumarin. They 
used monoclonal antibodies to B-cells, T-cells, helper and supp­
ressor T-cells and NK cells for their enumeration by fluoresence 
activated cell sorting (FACS).
There is some evidence that coumarin can activate the cellular 
immune system if it is suppressed. In particular coumarin has 
been found to increase the helper T-cells relative to the
suppressor T-cells (Thornes 1983a; 1983b). Because of the actions 
of coumarin on the immune system it is classed as a biological 
response modifier.
V.1.9 CANCER
Feuer et al., (1976) found that coumarin inhibited the formation 
of 7,12-dimethylbenz(a)anthracene (DMBA) induced tumours in mice 
when given prior to tumour induction. There was no effect when 
coumarin was given after the DMBA. Wattenberg et al., (1979) found 
similar results in mice with DMBA and benzo(a)pyrene induced 
tumours. They also found that 7-OHC had no effect on tumour 
occurence. In both cases there was a dose-dependent response in
relation to tumour inhibition by coumarin.
These results, and earlier work done on the effect of oral 
coumarin anticoagulants on fibrinolysis, and its role in cancer 
therapy (Thornes, 1975), resulted in pilot studies on the the use 
of coumarin in the treatment of melanoma. Melanoma was the main 
cancer under investigation since it is easily diagnosed at an 
early stage, and there is no adequate chemotherapy available for
it. Thus, there are no ethical reasons for not treating with
coumarin. Coumarin therapy is normally used after surgical ex-
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cision of the tumour Thornes et al ,(1982) used coumarin m  comb­
ination with cimetidme, while Zanker et al , (1984) used coumarin 
alone in treating melanoma Thornes found a decrease m  the 
recurrence rate during coumarin therapy, and a stabilisation of 
the disease m  some patients Zanker found similar effects in his 
study Thornes (1982, 1983b) found that the histamine H2 receptor 
antagonist, cimetidene (lg/day), when used to supplement preexist­
ing coumarin therapy (lOOmg/day) was more effective with melanoma 
Cimetidme is itself effective at activating the immune system 
At present multicentre trials are in progress to determine the 
effectiveness of coumarm in chemotherapy of melanoma, and to 
determine the appropriate dose regimen as well as the stages of 
the disease which are most susceptible to coumarin A report from 
a multicentre trial in Ireland indicated that the recurrence rate 
m  untreated patients was 10 m  14 patients after 2 years The 
rate in patients treated with 50mg coumarin per day was 2 m  13
Marshall et al , (1987a) used coumarm and cimetidme to treat
patients with renal cell carcinoma m  a pilot study In a total 
of 45 patients they reported 3 patients with a complete response^ 
11 with a partial response, and 12 with static disease All the 
patients that responded, and 75% of the static patients had 
nephrectomies
Conley et al ,(1987) found that coumarm inhibited the growth of 3 
cell lines (2 renal cell carcinomas and 1 erythroleukaemia) m  
vitro Tseng et al (1986) reported that coumarm inhibited 
tumourogemses m  a cell line containing the ras oncogene
Thus, it would appear that coumarm acts at 3 levels Firstly, 
it inhibits the growth of the tumour cells Secondly, it 
activates the immune system which prevents metastases, and 
possibly it is tumouncidal Thirdly, it is also anti-mutagenic 
It is probably most effective in combination with surgery, and 
with cimetidme therapy
V 1 10 CHRONIC INFECTIONS
Brucella abortus is a major cause of brucellosis m  humans It is 
estimated that 20% of acute cases become chronic During the 
chronic phase of the disease the organism infects macrophages, 
protecting it from the immune system The m a m  symptoms of 
chronic brucellosis are chronic tiredness, intermittent fever and
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night sweats, often accompanied by depression and anxiety There 
is also an associated anergy, also known as chronic fatigue 
syndrome, and Myalgic Myeloencepholopathy (HE) with the chronic 
infection (Thornes, 1977) This immune suppression is diagnosed 
by delayed hypersensitivity to 2,4-dinitrochlorobenzene and is 
characterised by a reduced helper/suppressor T-cell ratio
When immune stimulatory drugs such as coumarin and levamisole are 
administered the symptoms of the chronic infection disappear, 
often accompanied by an acute bout of brucellosis This indicates 
that the symptoms are caused by the immune suppression rather than 
by the infection (Thornes, 1977) Coumarin was found to be most 
effective, and the least toxic immune stimulant The sympathomim­
etic effects of coumarin would also be of benefit as they would be 
similar to the antidepressant effects of monoamine oxidase 
inhibitors
These results have encouraged the use of coumarin m  the treatment 
of other chronic infections, including mononucleosis, mycoplasm­
osis, toxoplasmosis, Q fever and psittacosis Coumarin is also 
undergoing trial as an anti-leprotic and anti-tubercular drug 
There is also a possible role for coumarin in preventing the 
progression of AIDS m  HIV positive patients
There are a number of unanswered questions about coumarin This 
project deals with 3 of these The first is whether coumarin has 
any effect on tumour cell growth The second is whether coumarin, 
or 7-hydroxycoumann, its major metabolite m  humans, is the 
active form of the drug Finally, the question of toxicity is 
also dealt with Does coumarin have an effect on liver function 
m  humans, or is it a drug condemned due to experiments performed 
on inappropriate animal models7
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C o u m a r in
OH
3-Hydroxycoumann
(3-OHC)
7-Hydroxycoumarin
(7-OHC)
CH.
Dicoumarol
FIG V 1 Showing the structures of coumarin and some of its 
derivatives
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J i g  V 2 METABOLISM OF COUMARIN
^  V »fY0^
3 - Hydroxycoumarm
OH
COOH
o-Hydroxyphenylpyruvic acid
o-Hydroxyphenyllactic acid o-Hydroxyphenyl* 
acetic acid
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Fig V 3 Showing the percentage of the administered dose of coumann excreted in the 
urine in man, rabbits, and rats Also shown are the major urinary metabolites expressed 
as a percentage of the administered dose
MAN (Schilling et alt9 1969)
RABBIT (Pekker and Schafer, 1969)
Fig V 4 Showing the L D o f  coumann for different strains of 
mice Also shown are the l d ^q s f°r different vehicles used m  
gastric lavage m  rats The ^or rabbits from different lab­
oratories are also shown
(1) Kitagawa and Iwaki, (1963)
(2) Endell and Seidel, (1978)
(3) Hazelton et al ,(1956)
(4) Foldi-Borcsok
(5) Feuer, (1974)
(6) Ellmger, (1980)
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Fig V 5 Showing the dose of coumarm needed to cause an effect on 
the liver m  2 year studies m  rats and baboons
□  BABOON (Evans et al , 1979)
V /  RAT (Brune and Deutschwenzel, 1985)(ll
No effect on Minor changes Serious/permanent 
the liver in the liver Liver damage
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RESULTS
V 2 1 STATISTICAL ANALYSIS
Table V 1 to V 10 summarise the effects of coumarm and 7-OHC on 
cell growth A t-test was used to test the hypothesis that the 
mean of the number of cells growing in drug 1 ( 1 )  was equal to 
the mean of the number of cells growing in drug 2 ( 2 )  The t 
test was performed using Minitab on a VAX 780 computer, and it 
was assumed that the variances of the means were unequal Figures 
m  parentheses are the standard error of the means (SEM) PI is 
the probability that 1 (coumarin control) was equal to 2 
(coumarm test dose) P3 gives the similar value for 
7-hydroxycoumarm P2 is the probability that 1 (coumarm test 
dose) equals 2 (7-OHC at the same dose) The level of 
significance selected was 0 05 (le 95%) NS indicates that the 
value was not significant The smaller the value of P, the less 
likely that the two means were equal
A second test was used to compare the effects of each drug with 
its control This was performed using Dunnett's test (Steel and 
T o m e ,  1980) This test produces a value d’ given by the 
equation
d' - t(Dunnett) x 2xs^
\J r
where r is the number of replicates of each test and s is the 
error mean square (obtained from analysis of variance using 
Minitab) The t value m  this equation was obtained from 
Dunnett's t table where p was the number of test doses excluding 
the control and df was the degree of freedom for the error mean 
square
A third test used was the least significant difference (lsd) 
(Steel and T o m e ,  1980) This was calculated from the equation
l s d t  /o X a/2 2xs^
\
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This was similar to Dunnett's test except that the t value was 
obtained from a t test The lsd results are expressed as line
graphs The mean values from the relevant table are ranked m*
order of magnitude (to simplify the results, the power of ten is 
left out), with the drug and concentration used printed above 
them Sometimes more than one drug, or concentration will yield 
the same mean number of celJLs Any values underscored by the same 
line are not significantly different from each other by the lsd 
test
Both Dunnett's test and the lsd give a value that represents the 
minimum difference between samples that is significant Thus, any 
two samples that differ by either the lsd or the d' value are 
significantly different at the selected probability level 
Dunnett's test is more conservative than lsd or the t test, and 
is therefore less likely to detect a difference
V 2 2 TO COMPARE THE EFFECTS OF COUMARIN AND 7-HYDROXYCOUMARIN ON
LAT CELLS
Table V 1 shows the results of an 8 day incubation of 5x10^ 
cells/well m  6 well plates (see also Fig V 6) There was a 
significant reduction in cell numbers when coumann or 7-OHC at a 
concentration of 500 jjH were used, compared with the controls 
There was also a significant reduction in the number of cells m  
wells containing 500 pH 7-OHC compared to the wells containing 500 
PH coumann (see also Table V 6) The effect of 7-OHC at a 
concentration of 500 MH was significant by Dunnett's test at the 1 
percentile level, while the effect of coumann at the same 
concentration was significant at the 5 percentile level The line 
graph below indicates the values that are significantly different 
by the lsd method at the 5 percentile level for the data m  Table
V 1
C C 7HC 7HC C 7HC 7HC C C 7HC
50 100 100 0 0 50 200 200 500 500
2 9  2 8  2 6  2 5  2 4  2 1  2 0  1 9  1 6  0 75
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Table V 2 shows a similar experiment after 7 days at 37°C This 
showed no significant difference m  cell numbers at any dose 
levels The reason for this was the high standard deviation m  
the 7-OHC control The line graph below shows that there is a 
significant difference between 500 jjM 7-OHC and its control by the 
lsd method
7HC 7HC 7HC 100 C 7HC 7HC 500 C
0 50 C 50 0/500 200 C 200 100
3 2  3 1  2 8  2 6  2 4  2 1  2 0
V 2 3 TO COMPARE THE EFFECTS OF COUMARIN AND 7-HYDROXYCOUMARIN ON 
SP2 CELLS
Table V 3 shows the results of incubation of 5x10^ SP2 cells m  6 
well plates for 6 days, with coumann and 7-OHC At no dose level 
did coumann have a significant effect on cell number compared to 
the control The reduction m  cell numbers by 7-OHC was signific­
ant at a concentration of 500 ^M by both the t test and Dunnett's 
test (5 percentile level) 7-OHC also had a significantly greater 
effect than coumann on cell numbers at a concentration of 500 ^M 
Below is the line graph representation of the data for the lsd 
test
C C C 7HC 0 7HC 7HC C 7HC 7HC
50 200 0 C 100 50 100 500 200 500
3 8 3 4 3 1 3 0 ____2 9 2 8  2 5  2 1  2 0
Table V 4 shows a similar experiment after a 9 day incubation 
period Coumann had a significant effect on cell number at both 
the 200 ¿jM and 500 pM dose levels 7-OHC only had an effect at the 
500 jjM concentration The reduction m  cell number by 7-OHC at 
500 pM was significantly greater than that of 500 pM coumann 
Dunnett’s test indicated that the effect of both coumann and 
7-OHC at a concentration of 500 jjM were significant at the 1
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percentile level, while the effect of coumarm at 200 M was 
significant at the 5 percentile level Below is the line graph 
for the lsd test for this data
C C 7HC 7HC C 7HC 7HC 200 7HC
0 50/100 50 0 200 100 G 500 500
2 8 2 6___ 2 3  2 1  1 9  1 8  1 6  0 42
Table V 9 shows the effects of couinann and 7-OHC on 1x10^ cells 
m  25 cm^ flasks after 9 days Both coumarm, at concentrations 
of 200 and 500 PM, and 7-OHC, at all concentrations, reduced 
the numbers of cells compared to their respective controls 7-OHC 
at all concentrations were significant by Dunnett's test at the 
one percentile level Coumarm at a concentration of 200 MM was 
significant at the 5 percentile level, while at a concentration 
of 500 it was significant at the 1 percentile level by
Dunnett's test The only significant difference between the 
effects of coumarm and 7-OHC were found at a concentration of 500 
PM Figure V 7 shows the dose-response curve for this data, and 
the line graph representation for the lsd test on this data is 
given below
7HC C 7HC C 7HC C 7HC C 7HC
0 0 100 100 50 200 200 500 500
5 4 5 0 4 4  4 3  4 1  3 9  3 3 2 6 1 1
Table V 5 shows the growth of 1 05x10^ SP2 cells m  24 well plates 
in the presence of coumarm and 7-OHC Coumarm significantly 
reduced cell numbers at both the 200 and 500 jjM concentrations, 
while 7-OHC reduced cell numbers at 500 ¿jM concentration These 
effects were significant by Dunnett's test at the 1 percentile 
level While the mean cell numbers at 500 pM 7-OHC were lower 
than that at 500 jjM coumarm, this difference was not significant 
at the 5 percentile level 7-OHC at a concentration of 50 PM and 
100 P M produced a significant increase m  cell number (t test), 
but this increase was not significant by Dunnett's test Below is
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t h e  l i n e  g r a p h  r e p r e s e n t a t i o n  o f  t h e  l s d  t e s t  f o r  t h i s  d a t a
7HC 7HC C 7HC 0 7HC/C C 7HC
50 100 0 C 100 200 500 500
14 13 11 10 8 3 2
V 2 4 COMPARING THE EFFECTS OF INCUBATION PERIOD AND CELL
NUMBER ON THE RESPONSE TO COUMARIN AND 7-HYDROXYCOUMARIN 
Table V 7 shows the effects of coumarin and 7-OHC on the growth of 
LAT cells in a 24 well plate 1 13x10^ cells were incubated in 24 
well plates for 18 hr There were no differences m  the cell 
numbers between the controls and any concentration of either drug 
used by either the t test or Dunnett's test There was a signif­
icant difference m  cell number between 7-OHC and coumarin at 100 
PM concentration Table V 8 shows the same experiment except the 
incubation period was increased to 72 hr There was no 
significant difference m  cell number between any of the wells by 
either the t test or Dunnett's test
Table V 6 shows the results obtained when 5x10^ cells were 
incubated for 9 days with both coumarin and 7-OHC m  the wells of 
24-well plates The only significant effect found was a reduction 
in cell numbers with 100 7-OHC compared with the control This 
was significant by Dunnett's test at the 5 percentile level
V 2 5 COMPARING THE EFFECTS OF COUMARIN AND 7-HYDROXYCOUMARIN ON
CELL DEATH
Table V 10 shows the number of dead cells found after the.
2
incubation of 1x10^ cells m  25 cm flasks for 9 days, m  the 
presence of coumarin and 7-OHC As can be seen, the only 
significant effect was the reduction in the number of dead cells 
m  the wells containing 500PM 7-OHC compared to both the control 
flasks and the flasks containing 500 ^  M coumarin
V 2 6 DOSE RESPONSE CURVES
Table V 11 shows the parameters for the dose response curve for 
both coumarin and 7-OHC (see also Fig V 7) The data used was 
from table VI 9, le SP2s m  25 cm^ flasks The linear correl-
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ation coefficient for 7-OHC dose-response curve was -0 952, while 
the linear correlation coefficient for the log-dose response curve 
was -0 89 The linear correlation coefficient for the 
dose-response curve for coumarin was -0 925, while for the log 
dose-response curve it was -0 857 This indicates that the data 
is linear on a dose-response curve The data from this experiment 
fitted a straight line better than the data from any other 
experiment In all cases log transformation of the data did not 
improve the linear fit
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TABLES AND FIGURES
TABLE V 1
This table shows the effects of coumarm, and 7-hydroxy- 
coumarin, on the growth of LAT cells after an 8 day
incubation of 5 10^ cells/well, m  a 6 well plate
1 1 
1 1 
| CONC |
1 ( W  | PI
|VIABLE CELLS| 
j/WELL (xl06)| 
| MEAN (+SEM)| 
I COUMARIN | P2
VIABLE CELLS| 
/WELL (xlO6) | 
MEAN (+SEM)| 
7-OHC | P3 |
1 o 1 ------- | 2 37 (0 05)| NS 2 45 (0 05)| -- 1
1 50 | NS | 2 88 (0 25)| 0 09 2 08 (0 3) | NS |
1 100 1 NS | 2 80 (0 3) | NS 2 55 (0 4) | NS |
| 200 | NS 1 1 85 (0 2) | NS 2 03 (0 2) | NS |
1 500 | 0 03 1 1 58 (0 2) | 0 03 0 75 (0 15)| 0 001 |
PI The probability that the mean no cells m  the control 
wells, are equal to the mean no of cells m  the test 
wells containing a given dose of coumarm
P2 The probability that the mean no cells m  the wells 
with a given dose of coumarm is equal to the mean no 
of cells m  the wells containing the same dose of 
7-OHC
P3 The probability that the mean no cells m  the control
wells, are equal to the mean no of cells in the test
wells containing a given dose of 7-OHC
NS Not significant, le a probability of greater than 0 05
(less than 95%)
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TABLE V 2
This table shows the effects of coumarm and 7-hydroxy- 
coumann on the growth of LAT cells after a 7 day incubation 
of 5 10^ cells/well, m  a 6 well plate
| CONC
i c m PI
|VIABLE CELLS] 
I/WELL (xlO6)| 
| MEAN (+SEM)j 
I C0UMARIN | P2
[VIABLE CELLS] 
I/WELL (xl06)| 
| MEAN (+SEM)| 
I 7-OHC | P3 |
1 o — | 2 58 (0 2) | NS | 3 18 (0 55)| —  1
1 50 NS | 2 83 (0 3) | NS | 3 13 (0 35) | NS |
| 100 NS | 1 98 (0 35)| NS | 2 78 (0 25)| NS |
| 200 NS | 2 05 (0 25)| NS | 2 35 (0 3) | NS j
I 500 NS I 2 63 (0 3) | NS 1 2 10 (0 35)| NS |
PI" The probability that the mean no cells in the control 
wells, are equal to the mean no of cells m  the test 
wells containing a given dose of coumarm
P2 The probability that the mean no cells m  the wells 
with a given dose of coumarm is equal to the mean no 
of cells in the wells containing the same dose of 
7-0HC
P3 The probability that the mean no cells m  the control
wells, are equal to the mean no of cells m  the test
wells containing a given dose of 7-0HC
NS Not significant, le a probability of greater than 0 05
(less than 95%)
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TABLE V 3
This table shows the effects of coumann and 7-hydroxy- 
coumann on the growth of SP2 cells after a 7 day incubation 
of 5 10^ cells/well, m  6 well plates
| CONC 
1 (^H) PI
|VIABLE CELLS| 
I/WELL (xlO6)| 
| MEAN (+SEM)| 
| COUMARIN 1 P2
|VIABLE CELLS! 
I/WELL (xl06)| 
| MEAN (+SEM)| 
1 7-OHC | P3 |
1 o ------- | 3 05 (0 25)| NS | 2 98 (0 25)| -- 1
1 50 NS 1 3 73 (0 4) | NS | 2 88 (0 35)| NS |
| 100 NS | 3 03 (0 2) | NS | 2 80 (0 4) | NS |
| 200 NS | 3 38 (0 45)| NS | 2 13 (0 25)| NS [
I 500 NS I 2 48 (0 25)! 0 017 I 2 03 (0 03)| 0 036 !
PI The probability that the mean no cells m  the control 
wells, are equal to the mean no of cells m  the test 
wells containing a given dose of coumann
P2 The probability that the mean no cells in the wells 
with a given dose of coumann is equal to the mean no 
of cells m  the wells containing the same dose of 
7-OHC
P3 The probability that the mean no cells m  the control
wells, are equal to the mean no of cells m  the test
wells containing a given dose of 7-OHC
NS Not significant, le a probability of greater than 0 05
(less than 95%)
i
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TABLE V 4
This table shows the effects of coumann and 7-hydroxy- 
coumann on the growth of SP2 cells after a 9 day incubation 
of 5 10^ cells/well in a 6 well plate
| CONC 
1 (^)_
1
1
I
1 PI
|VIABLE CELLS) 
I/WELL (xlO6)| 
| MEAN (+SEM)| 
f COUMARIN | P2
|VIABLE CELLS| 
I/WELL (xlO6)| 
| MEAN (+SEM)| 
I 7-OHC | P3 |
1 0 1 2 75 (0 15)| 0 062 | 2 13 (0 2) | —  1
1 50 | NS | 2 58 (0 25)| NS | 2 28 (0 3) | NS j
| 100 | NS | 2 60 (0 3) | 0 094 I 1 75 (0 25)| NS j
| 200 | 0 014 | 1 85 (0 2) | NS 1 1 63 (0 3) [ NS |
I 500 I 0 017 1 1 58 (0 25)| 0 022 I 0 42 (0 03)| 0 004 |
PI The probability that the mean no cells m  the control 
wells, are equal to the mean no of cells m  the test 
wells containing a given dose of coumann
P2 The probability that the mean no cells in the wells 
with a given dose of coumann is equal to the mean no 
of cells m  the wells containing the same dose of 
7-OHC
P3 The probability that the mean no cells m  the control
wells, are equal to the mean no of cells m  the test
wells containing a given dose of 7-OHC
NS Not significant, le a probability of greater than 0 05
(less than 95%)
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TABLE V 5
This table shows the effects of coumarin and 7-hydroxy
coumann on the growth of SP2 cells after a 7 days
incubation of 1 05 105 cells/well m  a 24 well plate
1 1 
1 1| CONC |
I (m i PI
VIABLE CELLS| 
/WELL (xl05)| 
MEAN (+SEM)j 
COUMARIN | P2
VIABLE CELLS| 
/WELL (xl05)| 
MEAN (+SEM)| 
7-OHC | P3 |
1 0 1 — 11 1 (0 7) | NS 9 5 (1 2) | —  |
1 50 I NS 10 8 (1 0) | NS 13 5 (1 1) | 0 029 |
1 ioo | NS 9 7 (12) | 0 038 13 1 (0 8) | 0 028 |
| 200 |0 0048 7 9 (0 3) | NS 7 5 (0 6) | NS j
I 500 | 0 0 3 3 (0 5) | NS 2 0 (0 5) I0 0009 |
PI The probability that the mean no cells m  the control
wells, are equal to the mean no of cells in the test 
wells containing a given dose of coumarin
P2 The probability that the mean no cells m  the wells 
with a given dose of coumarin is equal to the mean no 
of cells in the wells containing the same dose of 
7-OHC
P3 The probability that the mean no cells m  the control
wells, are equal to the mean no of cells in the test
wells containing a given dose of 7-OHC
NS Not significant, le a probability of greater than 0 05
(less than 95%)
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TABLE V 6
This table shows the effects of coumann and 7-hydroxy- 
coumarm on the growth of LAT cells after a 9 day incubation 
of 5 105 cells/well m  a 24 well plate
) CONC 
1 (pM) PI
¡VIABLE CELLS| 
I/WELL (xl05)| 
j MEAN (+SEM)| 
I COUMARIN | P2
[VIABLE CELLS) 
I/WELL (xl05)| 
j MEAN (+SEM)j 
| 7-OHC | P3 |
1 o — 1 10 2 (0 5) | 0 047 1 12 6 (0 5) | —  1
1 50 ND 1 ND I ND I 10 4 (0 7) | NS |
| 100 NS | 10 6 (2 0) I NS 1 9 8 (0 3) | 0 017 |
| 150 ND 1 ND I ND 1 10 7 (0 5) | NS |
I 200 NS 1 9 9 (0 6) | NS 1  ii i NS I
PI The probability that the mean no cells m  the control 
wells, are equal to the mean no of cells m  the test 
wells containing a given dose of coumann
P2 The probability that the mean no cells m  the wells 
with a given dose of coumann is equal to the mean no 
of cells in the wells containing the same dose of 
7-OHC
P3 The probability that the mean no cells m  the control 
wells, are equal to the mean no of cells m  the test
wells containing a given dose of 7-OHC
NS Not significant, le a probability of greater than 0 05
(less than 95%)
ND Not determined
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TABLE V 7
This table shows the effects of coumarm and 7-hydroxy- 
coumann on the growth of LAT cells after an 18hr incubation 
of 1 13x10^ cells/well m  a 24 well plate
| CONC 
1 (JJM) PI
(VIABLE CELLS| 
¡/WELL (xlO5)| 
| MEAN (+SEM)| 
I COUMARIN | P2
|VIABLE CELLS] 
I/WELL (xl05)| 
| MEAN (+SEM)| 
1 7-OHC | P3 j
1 0 ------- 1 17 2 (0 7) | NS 1 14 1 (2 7) | -- I| 100 NS 1 16 2 (0 8) | 0 012 | 19 8 (0 9) | NS |
I 200 NS ! 16 6 (0 9) I NS 1 18 1 (1 1) I NS |
TABLE V 8
This table shows the effects of coumarm and 7-hydroxy- 
coumarm on the growth of LAT cells after a 72hr incubation 
of 1 13x10^ cells/well m  a 24 well plate
| CONC
i c m
I •
i pi
|VIABLE CELLS| 
I/WELL (xl06)| 
| MEAN (+SEM)j 
I COUMARIN I P2
|VIABLE CELLS| 
I/WELL (xl06)| 
j MEAN (+SEM)| 
I 7-OHC | P3 |
1 o i — | 1 44 (0 1) | NS 1 1 43 (0 1) | -- 1| 100 | NS 1 1 59 (0 1) | NS 1 1 51 (0 1) | NS |
I 200 I NS 1 1 39 (0 1) 1 NS 1 1 26 (0 1) | NS |
PI The probability that the mean no cells m  the control 
wells, are equal to the mean no of cells m  the test 
wells containing a given dose of coumarm
P2 The probability that the mean no cells m  the wells 
with a given dose of coumarm is equal to the mean no 
of cells in the wells containing the same dose of 
7-OHC
P3 The probability that the mean no cells in the control
wells, are equal to the mean no of cells m  the test
wells containing a given dose of 7-OHC
NS Not significant, le a probability of greater than 0 05
(less than 95%)
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TABLE V 9
This table shows the effects of coumann and 7 -hydroxy- 
coumarm on the growth of SP2 cells after a 9 day incubation 
of 1x10^ cells per 25 cm^ flask
| CONC 
1 GjM)
1
1
1
1 PI
|VIABLE CELLS] 
I/WELL (xl06)| 
| MEAN (+SEM)| 
| COUMARIN | P2
|VIABLE CELLS 
I/WELL (xlO6) 
| MEAN (+SEM) 
I 7-OHC P3 |
1 0 | 4 96 (0 15)| NS | 5 38 (0 25) -- 1
1 50 | ND 1 nd | ND | 4 12 (0 15) 0 01 |
| 100 | NS | 4 25 (0 05)| NS | 4 36 (0 1) 0 03 [
| 200 | 0 009 | 3 93 (0 15)| NS | 3 34 (0 25) 0 002 |
I 500 I 0 004 1 2 61 (0 3) | 0 027 I 1 41 (0 05) 0 0005 |
PI The probability that the mean no cells m  the control 
wells, are equal to the mean no of cells in the test 
wells containing a given dose of coumarm
P2 The probability that the mean no cells m  the wells 
with a given dose of coumarm is equal to the mean no 
of cells in the wells containing the same dose of 
7-OHC
P3 The probability that the mean no cells m  the control
wells, are equal to the mean no of cells m  the test
wells containing a given dose of 7-OHC
NS Not significant, le a probability of greater than 0 05
(less than 95%)
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TABLE V 10
This table shows the effects of coumarin and 7-hydroxy- 
coumann on the death of SP2 cells after a 9 day incubation 
of 1x10^ cells per 25 cm^ flask
| CONC 
1 . (uM) PI
| DEAD CELLS | 
I/WELL (xl05)| 
| MEAN (+SEM)| 
I COUMARIN | P2
| DEAD CELLS | 
I/WELL (xl05)| 
| MEAN (+SEM)| 
I 7-OHC | P3 1
1 0 — I 10 8 (0 5) | NS I 6 50 (0 5) | —  |
1 50 ND 1 nd | ND | 6 70 (0 25)| NS |
| 100 NS 1 5 30 (1 0) | NS I 4 55 (1 0) | NS |
| 200 NS 1 6 45 (1 0) | NS I 7 30 (0 7) | NS |
I 500 NS 1 4 75 (0 2) | 0 03 I 3 05 (0 45)| 0 003 |
PI The probability that the mean no cells in the control 
wells, are equal to the mean no of cells in the test 
wells containing a given dose of coumarin
P2 The probability that the mean no cells m  the wells 
with a given dose of coumarin is equal to the mean no 
of cells in the wells containing the same dose of 
7-OHC
P3 The probability that the mean no cells m  the control 
wells, are equal to the mean no of cells m  the test
wells containing a given dose of 7-OHC
NS Not significant, le a probability of greater than 0 05
(less than 95%)
ND Not Determined
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TABLE V 11
This table shows the parameters for the least squares line 
(Y - mX + C) calculated for the data from Table V 9
| CORR | 1DRUG ICOEF (r)1 SLOPE (m) I INTERCEPT (C)
7-OHC | -0 952 | -0 727 | 4 96
COUMARIN I -0 925 | -0 449 I 4 84
r the correlation coefficient
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DOSE (jjM)
50 100 200 300 400 500
DOSE (jjM)
FIG V.7 This figure shows the dose-response curves
for coumarin(- - - a  —  ) and 7-0HC (---- ▲-----) on SP_
cells incubated m  25 cm flasks for 9 days at 37 C 
The initial cell concentration was 1x10^ cells per 
flask The lines represent the least squares line 
that best fits the data
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DISCUSSION
It was found that both 7-OHC and coumarm had effects on the 
growth of SP2 and LAT cells in culture The m a m  effect was a 
reduction in cell numbers at a concentration of 500 pM At this 
concentration the effect of 7-OHC was greater than the effect of 
coumarm At lower concentrations the effects are not so obvious 
This was found to be due to the test system Thus, when 25 cm^
flasks were used an effect was seen with 50 jjM 7-OHC, while m
24-well plates an effect was only seen with 500 jjM 7-OHC
The reason for the variation m  responses m  the different test
systems is due to the difference m  cell numbers Thus, to see a 
minor change in cell number, such as with a concentration of 50 
;14, a large number of cells are necessary However, with gross 
effects, such as with a concentration of 500 jjM of either drug, a 
reduction m  cell number could be seen, even with a low cell 
number Another limiting factor was m  the standard deviations of 
the counts When a low cell number was used, eg 24-well plates, a 
small variation in the counts produced a large standard deviation, 
resulting m  an increase m  statistical errors When larger cell 
numbers were used, le a 25 cm^ flask, the errors m  counting pro­
duced a smaller standard deviation, and a therefore statistical 
errors were reduced Thus, in the 24-well and 6-well systems, 
there was often a difference in the means, which was not signific­
ant due to the large standard deviation
There are a number of conditions necessary for the reduction m  
cell numbers to be detected The most important variable is cell 
number The optimum response occured with 1x10^ cells m  a 25 cm 
flask, or 5x10^ cells/well in a 6 well plate A second factor was 
the incubation period The cells should be counted before the 
control well becomes confluent If cells were not counted until 
after the control wells became confluent, the effect could be 
masked This was because the cells m  the control well stopped 
growing due lack of growth surface, a depletion of the media, and 
a drop m  pH However, cells in the test wells would continue to 
grow until they reached confluence, thus masking the effects of 
the drugs The time needed for cells to grow to confluence 
depended on the initial number of cells m  each well, on the batch
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of cells and the batch of media/serum Different batches of cells 
grow at different rates, and therefore different incubation 
periods would be required There is also a lot of variation m  
the growth promoting ability of different batches of serum This 
means that the incubation period has to be adjusted for each 
experiment
The decrease m  the number of viable SP2s was not reflected in an 
increase in the number of dead SP2s In fact, there was a 
decrease m  the number of dead cells following incubation in 500
7-OHC This decrease could be explained if the dead cells were
due to natural cell death If there were fewer viable cells
present, there would be less dead cells This would indicate that
neither drug had a cytotoxic effect on the cells, but rather
inhibited the growth of the cells This was found with both SP2 
and LAT cells
Both drugs failed to reduce the number of LAT cells when they were 
incubated at high cell concentration (1 xlO^ cells/well) for 18 hr 
or 72 hr The absence of an effect could be explained if the
drugs inhibit cell growth The high cell concentration would
prevent growth due to the lack of available surface area for
growth The short incubation period would also mask any effects 
since the cells would only undergo one or two cell cycles and 
divisions
There was also a second effect seen, with both coumarm and 7-OHC 
At low concentrations of either drug there was often an increase 
m  the mean number of cells, compared with the control (see Tables 
VI, V 2, V 3, V 5, V 7, and V 8) The relevance of this 
increase m  the mean number of cells is uncertain In only one
instance, Table V 5, was the increase significant, although it
was not significant by Dunnett's test It is not known whether 
this represents a mild growth stimulatory effect of coumarm, and 
7-OHC, or else it reflects an error in counting
It would appear that both drugs act by slowing the growth rate of
the cells rather than by killing them Thus, a low cell number
and long incubation period is necessary to detect the effect The 
LAT cells are not a good model system to study the effects of 
coumarm because they were passaged as an ascitic tumour m  mice, 
and therefore, were not adapted for growth m  culture Thus,
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their growth rate was poor after the initial transfer to in vitro 
growth m  tissue culture This problem can be overcome by growing 
the cells in culture for several passages prior to the assay, to 
enable them to adapt to in vitro growth
Inhibition of m  vitro cell growth by coumann was also found by 
Conley et al , (1987) They used 3 human malignant cell lines an 
erythroleukaemia (K562), and two renal carcinomas, (ACHN, and 
Caki-2) in their studies Coumann at 200 Vg/ml (approx 100 fJ M) 
reduced the growth of all 3 cell types They analysed the cells 
after incubation with the coumann, using a fluorescent activated 
cell sorter From this they concluded that coumann caused an 
accumulation of cells in phase Gq/G]_ of the cell cycle, and thus 
prevented entry of cells into the S phase
Pharmacokinetic studies m  humans have found that coumann has a
very short half-life This led to speculation that coumann was a
pro-drug, and that its major metabolite, 7-OHC, was the active
form However, the lack of data indicating that 7-OHC was as
effective as coumann caused problems with this The results
*
presented here show that 7-OHC is much more effective than 
coumann at slowing the growth of tumour cells in vitro This 
would suggest that m  the treatment of cancer coumarin is acting 
as a pro-drug The growth reducing effects of coumarin could be 
due to weak activity in coumarin, or else due to the formation of 
7-OHC from the coumarin due to metabolism by the test cells
When coumarin is used to treat patients with cancer it appears to 
have two effects Firstly, coumarin stimulates the immune system 
via the macrophages A second effect is due to its ability to 
prevent the growth of tumour cells In particular, this cyto­
static activity is enhanced after coumarin is metabolised to 7-OHC 
which has a longer half-life than coumarin This activation of 
the immune system, along with its cytostatic effects would be 
expected to reduce metastases Since the cytostatic activity of 
coumarin occurs at high concentrations, it explains the improve­
ment m  patients on high dose coumarin (up to 2 g/day)
It would appear that coumarin has a role to play m  the treatment 
of cancer It is especially effective m  the prevention of 
recurrence, which explains why Marshall et al , (1987) found that 
coumarin is more effective m  patients with nephroma, if they had
180
a nephrectomy Thus, therapy with coumarm would appear to be of 
benefit after removal of the tumour by surgery By activating the 
immune system and preventing cell growth it can prevent the tumour 
spreading Whether it has any benefit m  treating the primary 
tumour without prior surgery is uncertain It is also very safe 
for the long term therapy (2 years or more) that is necessary for 
preventing recurrence In section VI the results of a clinical 
trial indicate that there is a toxicity of only 0 2-0 3%, and that 
it is well tolerated at doses up to 2g/day
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SECTION VI 
COUMARIN A CLINICAL STUDY
VI 1 INTRODUCTION
VI 1 1 THE LIVER STRUCTURE AND FUNCTION
The liver is the largest single organ m  the body (approximately 
2% of the body weight) The liver consists of 4 major components 
the parenchymal cells or hepatocytes, which constitute 60% of the 
liver mass, the reticuloendothelial cells or Kupffer cells, the 
biliary tracts, and the blood vessels
The hepatic blood supply, which is approximately 1 5 litres per 
minute, comes from the hepatic portal vein (80%) and the hepatic 
artery (20%) The hepatic artery provides oxygenated blood and 
nutrients to the liver The hepatic portal vein drains the gas­
trointestinal tract
The classic functional units of the liver are called lobules 
Each lobule is hexagonal m  shape, with a cross sectional area of 
about 2 mm^ Portal triads, which contain the hepatic portal
vein, the hepatic artery, and the bile duct, run in the spaces
between the lobules Within each lobule the hepatocytes are 
arranged m  sheets that are orientated towards the central vein 
Biliary canaliculi run within these sheets, and carry secretions 
from the cells to the periphery of the lobule, where they connect
with cholangioles, which then drain into the bile ducts The
spaces between the sheets of hepatocytes are occupied by 
sinusoids The sinusoidal walls consist of endothelial cells and 
Kupffer cells The sinusoids receive blood from the hepatic 
portal venules and hepatic arterioles The sinusoids dram into 
the central vein which m  turn drains into the hepatic vein
Rapporort and coworkers (1969, 1976) suggested that the classic
lobular structure does not represent the functional unit of the 
liver They defined the functional unit m  terms of liver acini 
A liver ascmus consists of a mass of hepatocytes of irregular 
shape and size, arranged around an axis consisting of a portal 
triad, along with lymph vessels, and nerves The ascmus lies 
between 2 or more central veins (terminal hepatic venules) The 
ascini can be divided into 3 zones based on their distance from 
the terminal afferent vessel The periportal region, which 
surrounds the hepatic and portal vessels, is zone 1 This zone 
has the highest oxygen tension and respiratory enzyme activity
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The centrilobular region, which surrounds the central vein, is 
zone 3 The oxygen tension is lowest here, and the activity of 
the microsomal enzymes is highest here The midzonal region 
between the two is zone 2
The liver has a major role to play in carbohydrate, lipid and 
protein metabolism It is also the major site of metabolism of 
drugs and other foreign compounds Metabolism by the microsomal 
enzymes, converts foreign substances into more water soluble 
forms, which enables them to be excreted into the urine There 
are 2 phases involved Phase I consists of oxidation of the 
compound by cytochrome P4 5 0» which uses molecular oxygen and 
NADPH This results m  the introduction of polar groups into the 
molecule This step is often called detoxification, since the 
end result is usually a less potent/toxic compound This is a 
misnomer because metabolism can sometimes yield a more potent/ 
toxic compound Phase II involves a conjugation reaction, usually 
to a glucuronide This uses the polar group, mainly hydroxy 
groups, introduced m  phase I
«s.
The liver is highly susceptible to damage for 3 reasons Firstly, 
it has a high blood flow through it, and thus it is exposed to 
more of a circulating compound than other organs Secondly, its 
role in metabolism means that it has proteins which bind the 
compound, eg cytochrome P450 This binding results m  an 
accumulation of the compound m  the liver cells Thirdly, the 
liver, being the site of metabolism, has a higher concentration of 
metabolites than any other organ, which can leave the liver open 
to damage if these metabolites are toxic
VI 1 2 TYPES OF HEPATIC TOXICITY
Many attempts have been made to classify hepatic injury on the 
basis of mechanism and type of injury The system proposed by 
Zimmerman (1972, 1978) is probably the most useful, and the most 
used There are 2 major types of hepatotoxicity, acute and 
chronic Each have their own pattern of liver damage In each 
case the damage can be cytotoxic (hepatocellular) if the damage is 
mainly to the hepatocytes, cholestatic if bile flow is 
interrupted, and mixed if elements of both are present
There are 3 types of cytotoxic injury necrosis, degeneration 
and steatosis
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(i)Necrosis is due to the death of cells, as a result of leakage 
of the contents of cells, after damage to the cell membrane 
Necrosis can be zonal, massive or diffuse Zonal necrosis can be 
peripheral (zone 1), central (zone 3) or midzonal (zone 2) 
Necrosis in zone 3 is characteristic of carbontetrachloride and 
chloroform Necrosis of zone 1 is characteristic of phosphorous 
Necrosis of zone 2 can be caused by ngaione The zonal nature of 
necrosis may reflect the distribution of enzymes that produce 
toxic metabolites Instead of producing necrosis in a localised 
zone, some drugs produce a massive necrosis throughout the lobule/ 
ascmus, eg aflatoxms, while others produce a diffuse necrosis 
throughout the lobule/ascmus, eg galactosamine In general, 
zonal necrosis is due to intrinsic hepatotoxms, while idiosync­
ratic hepatotoxicity produces massive, or diffuse necrosis
Viral hepatitis also produces diffuse necrosis
(n)Degeneration, which is a form of sub-necrotic damage, is also 
produced by agents which cause necrosis This is seen prior to 
the development of necrosis, or concomitantly m  non-necrotic 
cells Ballooning degeneration produces large vacuole filled 
hepatocytes, while eosinophilic degeneration forms the acidophilic 
bodies
(m)Steatosis is caused by interference m  lipid metabolism,
resulting in accumulation of lipid in the cells It is uncertain 
if there is a zonal distribution m  steatosis There are 2 types 
of steatosis micro- and macro-vesicular In microvesicular
steatosis small droplets of fat, which do not displace the
nucleus, form m  the hepatocytes This type of fatty liver is 
caused by tetracycline, among other drugs In macrovesicular
steatosis, a large droplet of fat, which displaces the nucleus, 
forms in the hepatocyte This type of steatosis can be caused by 
alcohol
In cytotoxic injury to the liver, any combination of the above may 
be present
Cholestatic injury occurs when the bile flow is halted There are 
2 types of cholestasis canalicular jaundice, which is 
characterised by little or no injury to the hepatocytes, and no 
evidence of portal inflammation, and hepatocanalicular jaundice,
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which is usually accompanied by some damage to the hepatocytes, 
along with portal inflammation Bile casts and jaundice are 
present m  both types Anabolic and contraceptive steroids can 
cause canalicular jaundice, while chlorpromazme can cause 
hepatocanalicular jaundice
Some drugs produce liver damage that is characteristic of both 
cytotoxic and cholestatic damage Sulphonamides can produce a 
mixed hepatocellular toxicity, while chlorpromazme can produce a 
mixed hepatocanalicular toxicity
Repeated exposure to drugs can lead to various types of chronic 
liver damage There are 2 m a m  characteristic lesions m  chronic 
liver disease cirrhosis and fibrosis Necrosis, degeneration 
and steatosis can also be present Fibrosis is due to an increase 
m  fibrous tissue, which can lead to cirrhosis Cirrhosis is 
characterised by a loss of hepatocytes, and their replacement with 
fibrotic tissue There is also a resulting distortion of the 
normal hepatic architecture Cirrhosis can be micro- or macro- 
nodular Chronic exposure to ethanol can cause cirrhosis
A second type of chronic liver damage is chronic active hepatitis 
(CAH), also called chronic persistent/aggressive hepatitis This 
is characterised by necrosis, lymphocyte infiltration and mild 
fibrosis, and can lead to cirrhosis It can be caused by chronic 
administration of methyldopa
VI 1 3 MECHANISMS OF HEPATIC INJURY
Zimmerman (1972, 1978) classifies hepatotoxms as being either
intrinsic, or idiosyncratic Intrinsic hepatotoxicity is char­
acterised by high incidence of toxicity, reproducibility of 
toxicity m  animals, short latent period and dose-dependence The 
toxicity is thought to be due to a direct effect by the drug 
Idiosyncratnc hepatotoxicity is characterised by a very low 
incidence, it is not experimentally reproducible, it has a long 
latent period and it is not dose-dependent This is thought to be 
due to a host-dependent response, rather than any intrinsic 
property of the drug
Zimmerman (1972, 1978) subdivides intrinsic hepatotoxms into 2 
types The first are direct hepatotoxms These cause widespread 
damage to the liver, and also, ( to other tissues They are char­
acterised by a very short interval between exposure and evidence 
of liver damage They produce characteristic lesions, and are 
highly reproducible An example of a direct-acting hepatotoxin is 
carbontetrachloride Within hours of exposure to carbontetra- 
chloride there is evidence of liver damage The toxic components 
are free radical metabolites, which damage the cell membranes
The second type of intrinsic hepatotoxm are the indirect hepato- 
toxins There is a longer interval between exposure to these
agents and the onset of liver damage Their dose-dependence, and 
reproducibility, are not as obvious as that with direct-acting 
hepatotoxms Indirect hepatotoxms act by interfering with 
metabolic pathways withm the cell Their effect is very
specific, and localised, m  comparison to that of the direct
acting hepatotoxms There are 2 m a m  types The first acts on
the hepatocytes, interfering with essential metabolic pathways 
The other interferes with the secretion of bile
Zimmerman (1972, 1978) proposes 2 mechanisms of idiosyncratic
reactions The first involves hypersensitivity to the drug This 
involves the drug, or a reactive metabolite, binding to a
protein, which would make the protein antigenic Subsequently,
antibodies produced against this antigen would be able to 
recognise the native protein, and on binding to it, would
interfere with the cells function A long latent period would be 
required to allow antibody production to occur Desensitisation 
can also occur
The second type of idiosyncratic hepatotoxicity is caused by the 
production of "novel" metabolites This involves the use of an 
alternative metabolic pathway to metabolise the drug m  certain 
patients The metabolites produced by this pathway then exert
their toxic action on the liver The delay m  onset of the 
toxicity would be due to the time required for the accumulation of 
the toxic metabolite
It is very difficult to determine the mechanism involved in most 
cases of idiosyncratic hepatotoxicity, since the number of 
patients involved is usually very low, and there are no animal 
models available to obtain experimental data Evidence for a role 
for novel metabolites in hepatotoxicity, is difficult to obtain, 
since they are difficult to detect and identify Usually, the
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only evidence of an immunological basis m  a case of hepatotox­
icity, is the presence of extrahepatic symptoms which are 
suggestive of an allergy, eg a rash Drug specific antibodies m  
a patients serum, cannot be used to establish an immunological 
basis for hepatotoxicity, as their presence does not necessarily 
imply a role for them m  the toxicity Thus, many cases of idio­
syncratic hepatotoxicity are considered to be due to an allergic, 
or immune reaction if there are extrahepatic signs If these are 
absent the mechanism is often considered to be that of a novel 
metabolite
VI 1 4 DIAGNOSIS OF HEPATIC INJURY
Hepatic injury can be diagnosed biochemically, and histologically 
Histological examination of a biopsy preparation gives information 
about the type of lesion, and location Biopsy is an invasive 
technique, and is not routinely performed, but this technique 
provides the best information on type and cause of the injury
The tests that are routinely used to establish the presence, and 
nature of hepatitis are serum levels of certain enzymes The most 
important indicator of hepatic injury are the serum levels of 
transaminases The 2 transaminases used are Aspartate 
aminotransferase (GOT/AST) and Alanine aminotransferase (GPT/ALT) 
These are strictly intracelluar enzymes, found mainly m  the 
liver There is usually a low level of these enzymes m  the 
serum, but an increase above the normal level indicates probable 
cell damage, as this is the only source of these enzymes Another 
very important indicator of liver damage is serum bilirubin Its 
level rises during cholestasis, and high levels result m  deposits 
m  the skin, resulting m  a yellow pigmentation Other enzymes 
used in diagnosis are Alkaline phosphatase (AP),y-Glutamyl trans­
ferase (GGT), Lactate dehydrogenase (LDH), Glutamate dehydrogen­
ase (GLDH) , Creatine kinase (CK) and cholmesterase (ChE)
The serum enzyme pattern is very useful in determining the type 
and cause of hepatic injury Elevated levels of the transaminases 
indicates cytotoxic damage to the hepatocytes Elevated levels of 
bilirubin are indicative of cholestasis In alcoholic cirrhosis, 
the levels of GGT are Glevated more than any other enzyme GLDH 
is a marker for chronic active hepatitis and acute occlusion of 
the biliary tract AP is a marker of cholestasis and also of 
tumours
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The relative levels of enzymes m  the serum does not always 
reflect the distribution in tissue This distortion of the the 
enzyme pattern can be of diagnostic use (Schmidt, 1986) In the 
hepatocytes GOT activity is slightly higher than GPT activity, but 
40% of the GOT is mitochondrial, thus in the cytoplasm GPT 
activity is higher than GOT In acute hepatitis there is mainly a 
loss of cytoplasmic enzymes, thus, GPT levels are greater than GOT 
m  the serum In necrosis there is leakage of all intracellular 
enzymes, regardless of their location, and serum levels reflect
that m  the hepatocytes, le GOT activity is higher than that of 
GPT This distortion is due to the nature of the injury In acute 
hepatitis a large number of cells are involved, but the damage is 
only minimal, thus only the soluble enzymes leak out During 
necrosis, there is severe damage done to the cells, but this is 
usually localised This allows all enzymes to leak out
The levels of serum enzymes are not independent of each other
Their levels vary along with the other enzymes Thus, the
relationships between certain enzymes, measured as quotients, is
*
also useful m  diagnosis One of these is the deRitis ratio (DR), 
which is the ratio of GOT to GPT (deRitis et al , 1955) This has
4 different levels around 0 7, below 0 7, above 0 7 and far
above 0 7 Levels far above 0 7 usually indicate either primary,
or secondary carcinoma of the liver While the DR cannot neccess- 
anly distinguish between viral hepatitis, and drug-induced hepat­
itis, since different types of each can have different DR values, 
it can help establish a clinicopathological (CP) pattern for a 
given hepatotoxm Other ratios can also be used, such as the 
ratio of the total transaminase levels (GOT + GPT) to that of GLDH 
(useful for obstructive jaundice), and the ratio of GGT levels to 
those of GPT (Schmidt, 1986) These are especially useful in 
differential diagnosis when used together, and m  combination 
with the absolute levels of the serum enzymes
VI 1 5 ETIOLOGY OF HEPATITIS
The 4 major causes of hepatitis are viral infection, drug 
toxicity, alcohol abuse and exposure to chemicals, especially 
organic solvents The climcopathalogical pattern (le the 
patients symptoms, serum enzyme levels, biopsy studies etc), can 
sometimes indicate the cause of the hepatitis, eg alcoholic 
cirrhosis has a distinctive CP pattern The etiology of most
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cases of hepatitis is not easily elucidated, thus in most cases, 
the elimination of other possible causes plays a major role m  
determining the etiology of a case of hepatitis Most of the liver 
disorders seen m  patients, can be caused by either drugs, or non 
drug related factors (Sherlock, 1986) Thus, m  any case of 
hepatitis, an iatrogenic cause should be considered until evidence 
to the contrary is obtained This is especially so m  high risk 
patients, eg elderly patients
Strieker and Spoelstra (1985) recommend a 3 step process for 
determining the role of a suspect drug m  hepatitis (l) the
identification of the CP pattern, (n) the establishment of a
temporal relationship between exposure to drug/chemical, and the 
hepatitis, (in) the exclusion of other possible causes
If the CP pattern is highly specific, le it has features that are 
only found after exposure to the suspect agent, this can be used 
as confirmation of the etiology Sometimes, a specific CP pattern 
is observed, le it is similar to that found m  other cases of
exposure to drugs, and these can be a strong indicator of the
etiology
A strong temporal relationship between exposure to the suspect 
chemical, and occurrence of the hepatitis, especially if a 
specific CP pattern is present, is a strong indicator of
hepatotoxicity Even if there is no specific CP pattern, the
absence of other possible causes is a strong indicator of
hepatotoxicity, when associated with a temporal relationship The 
establishment of a temporal relationship between drug administrat­
ion, and the hepatitis, is best achieved by re-treating the
patient with the suspect drug, but this is not always ethically 
possible This can also be hampered by the fact that the doctor 
treating the hepatitis is sometimes not the doctor that prescribed 
the medication Patient compliance, and the use of other non-pre­
scribed medication, also has to be examined The failure to 
establish a temporal relationship between exposure to a suspect 
agent, and occurrence of hepatitis, does not necessarily imply 
that the drug was not responsible as desensltization may have 
occured, the dose could be too low, or the challenge period too 
short
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The third step involves screening for possible viral infection, m  
particular hepatitis A and B antigen, infectious mononucleosis and 
cytomegaly virus Liver biopsy cannot distinguish between viral 
hepatitis and hepatocellular toxicity (Scheuer, 1968) Thus, the 
levels of viral antigens m  the blood have to be used Non-A, 
non-B hepatitis can be excluded, if blood transfusion/surgery, 
intravenous drug abuse, and a promiscuous life style can be 
eliminated Other causes of hepatitis can be excluded, if the 
patients liver scan is normal Exposure to organic solvents, 
especially m  work, should also be excluded, but this can be 
difficult, as many patients may not suspect that they are exposed 
to these solvents
In many cases there is a correlation between the type of drug, and 
the type of hepatotoxicity Anesthetic agents cause cytotoxic 
injury only Among the neuroleptics, antidepressants usually 
cause cytotoxic hepatitis, tranquilizers mainly cause cholestatic 
injury and tricyclic antidepressant drugs can cause both Most of 
the anti-inflammatory drugs cause hepatocellular, or mixed hepato­
cellular toxicity, eg lbuprofen, indome thacm, etc , but, gold 
compounds and phenylbutazone can cause either cytotoxic, or 
cholestatic injury C-17 alkylated steroid hormones cause canal­
icular hepatitis Many antimicrobial agents produce cytotoxic 
damage eg tetracyclines, sulphonamides etc, while others, eg 
erythromycin, produce cholestatic injury The fact that so many 
drugs from the same class, produce the same lesions, would suggest 
that the mechanism of action of some drugs, and the mechanism by 
which they produce injury, are related However, many drugs cause 
hepatic injury that does not appear to be related to their 
therapeutic action
VI 1 6 PROGNOSIS WITH HEPATITIS
The prognosis with hepatitis depends on its etiology, the time 
taken to diagnosis, and the type of hepatitis
For viral hepatitis, the time taken to diagnosis is irrelevant, 
as there is no treatment for it If drug related hepatitis is 
diagnosed early, and therapy with the suspect drug stopped, the 
patient will often suffer no permanent damage To facilitate 
early diagnosis, patients undergoing therapy with drugs that are
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suspected of causing hepatitis, should be routinely monitored for 
any signs of abnormal liver function
The major factor m  the prognosis is the type of hepatitis In 
particular, drug-induced hepatocellular toxicity, if undetected, 
can have a high mortality rate, ranging from 10 to 50% of patients 
affected (Zimmerman, 1978) Patients, who survive acute hepato­
cellular disease, usually make a full recovery and their necrosis 
does not usually lead to chronic disease The prognosis for 
patients with other types of hepatitis is usually very good, with 
a very low mortality rate Thus, it is essential to diagnose any 
cases of hepatocellular toxicity as early as possible
The purpose of the work presented here was to determine if 
coumarm had any toxic effects on liver function If any toxic 
effects were detected it was hoped that they could be 
characterised, and a safe dose (if any) determined
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V I .  2 RESULTS
VI.2.1 COUMARIN CLINICAL TRIAL
2,163 patients in a sequential trial, were treated with coumarin 
at doses ranging from 25mg every two days to 2,000 mg daily. 38 
patients had elevated serum transaminase levels during therapy 
with coumarin. These were divided into two groups. The first 
showed an increase of less than twice the normal maximum levels of 
serum transaminases, which was accompanied by an exacerbation of 
their symptoms. This was usually followed by a period, in which 
their condition was much improved. The second group had a much 
higher elevation in serum transaminase levels, without an exacer­
bation of their condition, nor an improvement. Hepatotoxicity was 
only considered in patients with a rise of at least twice the 
normal maximum levels of serum transaminases, without an exacer­
bation, nor improvement in their condition. 17 of the 38 patients 
fitted this classification, and were examined for evidence of 
abnormal liver function. Four of these patients had chronic bru­
cellosis, 4 had carcinoma, 4 had melanoma, and 1 had a
nephroma. All patients with elevated LFTs were screened for
hepatitis A and B infection.
VI.2.2 CASE HISTORIES
Brief case histories of the 17 patients suspected of having
hepatotoxicity to coumarin are given below. See also Tables VI.1 
to VI.6. The different levels of hepatotoxicity, mentioned
below, are described in Section III.12.4.
CW: male, aged 41 with chronic brucellosis; received two courses 
of coumarin (50mg/day). On the first occasion his transaminase 
levels rose to 248 IU/1 (SGOT) and 500 IU/1 (SGPT), with a DR of 
0.50, after 6 months. These returned to normal when coumarin was 
stopped. The second course, two years later, resulted in a rise 
in SGOT to 136 IU/1, an SGPT to 326 IU/1 and a DR of 0.42, after 
4 months. These also returned to normal when coumarin was 
stopped.
COMMENT: There were no obvious reasons for the coincidence of
coumarin therapy and abnormal LFTs other than the administration 
of coumarin. There was a strong temporal relationship between the 
toxicity and the administration of coumarin and thus, this patient
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w as d e f i n i t e  m  l e v e l  B
ML female, aged 38 with chronic infectious mononucleosis,
received two courses of coumarin (50mg/day) After 5 months on
her first course of coumarin her SGOT rose to 440 IU/1, her SGPT 
rose to 696 IU/1, her AP rose to 253 IU/1, and her DR was 0 63 
These levels all returned to normal when coumarin was stopped
After 1 month on her second course of coumarin, her SGOT rose to 
125 IU/1 and her SGPT rose to 296 IU/1 Her DR was 0 42 These 
also returned to normal when coumarin was stopped
COMMENT There was no clinical reason for the coincidence of 
abnormal LFTs and coumarin therapy Thus, this patient was 
definite m  level B
DM female, aged 64 with carcinoma of the stomach, received one
course of coumarin (lOOmg/day) and cimetidme (400mg/day) She 
was admitted to hospital 5 weeks later with suspected hepatitis
Her serum level of bilirubin were 227 pM/1, her SGPT was 467
IU/1, her AP levels were 136 IU/1, and. her serum albumin levels 
were 34 g/1 (normal is 37-50 g/1) Coumarin therapy was stopped,
and 2 weeks later her LFTs were repeated Her bilirubin level had 
risen further to 440 pM/1, her SGPT had fallen to 410 IU/1, her AP 
levels had fallen to 85 IU/1, her albumin levels had fallen 
further to 32 g/1, her globulin levels had risen to 35 g/1 (normal 
is 23-32 g/1), and her prothrombin time had risen to 17 sec
(normal is 14 sec) By the following week, all enzyme levels 
started to return towards the normal values The patient had a 
white blood cell count of 3 5 (normal 4-11) and she had no smooth 
muscle nor nuclear autoantlbodies She was negative for lepto­
spirosis, cytomeglia virus, hepatitis A and B and infectious 
mononucleosis Her liver ultrasound was normal A needle biopsy 
was performed on the liver This showed ballooning degeneration
and liver cell regeneration Zonal hepatic cell necrosis, 
hyaline bodies and mild diffuse lymphocytic infiltration were
present There were bile thrombi in the canaliculi There was no 
evidence of metastatic cells 7 months later the patient was 
retreated with coumarin (100 mg/day) and within 1 month her ALT 
level had risen to 944 IU/1, her AP was 149 IU/1 and her
bilirubin level was 227 jjM/1 Coumarin treatment was stopped and 
her LFTs returned to normal within 5 weeks An abdominal 
ultrasound scan showed no abnormalities and the patient was
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clinically recurrence-free (see Fig VI 1)
COMMENT Her liver biopsy was consistent with viral hepatitis, 
but since she was negative for both hepatitis A, and B, and had no 
history of drug abuse (thus, non-A, non-B hepatitis was unlikely) 
a cause other than viral infection was probably involved Since 
neither ultrasound, nor biopsy showed metastatic cells, and the 
levels returned to normal, cancer could be ruled out Due to the 
strong temporal relationship between abnormal LFTs and coumarin 
therapy this patient was definite m  level B
ER female, aged 77 with melanoma, received four courses of 
coumarin Her serum transaminase levels were raised prior to
treatment (her SGOT was 65 IU/1 and her SGPT was 116 IU/1) By
the fifth month on coumarin (100 mg/day) her SGOT was 360 IU/1 and 
her SGPT was 625 IU/1, with a DR of 0 58 These returned to normal 
when coumarin was stopped After 1 month on coumarin the second 
time, her SGOT was 124 IU/1 and her SGPT was 190 IU/1, with a DR 
of 0 65 These returned to normal again when coumarin was 
stopped She was treated a third time with coumarin (50 mg/day), 
and after 1 month her SGOT was 61 IU/1, her SGPT was 96 IU/1, and 
her DR was 0 63 Again, these returned to normal when coumarin 
was stopped The patient was treated a fourth time, and after 1 
month her SGOT was 74 IU/1 and her SGPT was 103 IU/1 with a DR of 
0 72 These returned to normal within 2 months when coumarin was 
stopped The patients isotope liver scans were normal (see Fig 
VI 2)
COMMENT This patient had slightly elevated serum transaminase 
levels prior to treatment, but her liver scans were all normal 
Her levels returned to normal when not on coumarin There were no
clinical reasons for her abnormal LFTs other than treatment with
coumarin The very strong temporal relationship between coumarin 
therapy, and elevated LFTs, would indicate that the patient was 
definite m  level B
NM female, aged 40 with melanoma, received two courses of 
coumarin After 4 months on coumarin (25mg per day) there was an 
increase m  SGOT to 512 IU/1, m  SGPT to 648 IU/1 and m  bilirubin 
to 29 -M/1 Her DR was 0 79 These returned to normal when 
coumarin was stopped The patient had brain metastases removed, 
and was retreated with coumarin (300mg per day), cimetidine
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(lOOOrag per day) and dexamethasone (lOmg/day) Enzyme levels 
remained normal (SGPT rose very slightly) until the dexamethasone
course was completed Coumarin was lowered to lOOmg per day and
the cimetidine stopped The serum transaminase levels started to 
rise after 1 month, and had reached 220 IU/1 (SGOT) and 260 IU/1 
(SGPT) by the second month, and her DR was 0 85 These returned 
to normal when coumarin was stopped All liver scans were normal 
The patient died a short while later (see Fig VI 3)
COMMENT This patient had advanced melanoma, with brain 
metastases, and thus, liver secondaries would be an obvious 
source of liver problems This possibility can be ruled out for a 
number of reasons Firstly, her LFTs returned to normal when 
coumarin therapy was stopped, and remained normal until her 
death, a few months later This would not be expected m  a
patient with cancer of the liver Secondly, the lack of
involvement of AP m  the abnormal LFT, and the low level of 
bilirubin are not characteristic of liver cancer Thirdly, the 
patient had liver scans, which were all negative This would 
indicate that, if present, any liver tumour would have been very 
small, and thus unlikely to cause any change m  LFTs There was 
no other obvious reason for abnormal LFTs with this patient, 
thus, she probably had hepatotoxicity to coumarin The return to 
normal of her LFTs while on dexamethasone, which is a powerful 
immunosuppressant/anti-inflammatory drug, would indicate that it 
suppressed an inflammation m  the liver, or immune reaction, 
induced by coumarin This patient was definite m  level B
AH female, aged 60 with breast carcinoma, stage IV, received 
one course of coumarin (25 mg alternate days, increased to 25 
mg/day after 8 months) Her SGOT and SGPT had risen after 3
months, and had reached 340 IU/1 and 380 IU/1 respectively, after 
7 months, with a DR of 0 89 Her dose of coumarin was then 
increased to 25mg/day and she was put on prednisone (60 mg) and 
cyclophosphamide (50 mg) on alternate days Her enzyme levels 
returned to normal, even though coumarin treatment was continued 
Her liver scan was normal (Fig VI 4)
COMMENT Since the patient had breast carcinoma, stage IV, a 
likely cause of the rise m  serum transaminases was liver 
secondaries The patient had a liver scan, which showed no 
evidence of metastases Her LFTs further support this The small
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rise in serum transaminases is not consistent with liver 
secondaries, especially since it disappeared so quickly Since 
cyclophosphamide and prednisone are potent anti-inflammatory and 
immunosuppressive agents, it is possible that they are reducing 
an inflammatory/immune response induced by coumarin This patient 
was possible m  level D
CD Male, aged 70 with hypernephroma Patient had a nephrectomy 
prior to treatment with coumarin After 1 month on lOOmg coumarin 
and l,000mg cimetidine per day his LFTs started to rise, and 
within 4 months his SGPT level was 273 IU/1 and his SGOT was 175 
IU/1 Cimetidine was then stopped and prednisone (60mg), and 
cyclophosphamide(50mg), 3 days per week, 1 week in 4,were started 
Within 1 month his LFTs had returned to near normal Coumarin was 
then increased to l,600mg/day and the patient was continued on 
cyclophosphamide and prednisone His LFTs then started to rise 
again and reached a peak 3 months later with SGOT levels of 427 
IU/1 and SGPT levels of 626 IU/1 3 weeks later these had started 
to drop but his AP level had risen to 307 IU/1 A liver scan 
showed no abnormalities (Fig VI 5)
COMMENT Since coumarin therapy was never stopped, as the patients 
condition was too serious for therapy to be stopped, it is very 
difficult to confirm the role of coumarin in the elevated
transaminases One possibility for this rise m  LFTs would be
liver secondaries, especially since the patient had lung second­
aries But, a liver scan showed no abnormalities This patient 
probably has an adverse reaction to coumarin Immunosuppressive 
therapy seemed to reduce the LFTs with the lower dose of coumarin, 
but not at the higher dose Possibly continuous immunosuppressive 
therapy may have a stronger effect m  lowering LFTs
DN male, aged 51 with chronic brucellosis, received two courses 
of coumarin The first course (lOOmg, 3 days per week) resulted
in a rise m  serum transaminases to 104 IU/1 (SGOT) and 208 IU/1
(SGPT), after 5 months, with a DR of 0 5 The second course of 
coumarin (50mg/day) resulted in a rise in serum transaminase 
levels to 46 IU/1 (SGOT) and 66 IU/1 (SGPT) after 1 month, with a 
DR of 0 7 Four months later, these levels were much the same, 
and they eventually returned to normal while the patient was still 
on coumarin (not shown)
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COMMENT His LFTs returned to normal while still on coumarin, and 
thus the role of coumarin in the elevated LFTs is uncertain 
Possibly the elevation is not due to a toxic effect, but reflects 
some therapeutic response to the drug It could also be due to a 
mild, transient toxic effect Thus, the role of coumarin is 
uncertain
JG male, aged 60 with melanoma, received three courses of
coumarin (50mg per day) During the first course his LFT's
started to rise after 3 months and by month 6 his SGPT had reached
170 IU/1, his SGOT was normal and his DR was 0 1 These returned 
to normal when coumarin was stopped After 2 months on coumarin,
the second time, his SGPT was 140 IU/1, his SGOT was 68 IU/1, and
his DR was 0 48 Again, these returned to normal when coumarin
was stopped On the third occasion (not shown on table), the
increase was only slight, and the levels returned to normal during
treatment with coumarin (see Fig VI 6)
COMMENT His LFTs returned to normal while still on coumarin, and 
thus the role of coumarin m  the elevated LFTs is uncertain 
Possibly the elevation is not due to a toxic effect, but reflects 
some therapeutic response to the drug It could also be due to a 
mild, transient toxic effect Thus, the role of coumarin is
uncertain
PW male, aged 59 with melanoma, received two courses of coumarin 
(50mg/day) After 4 months on the first course his SGOT was 64 
IU/1, his SGPT was 138 IU/1 and his DR was 0 46 These returned to 
normal when coumarin was stopped During the second course of 
coumarin, the serum transaminase levels started to rise after 1 
month, and reached a peak after 3 months, when, his SGOT was 47 
IU/1, his SGPT was 110 IU/1 and his DR was 0 43 These returned 
to normal, even though coumarin therapy was continued
COMMENT His LFTs returned to normal while still on coumarin, and 
thus the role of coumarin in the elevated LFTs is uncertain 
Possibly the elevation is not due to a toxic effect, but reflects 
some therapeutic response to the drug It could also be due to a 
mild, transient toxic effect Thus, the role of coumarin is
uncertain
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MN female, aged 54 with immune suppression, received three 
courses of coumarin (only two shown) During the first course 
(25mg/day), her SGOT rose to 87 IU/1 and her SGPT rose to 115 
IU/1, with a DR of 0 74, after 10 months on coumarin During the 
second course on coumarin (25mg/day), her SGOT rose to 76 IU/1 and 
her SGPT rose to 96 IU/1, with a DR of 0 79, after 3 months of 
treatment During her third course of coumarin (50mg/day), her 
SGOT rose to 51 IU/1, and her SGPT rose to 65 IU/1, with a DR of 
0 78, after 2 months of treatment In each case her LFT's 
returned to normal when coumarin was stopped
COMMENT Her LFTs returned to normal while still on coumarin, and 
thus the role of coumarin m  the elevated LFTs is uncertain 
Possibly the elevation is not due to a toxic effect, but reflects 
some therapeutic response to the drug It could also be due to a 
mild, transient toxic effect Thus, the role of coumarin is 
uncertain
TB male, aged 36 with chronic brucellosis, received one course 
of coumarin (50mg/day) His transaminase levels rose to 271 IU/1 
(SGOT) and 360 IU/1 (SGPT), his AP levels rose to 278 IU/1 and his 
DR was 0 75 His LFT's had started to rise after 8 months on 
coumarin Coumarin was stopped but the patient never returned to 
the clinic for further treatment
COMMENT There were no clinical reasons for the rise m  his LFTs 
other than the administration of coumarin Thus, hepatotoxicity 
to coumarin was a probable cause of the hepatitis, but without 
being retreated, it is impossible to be certain This patient was 
probable in level D
LS female, aged 60 with immune suppression, received one course 
of coumarin (50mg/day), and her serum transaminases levels rose 
to 129 IU/1 (SGOT) and 196 IU/1 (SGPT), and her DR was 0 66 Her
LFT's started to rise after 1 month on coumarin, but they
returned to normal while still on coumarin
COMMENT Her LFTs returned to normal while still on coumarin, and
thus the role of coumarin in the elevated LFTs was uncertain 
Possibly the elevation is not due to a toxic effect, but reflects 
some therapeutic response to the drug It could also be due to a
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mild, transient toxic effect Thus, the role of coumarin is 
uncertain
JF female, aged 60 with breast carcinoma, stage II, was treated 
with coumarin (25 mg/day, increased to 300 mg/day after 5 months) 
After 7 months she was started on lbuprofen 2 months later her 
SGOT rose to 141 IU/1 and her SGPT rose to 190 IU/1 and her DR was 
0 74 These returned to normal when coumarin and lbuprofen were 
stopped Her liver scan was normal and she was not retreated with 
coumarin
COMMENT Since the rise in transaminases only occured after 9
months it would seem unlikely to be due to coumarin In most cases 
the rise came by the sixth month of therapy The coincidence of 
treatment with lbuprofen 2 months prior to the rise m  transamin­
ases suggests a possible interaction between coumarin and 
lbuprofen But, without being retreated it is impossible to be 
certain
EL male, aged 70 with oesophageal carcinoma, received one course 
of coumarin (50mg/day) After the first month his SGOT had 
started to rise Coumarin was then increased to 200 mg/day, and
by the second month his SGOT had risen to 330 IU/1, and his SGPT 
had risen to 254 IU/1 His DR was 1 3 These started to fall 
when coumarin was stopped and prednisone (60mg/day) therapy was 
commenced, but within 2 months these had started to rise again 
His LFT's continued to rise, even though coumarin therapy was not 
restarted The patient died soon afterwards
COMMENT This patient was 70 years of age with oesophageal 
carcinoma and died soon after coumarin was stopped While
coumarin could possibly have had a role to play m  the rise in
LFTs, the major cause was probably liver secondaries, especially 
since his LFTs continued to rise after coumarin was stopped 
Thus, the patient was classed as unlikely since there was no 
temporal relationship between the elevated LFTs and coumarin 
therapy
ED male, aged 65 with chronic brucellosis, received one course 
of coumarin (50mg per day) His LFTs rose while on coumarin, 
after 7 months, but they continued to rise when coumarin was 
stopped Bilirubin levels rose to 38 PM/1, serum transaminases
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rose to 680 IU/1 (GOT) and 960 IU/1 (GPT), serum AP levels rose to 
109 IU/1 and his DR was 0 71 AP levels were elevated before 
coumarin treatment commenced, and fluctuated with coumarin 
therapy All levels returned to normal by month 17 The patient 
was hepatitis A and B negative, but there was infectious hepatitis 
m  his family
COMMENT Coumarin may have had a role to play in this patients 
hepatitis, but this could not be confirmed, as the patient was not 
retreated While the patient was hepatitis A and B negative, the 
incidence of infectious hepatitis m  his family would indicate a 
possibility of non-A, non-B hepatitis infection The delay in 
the LFT returning to normal after coumarin therapy was stopped, 
would also indicate that coumarin was unlikely to be involved
EN male, aged 59 with toxoplasmosis, received two courses of 
coumarin treatment During the first course (lOOmg/day) his serum 
transaminase levels started to rise after 3 months and continued 
to rise for a further 4 months, at which stage his SGOT was 192 
IU/1, his SGPT was 380 IU/1, and his DR was 0 5 These levels
returned to normal even though coumarin was continued One year 
later the patient was retreated with coumarin (50mg/day) Three 
months after treatment, the patient, while on holidays m  Spain, 
felt unwell and doubled his dose of coumarin to lOOmg/day On 
returning to the hospital (5 months after the course began), his 
SGOT was 370 IU/1, his SGPT was 824 IU/1, and his DR was 0 45 
Infectious hepatitis was suspected and his LFTs were repeated 
His SGOT and SGPT had fallen, even though coumarin treatment had 
not been stopped The patient was kept on coumarin, and his LFTs 
returned to normal
COMMENT This second rise occured while the patient was holidaying 
in Spain, so a viral infection could be possible The patient was 
found to be hepatitis A negative, and had no history of drug 
abuse or recent blood transfusion Possibly a non-A, non-B 
hepatitis was involved Other liver infections are unlikely, 
since the patient did not suffer from jaundice, and only his 
serum transaminases were affected (and these were affected to a 
small degree compared to patients with hepatitis A) The patient 
had toxoplasmosis, which does not usually cause abnormal LFTs, 
especially of such a limited nature Since m  each case his LFTs 
returned to normal while still on coumarin it was unlikely that
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coumarin was involved m  the rise m  LFTs
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TABLE VI 1
This table shows the liver functon test results of the patients with 
definite or possible/probable hepatoxicity, excluding those on
immunosuppressive therapy
PARA- MONTHS ON DRUG
NAME METERS PRE 1 1 2 1 3 4 5 6 7 8 9 1 10 11 12 13 1 14
DOSE 0 5 1 5 1 3 3 3 3 0 0 1 1CW SGOT 17 19 1 1 19 248 30 1 1SGPT 25 211 1 20 500 66 1 1DOSE 0 1 1 3 0 1 ICW SGOT 18 I 1 136 27 1 1* SGPT 19 1 1 326 57 1 1DOSE 0 5 1 3 1 3 3 3 0 0 3 o 1 0 1ML SGOT 17 211 1 440 57 23 125 321 21 1SGPT 28 301 1 696 118 39 296 49 1 27 1AP 19 19 1 1 253 145 128 128 1091 92 1DOSE 0 3 1 3 1 3 3 3 3 5 3 3 1 3 3 1EN SGOT 21 1 1 64 144 192 1 31 1SGPT 23 1 1120 200 380 1 34 1DOSE 3 3 1 3 1 5 5 5 5 5 5 5 1 5 0 0 3 1EN SGOT 20 1 I 370 53 56 I 30 231* SGPT 17 1 1 824 94 60 1 28 18 IDOSE 0 5 1 5 1 5 0 0 0 0 0 o 1 0 0 5 0 1 0DM SGPT 7 1 1467 410 16 10 10 1 11 944 178 1 16Blrbn <17 1 1 227 440 83 <17 <17 1 <17 149 851 19AP 44 1 1136 85 47 51 51 1 48 227 551 47DOSE 0 5 1 5 1 5 5 5 0 5 0 ° 1 3 0 3 0 1 0ER SGOT 65 581 1 360 3^ 124 44 201 61 34 74 1 30SGPT 102 116 1 1 625 46 190 66 271 96 40 103 1 33
NORMAL LEVELS SGOT (AST) < 40 IU/L 
SGPT (ALT) < 35 IU/L
Bilirubin < 17 uMol/L 
AP < 50 IU/L (or < 230 IU/L)
Dose regimens 0= Omg/day 1« 25mg alternate days 2=
3= 50mg/day 4= lOOmg 3 days per week 5s
7=* 30Omg/day 8= 1,600 mg/day
* Indicates a second course of drug, given much later than the first course
25mg/day
100mg/day
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TABLE VI 2
This table shows the liver function test results and 
regimens for patients on immunosuppressive therapy
c o u m a n n  d o s a g e
PARA- MONTHS ON DRUG
NAME METERS PRE 1 1 2 1 3 4 1 5 6 7 8 9 1° 1 11 12 I 131 14DOSE 0 2 1 2 1 2 2 1 0 7 7 7 7 7 1 5 5 1 0 1 0NM SGOT 20 12 1 1 5121 18 28 16 31 I 90 2201 19 1 10SGPT 21 101 1 648 1 18 74 28 50 1 90 2601 28 1 10Blrbn 4 6 1 1 29 I 8 6 6 6 1 11 9| HI 9DOSE 0 1 1 1 1 1 1 1 1 1 1 2 2 2 1 2 2 1 2 1SGOT 14 1 1120 1 340 28 1 1 18 1AH SGPT 16 1 1274 1 380 27 1 I 18 1Blrbn 5 1 1 io 1 17 12 1
1
1 HIAP 33 1 1 38 1 61 38 1 1 321DOSE 0 5 1 5 1 5 5 1 5 5 5 8 8 8 1 1 1SGOT 29 118 1 1 175 1 165 40 92 427 233 1 1
1
1CD SGPT 39 162 1 1 273 1 216 63 120 626 309 1 1 1AP 159 1611 1 245 187 127 164 242 3071 1 1
NORMAL LEVELS SGOT (AST) < 40 IU/L 
SGPT (ALT) < 35 IU/L
Bilirubin < 17 uMol/L 
AP < 50 IU/L (or < 230 IU/L)
Dose regimens 0= Omg/day 1= 25mg alternate days
3“ 50mg/day 4=“ lOOmg 3 days per week
7« 300mg/day 8= 1,600 mg/day
* Indicates a second course of drug, given much later than the first course
2= 25mg/day 
5= 100mg/day
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TABLE VI 3
This table shows the liver function test results of the patients not 
shown in table VI 1 or VI 2
PARA- MONTHS ON DRUG
NAME METERS PRE 1 1 2 3 4 5 6 7 8 9 10 HI 12 I 131 14DOSE 0 1 5 5 7 7 7 0 0 0 3 3 3 1 3 1 3 1DN SGor 30 34 104 27 24 46 1 1 411SGPT 36 52 208 41 25 66 1 1 79 1DOSE 0 1 3 3 3 3 3 3 0 0 0 5 5 1 0 1 1JG SGOT 19 26 17 16 681 20 1 1SGPT 20 39 170 17 1401 221 1DOSE 0 1 3 3 3 3 0 3 3 3 3 3 3 1 3 1 3 1PW SGOT 16 1 18 64 23 38 47 26 23 1 1 311SGPT 17 1 23 138 34 70 110 43 31 1 1 461DOSE 0 1 5 3 3 3 3 3 3 3 3 3 o 1 3 1 3 1 3MN SGOT 18 1 25 19 19 87 201 1 1 76SGPT 14 1 22 20 16 115 15 1 1 1 96DOSE 0 1 5 5 5 5 5 5 5 5 5 1 1 1TB SGOT 19 20 22 37 271 1 1 1SGPT 18 20 25 65 360 1 1 1AP 39 27 34 282 278 1 1 1DOSE 0 1 5 3 3 3 3 3 1 1 ILS SGOT 20 1 69 129 38 I
1
1 1I
SGPT 19 1103 196 60 11
1
1
1
IDOSE 0 1 2 2 2 2 7 7 7 7 7 0 0 1 0 1 0 1JF SGOT 17 21 26 141 31 1 1 37 1SGPT 19 19 33 190 60 1 1 25 1DOSE 0 1 3 6 0 0 0 0 I I IEL SGOT 36 1 47 330 27 46 52 11 1
I
ISGPT 18 1 22 254 35 28 120 1
1
1
1
IAP 95 1 90 152 114 150 192 1
1
1
1
IDOSE 0 1 3 3 3 3 3 3 3 0 0 0 1 1 ISGOT 18 1 28 26 172 680 150 1 1
1
1ED SGPT 20 1 41 33 240 960 192 1 1 1BLRBn 6 1 8 6 6 38 6 1 ! 1
NORMAL LEVELS SGOT (AST) < 40 IU/L 
SGPT (ALT) < 35 IU/L
Bilirubin < 17 uMol/L 
AP < 50 IU/L (or < 230 IU/L)
Dose regimens 0= Omg/day 
3=* 50mg/day 
7= 300mg/day
1= 25mg alternate days 2= 25mg/day
4= lOOmg 3 days per week 5= lOOmg/day 
8=* 1,600 mg/day
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TABLE VI 4
This table shows the deRitis ratio (SGOT/SGPT) for the 
initial (DR1) and subsequent elevations in serum 
transaminase levels for all the patients
I PATIENT NAME I DR1 1 DR2 I DR3 I DR4 |
| CW | 0 50 | 0 42 1 -- I -- I
| ML | 0 63 | 0 42 1 -- | -- |
| EN | 0 50 | 0 45 | -- j -- |
| ER | 0 58 | 0 65 I -- I -- I
| AH | 0 89 1 -- | 0 63 | 0 72 || NM | 0 79 | 0 85 I — | __ I| ED | 0 71 1 — j — j -_ I
| DN | 0 50 | 0 70 I — j ._ I
| TB | 0 75 1 — I 1 __ I
| LS | 0 67 I 1 — 1 __ j
| MN | 0 74 1 — I __ 1 __ I
1 JF | 0 74 | 0 79 | 0 79 j __ j
| EL | 1 30 1 -- I -- 1 __ i| JG | 0 10 | 0 48 I -- 1 __ I
| PW | 0 46 | 0 43 | -- 1 __ |
I CD I 0 64 | --- | -- | —  |
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TABLE VI 5
This table summarises the data on the number of courses of 
coumann and the role this played in the hepatitis
1 PATIENT 
1 NAME
1 NO OF COURSES 
1 OF COUMARIN
1 1
1 LEVEL * 1 STATUS * |
1 CW t 2 1 B 1 def |1 ML 1 2 1 B I def |1 EN 1 2 I B 1 uni |1 DM 1 2 I B 1 def |
1 ER 1 4 j B j def |
1 NM 1 2 1 B 1 def |1 DN 1 2 1 B 1 pos/unl j1 J G 1 3 i B 1 pos/unl j1 PW 1 2 1 B 1 pos/unl jI MN 1 2 1 B i pos/unl |1 CD 1 1 1 D 1 pos/prob |I AH 1 1 I D 1 pos/prob |j TB 1 1 1 D 1 pos/prob j1 LS 1 1 1 D 1 pos/unl j
1 JF 1 1 I D 1 uni |1 EL 1 1 1 D 1 uni |1 ED L 1 1 D I uni |
* See section II 8 4 for definition of these terms
def- definite , prob= probable, pos- possible, uni- unlikely
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TABLE VX 6 S u m m a r i s in g  t h e  d a t a  on  a l l  p a t i e n t s
PATIENT DOSE (mg/day) DIAGNOSIS
CW 50 Brucellosis
ML 50 Mononucleosis
DM 100 Carcinoma stomach
ER 100/50 Melanoma
CD 100/1,600 Hypernephroma
NM 25/300 Melanoma
AH 25 Brucellosis
TB 50 Brucellosis
EN 300/50 Brucellosis
JG 50 Me1anoma
PW ’ 50 Melanoma
MN 50 Chronic Fatigue Synd
LS 50 Chronic Fatigue Synd
JF 25/300 Carcinoma Breast
EL 200 Carcinoma Oesophagus
ED 50 Brucellosis
EW 50/100 Toxoplasmosis
PEAK ALT ilMn TO 1st TIME TO 2nd
LEVELS (1U/1) ALT RISE (mONiHS; ALI RISE (MONlHSj
500 6 4
696 5 1
467 3 1
625 1 1
626 4 —
648 4 6
380 3 -•
360 8 —
208 2 1
170 3 2
138 4 1
115 4 1
196 1 —
190 9 -
254 1 —
960 7 —
380 3 5
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FIG VI 1 Show ing  t h e  e f f e c t s  o f  c o u m a n n  on  s e r u m  GPT (ALT) a n d  b i l i r u b i n  l e v e l s  f o r
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FIG V I . 2 Show ing  t h e  e f f e c t s  o f  c o u m a n n  on  s e r u m  GPT(ALT)
l e v e l s  i n  p a t i e n t  ER
Cl, C2 = 100 mg/day 
C3, C4 = 50 mg/day
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FIG V I . 3 S how ing  t h e  e f f e c t s  o f  c o u m a n n  on  s e r u m  GPT(ALT)
a n d  b i l i r u b i n  l e v e l s  i n  p a t i e n t  NM
C1 * 25 mg coumann per day 
C2 = 300 mg coumann per day 
03 33 100 mg coumann per day 
DEX = 10 mg dexamethasone per day
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SERUM 
BILIRUBIN 
LEVELS 
(jjM/1)
TIME (MONTHS)
FIG VI,4 Showing the effects of coumarm on serum GPT (ALT)
levels for patient AH
C1 = 25mg coumarm on alternate days 
C2 = 25 mg coumarm per day
C+P = 50 mg cyclophosphamide and 60 mg prednisone on
alternate days
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F i g  VI 5 Show ing  t h e  e f f e c t s  o f  c o u m a r i n  on  s e r u m  GPT(ALT) a n d  a l k a l i n e
p h o s p h a t a s e  l e v e l s  f o r  p a t i e n t  CD
C3 = 1600 mg coumarin per day
C+P = 60 mg prednisone and 50 mg cyclophosphamide on alternate days (1 week m  4)
Range TIME (MONTHS)
Fig VI 6 Showing the effects of coumarm on serum GPT(ALT) levels 
for patient JG
C1, C2, and C3 * 50mg coumarm per day
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VI 3 DISCUSSION
38 patients treated with coumarm had abnormal LFTs during 
therapy Only 16 of these had increases in their enzyme levels 
that were sufficiently large (le twice normal value) to warrant
further investigation This level was selected to eliminate
patients with small rises in LFTs due to variation m  assay 
procedure, or due to other stresses upon the liver Patients 
were classified according to the method of Strieker and Spoelstra
(1985) They divide cases into different levels and also into the 
categories definite, probable, possible and unlikely (see 
Materials and Methods) Since there has only ever been 1 reported
case of hepatotoxicity to coumarm (Faurschou, 1982), level A
does not apply
VI 3 1 THE ROLE OF COUMARIN
17 patients in the study showed a sufficiently large rise m  their 
LFTs to have further investigation for hepatotoxicity 4 of these 
(ED, EL, JF, and EN), were considered unlikely to be adverse 
reactions to coumarm, due to the nature of the hepatitis EL’s 
hepatitis was probably due to liver secondaries, both ED's and 
EN's hepatitis were thought to be infectious m  nature, and JF's 
hepatitis was possibly due to an interaction with lbuprofen 5 
patients (DN, JG, PW, MN, and LS) developed elevated LFTs which 
returned to normal while still on coumarm The significance of 
this is uncertain, and whether it represents a mild hepatotoxic 
effect to which the patients became tolerant, or a therapeutic 
response by coumarm is unknown
8 patients (CW, ML, DM, ER, NM, AH, CD, and TB) developed 
elevated LFTs which had no apparent clinical cause other than as a 
result of the administration of coumarm 5 of these patients 
were retreated with coumarm, and were thus m  level B These 5 
had definite hepatotoxicity, due to the strong temporal 
relationship, and the lack of other possible causes TB never 
returned for treatment after coumarm therapy AH's LFTs returned 
to normal when immunosuppressive therapy began, so her coumarm 
therapy was never stopped CD's prognosis was very poor, so it 
was considered too risky to stop coumarm therapy as long as his 
LFTs did not rise to a dangerous level These 3 patients who were
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not retreated, or who did not have a break m  therapy were m  
level D, and their elevated LFTs were possible/probable, rather 
than definite hepatotoxicity drug Thus, m  8 of the 17 
patients, there was a very strong association between adminis­
tration of coumarm, and appearance of the hepatitis, in 5 of the 
patients there was a weak association while m  3 of the patients 
the association was probably coincidental
VI 3 2 THE NATURE OF THE ADVERSE REACTION TO COUMARIN 
In 15 cases there was a distortion of the enzyme pattern, with 
SGPT levels higher than SGOT levels This indicates that the loss 
of enzymes was mainly cytoplasmic Thus, while the necrosis may 
have been extensive, it was not severe 5 patients had a slight 
rise m  AP levels, and 3 had elevated bilirubin levels 8 
patients had a deRitis ratio of less than 0 7
In all, 8 patients had a relationship between coumarm, and their 
hepatitis, which was predominantly hepatocellular This was 
indicated by the relatively large elevations m  serum transamin­
ases, and the limited rise m  AP and bilirubin levels The 
presence of zonal necrosis, and baloonmg degeneration, m  the 
needle biopsy, further confirms this The jaundice experienced 
by 3 of the patients, and the presence of bile casts m  the 
needle biopsy, would indicate that it was possibly mixed hepato­
cellular hepatotoxicity
The liver toxicity seen m  these patients was unpredictable m  
nature The dose that produced abnormal LFTs varied from patient 
to patient, the time taken to produce an elevated LFT varied from 
3 to 8 months, subsequent elevations usually occured much quicker 
than the first elevation, and the number of patients affected was 
very small (0 3%) All these factors suggest an idiosyncratic 
hepatotoxicity (Zimmerman, 1972, 1982)
Three patients responded favourably to immunosuppressive therapy 
Since there was no evidence of inflammation from the biopsy, and 
none of the patients had a palpable (enlarged) liver, these drugs 
were unlikely to be controlling the toxicity via an 
anti-inflammatory effect They were more likely suppressing an 
immune reaction, induced by coumarm Shoham (1985) reports on a 
number of adverse effects to treatment with immunostimulatory 
drugs Many of these responses are directly due to stimulation of
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the immune system In some cases an inappropriate response is 
created, while in other cases, eg interferon therapy, many of the 
side effects are due to the therapeutic effects of the treatment 
This can be seen m  viral infections where many of the symptoms 
are absent when the immune system is suppressed However, when the 
immune system is restored these symptom reappear In this case 
the effect is not a toxic effect, but a therapeutic effect This 
could be the case with patients treated with coumarm, especially 
those with the transient elevated LFTs
The abnormal liver function seen here is different to the 
hepatotoxicity seen in animal studies Hepatotoxicity data from 
rats cannot be extrapolated to humans, as the metabolism of 
coumarm m  rats is very different to that m  humans (Cohen et al, 
1979) The doses used clinically are much lower than the doses 
that caused hepatotoxicity m  baboons (67 5 mg/kg/day) (Evans et 
al , 1979) The toxicity seen m  baboons was dose dependent, and 
resulted in liver enlargement, unlike the dose independent 
toxicity seen m  humans
There was one previously reported case of hepatotoxicity to 
coumarm m  humans (Faurschou, 1982) This was in a 33 year old 
woman with Turner's syndrome She had elevated bilirubin, AP and 
SGOT levels Her biopsy showed portal tract inflammation with 
eosinophilia, multmucleated hepatocytes (a form of degeneration), 
and moderate centnlobular cholestase This could have been 
hepatocanilicular, but since her SGOT was very high (843 IU/1), 
it would indicate that there was extensive necrosis, and 
therefore, this was probably mixed hepatocanalicular Her 
jaundice cleared up when coumarm was stopped She was not 
retreated with coumarm
VI 3 3 CONCLUSION
This study shows that 0 23% of patients treated with coumarm had 
a definite, and 0 13% had a probable/possible, adverse reaction to 
coumarm This adverse reaction was expressed as hepatotoxicity, 
which was idiosyncratic and hepatocellular Since hepatocellular 
toxicity is potentially very serious, patients, undergoing treat­
ment with coumarm, should have liver function tests every 3-6 
months These LFTs should include the determination of serum 
bilirubin, GOT, GPT and AP levels If there is evidence of 
abnormal liver function m  any patient, coumarm therapy should
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be stopped When the patient's LFTs return to normal, coumann 
therapy can be restarted, with more frequent LFTs (eg monthly) 
If the patient reacts again, coumann therapy should be stopped 
completely In all 14 cases, liver function returned to normal 
when coumann therapy was stopped, without any permanent liver 
damage There was some evidence to show that immunosuppressive 
therapy can moderate the toxicity Thus, m  any patient who has a 
severe reaction to coumann, immunosuppressive therapy (eg 
glucocorticoids) may help to control the toxicity
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SECTION VII 
CONCLUSIONS
V I I CONCLUSION
The work presented here focuses on the production and 
characterization of antibodies, as well as a study of the in vivo 
and the i n vitro effects of coumann Monoclonal antibodies 
against FVIII CAg and fibrinogen were successfully produced and 
characterised While the monoclonal antibody technique proved 
successful m  this case, it did not produce any results when a 
diazepam conjugate was used This highlights one of the problems 
with the technique - variability Part of the reason for this 
variability is a lack of data on the essential parameters for a 
successful fusion Thus, different operators have different 
methods for fusions, and no particular reason for using them other 
than that "they work" Two other sources of variability are 
batch-to-batch variation m  foetal calf serum, and m  the 
Polyethylene glycol Once fusions work, this variability is 
unimportant However, it is very difficult to determine the 
cause(s) for unsuccessful fusions when the essential factors are 
unknown
Despite the problems with monoclonal antibody production the 
technique has a very important role to play, especially m  the 
production of antibodies to conjugates If 10% of the antibodies 
against a particular conjugate are directed against the hapten 
portion, then 90% of the antiserum from an immunised animal would 
be lost during purification of the antiserum This makes 
polyclonal antiserum against haptens very expensive This problem 
can be overcome by selecting a clone of cells that produces 
antibodies against the hapten only
While antibodies have a role to play in vivo, their major role is 
m  analysis The monoclonal antibodies produced against the blood 
coagulation factors will all be used for development using 
voltammetry, bifunctional antibodies, and a novel method of 
lmmunoana lysis using lodmated Bolton Hunter-conjugated anti­
bodies These antibodies have recently been developed m  our 
laboratories, and those of our collaborators (Rodriguez Flores et 
al , 1988a, 1988b, Q'Kennedy et al f 1988, Reading et al., 1988)
Blood coagulation factors have a role m  tumour growth Brown et 
al , (1988) reported a role for fibrin in the growth of tumours
McCulloch and George, (1988) ,found that a complex of blood 
coagultaion factors had ablity to promote tumour metastasis 
idependently of fibrin Métastasés can be inhibited by certain 
coumarins, such as the anticoagulant warfarin This association 
between coumarin anticoagulants and cancer, led to a study of the 
effects of other coumarins on tumour growth This resulted m  
research on coumarin, and more recently a synthetic coumarin-like 
compound, Flavone acetic acid (Urba et al , 1988), as anticancer 
agents Thus, a study on both blood coagulation factors and 
coumarin are very relevant to understanding tumour growth, and may 
have a role to play in cancer therapy
219
SECTION VIII 
REFERENCES
V I I I REFERENCES
ASTALDI, G C B , Janssen, M C , Lansdorp, P , Willems, C , 
Zeijlemaker, W P , and Oosterhof, F , (1980) "Human endothelial 
culture supernatant (HECS) A growth factor for hybridomas " J 
Immunol , 125 1411-1414
#
BAR, F , and Griepentrog, F , (1967) "Die Situation m  der ges- 
undheitlichen Beurteilung der Aromatisierungsmittel fur Lebens- 
mittel " Med u Ernahrg , 8 244-251
BARROWCLIFFE, T W , and Kirkwood, T B L , (1981) "Principles of 
bioassay of haemostatic components " Haemostasis and Thrombosis, 
Ed's Bloom, A L , and Thomas, D P , Churchill Livingston, 
Edinburgh pp 832-844
BLOMBACK, B , Blomback, M , Henschen, A , Iwanaga, S , and Woods,
K R , (1968) "The N terminal disulphide knot of human fibrino­
gen " Nature (London), 218 130-134
BLOMBACK, M , (1981) "Chromogenic substrates in the laboratory
diagnosis of clotting disorders " Haemostasis and Thrombosis,Ed*s 
Bloom, A L , and Thomas, D P , Churchill Livingston, Edinburgh 
pp 809-823
BLOOM, A L , (1981) "Inherited disorders of coagulation",
Haemostasis and Thrombosis, Ed's Bloom, A L , and Thomas, D P 
Churchill Livingstone, Edinburgh pp 321-370
BLOOM, A L , (1983) "Benefits of cloning genes for clotting
factors" Nature (London), 303 474-475
BOLTON, T , and Casley-Smith , J R , (1975) "An m  vitro demon­
stration of proteolysis by macrophages and its increase with
coumarin " Expenentia, 31(3) 271-273
BOWERY, N G , (1982) "Baclofen 10 years on " TIPS, 3 400-403
BRAESTRUP, C , and Squires, R F , (1977) "Specific benzodiazepine 
receptors m  rat brain characterized by high affinity 3H-diazepam 
binding " Proc Nat Acad Sci (USA), 74 3805-3809
220
BRILES, D E , and Kearney, J F , (1985) "Antiidiotypic anti­
bodies" Meth Enz , 116 174-189
>
BROWN, L F , Asch, B , Harvey, S , Buchinski, B , and Dvorak, H , 
(1988) "Fibnnogenn influx and accumulation of cross-linked 
fibrin in mouse carcioma's " Cancer Res , 48 1920-1925
BROZOVIC, M , (1981) "Acquired disorders of blood coagulation", 
Haemostasis and Thrombosis, Ed’s Bloom, A L , and Thomas, D P 
Churchill Livingstone, Edinburgh pp 411-438
BRUNE, H , and Deutschwenzel, R , (1985) "Toxicity testing of
coumann in a 30 month feeding study m  rats " Presented at 
Coumann Symposium of Schaper and Brummer, Goettingen, Oct , 1985
BUDD, R D , and Walkm, E , (1980) "Mass screening and confirm­
ation of diazepam in urine by EMIT-thin layer chromatography " 
Clin Toxicol , 16 201-207
BUTLER, V P , Watson, J F , Schmidt, D H , Gardner, J D , Mandel, 
W , and Skelton, C L , (1973) "Reversal of the pharmacological 
and toxic effects of cardiac glycosides by specific antibodies " 
Phamacol Rev , 25^ 239-248
CARROLL, K and O'Kennedy, R , (1988) "The elimination of myco­
plasma from infected hybndomas by passage m  Balb/C mice" J 
Immunol Meth , 108 189-193
CASLEY-SMITH, J R , Foldi Borcsok, E , and Foldi, M , (1975) "A
fine structural demonstration that some benzopyrones act as 
"vitamin P" m  the rat " Am J Clin Nutr , ^8 1242-1254
CASLEY-SMITH, J R , and Window, J , (1976) Quantitative
morphological correlations of the increased vascular pereability 
caused by burning and histamine, with the effect of benzopyrones " 
Microvasc Res , 11 279-305
CERLEK, von S , (1977) "Die Wirkung ernes BenzopyronPraparates 
auf die Leberfunkton 1 Arzneim-Forsch (Drug-Res ), 27(3) 611-
612
221
CHEN, R , and Doolittle, R , (1970) "Isolation, characterisation 
and location of donor-acceptor unit from cross-linked fibrin" 
Proc Nat Acad Sci (USA), 66 472-479
CHIU, T H , and Rosenberg, H C , (1983) "Multiple conformational 
states of benzodiazepine receptors " TIPS, 4 348-352
CHOPEK, M W , Girma, J P , Fujikawa, K , Davie, E W , and Titani, 
K , (1986) "Human von Willebrand Factor A multivalent protein
composed of identical subunits" Biochemistry, 25^ 3146-3155
CLAUSS, A , (1957) "Gerinnungs physiologische schnell Methods 
zur bestimmung des Fibrinogens" Acta Haematol , 17 237-240
COHEN, A J, (1979) "Critical review of the toxicology of 
coumann with special reference to interspecies differences m  
metabolism and hepatotoxic response and their significance to 
man " Fd Cosmet Toxicol 17 277-289
COHEN, I R , (1988) "The self, the world and autoimmnity" Sci 
AM , 258 34-42
COHN, E , Strong, L , Hughes, W , Mulford, D , Ashworth, J ,
Melm, M , and Taylor, H , (1946) "Preparation and properties of
serum and plasma proteins IV A system for the separation into 
fractions of the protein and lipoprotein components of biological 
tissues and fluids " J Am Chem Soc , 68 459-64
COOPER, S J , (1985) "Possible endogenous basis for anxiety "
TIPS, 6 312-313
COSTA, E , Guidotti, A , and Mao, C C , (1975) "Evidence for the 
involvement of GABA m  the action of benzodiazepines studies on 
rat cerebellum " In "Mechanisms of action of benzodiazepines"
Ed's Costa, E , and Greengard, P Raven Press, NY pp 113-130
CLODIUS, L , and Piller, N B , (1978) "Conservative therapy for 
postmasectomy lymphoedema " Chir Plastica (Berl ), 4 193-202
CONLEY, D , and Marshall, M E , (1987) "Effects of coumann on 
, human tumour cell growth and cell cycle analysis in vitro " Proc
222
A A C R , 28 63
De BLAS, A L , Sangameswaran, L , Haney, S A , Park, D , Abraham,
C J , and Rayner, C A , (1985) "Monoclonal antibodies to benzo­
diazepines " J Neurochem , 45 1748-1753
DIXON, R , (1982) "Radioimmunoassay of benzodazepmes" Meth
Enzymol , 84 490-497
DOOLITTLE, R F , Cassman, K G , Cottred, B A , Fnezner, S J ,
Hucko, J , and Takagi, T , (1977) "Ammo acid sequence
studies on the alpha chain of human fibrinogen Characterisation 
of 11 cyanogen bromide fragments" Bichemistry, 16(8) 1703-1709
DOOLITTLE, R F , (1981a) "Fibrinogen and fibrin” Sci Am , 245
92-101
DOOLITTLE, R F , (1981b) "Fibrinogen and fibrin”, Haemostasis 
and Thrombosis, Ed's Bloom, A L , and Thomas, D P Churchill 
Livingstone pp 163-191
DUC-NGUYEN, H , Rosenblum, E N , and Zeigel, R F , (1966)
"Persistent infection of a rat kidney cell line with Rauscher 
murine leukaemia virus " J Bactenol , 92 1133-1137
EARLEY, J V , Fryer, R I , and Ning, R Y , (1979)
"Quinazolmes and 1,4-Benzodiazepines LXXXIX Haptens useful in 
Benzodiazepine immunoassay development " J Pharmaceut Sci , 68 
845-850
EHLERT, F J , (1986) "'Inverse agonists’, cooperativity and drug 
action at benzodiazepine receptors " TIPS, 7 28-32
ENDEL, W , and Seidel, G , (1978) "Coumann toxicity m  diff­
erent strains of mice " Agents Actions, 8 299-302
ERLANGER, B F , (1973) "Principles and methods for the prearation 
of drug protein conjugates for immunological studies " Pharmacol 
Rev , 25 271-280
ERLANGER, B F , (1980) "The preparation of antigenic hapten- 
carrier conjugates" Meth Enzymol , 70 85-104
223
EVANS, J G, Gaunt, I F, and Lake, B G, (1979) "Two year toxicity
study on coumarin m  the baboon " Fd Cosraet Toxicol , 17 187-
193
FASS, D N , Knutson, G J , and Katzmann, J A , (1982) "Monoclonal 
antibodies to porcine Factor VIII coagulant protein and their use 
in the isolation of active coagulant protein " Blood, 59(3) 
594-600
FAURSCHOU, P (1982) wToxic hepatitis due to benzo-pyrone " Human
Toxicology 1(2) 149-150
FAY, P J , Chavm, S I , Schroder, D , Young, F E , and Marder,
V J (1982) "Purification and characterisation of a highly 
purified human factor VIII, consisting of a single type of 
polypeptide chain" Proc Natl Acad Sci (USA), 79 7200-7204
FAY, P J , Kawai, Y , Wagner, D , Gmsburg, D , Bonthron, D , 
Ohlsson-Wilhelm, B , Chavm, S I , Abraham, G , Handm, R ,
Orkm, S , Montgomery, R , and Marder, V , (1986) "Polypeptide of 
von Willebrands factor circulates m  blood and is identical to von 
Willebrands antigen II" Science, 232 995-998
FEDERAL REGULATIONS, (1954), 19 1239
FERRER0, P, Guidotti, A , Conti-Tronconi, B and Costa, E , (1984) 
"A brain octadecaneneuropeptide generated by tryptic digestion of 
DBI (diazepam binding protein) functions as a proconflict ligand 
of benzodiazepine recognition sites" Neuropharmacol , 23^ 1359-
1362
FERRY, J , (1952) "The mechanism of polymerisation of fibrin­
ogen" Proc Natl Acad Sci (USA), 38 566-569
FEUER, G , (1974) "The metabolism and biological actions of
coumarms " Progr Med Chem , 10 85-158
FEUER, G , Goldberg, L , and Gibson, K I , (1966) "Liver
response tests VII Coumarin metabolism in relation to the
inhibition of rat liver glucose-6-phosphatase " Fd Cosmet 
Toxicol , 4 157-167
224
FEUER, G , Kellen, J A , and Kovacs, K , (1976) "Suppression of 
7,12-dimethylbenz(a)anthracene induced breast carcinoma by
coumarin m  the rat " Oncology, 33 35-39
FOLDI-BORCSOK, E , Bedall, F K , and Rahlfs, V W , (1971) "Die 
antiphlogistische und odemhemmende Wirkung von cumarin aus 
Melilotus officinalis " Arzeneim-Forsch (Drug Res ), 21 2025-
2030
FONTAINE, L , Grand, M , Molho, D , and Boschetti, E , (1967) 
"Activite antnnflammtorie experimentale de coumannes, mdane- 
diones et acyl-’.ndane-diones apparantees aux anticoagulants oraux" 
Med Pharmacol Exp , 17 497-507
FOSTER, P A , Fulcher, C A , Houghten, R A , and Zimmerman,
T S , (1988) "An immunogenic region within residues Val 1670 - 
Glu 1684 of the factor VIII light chain induces antibodies which 
inhibit binding of factor VIII to von Willebrand factor " J 
Biol Chem , 263 5230-5234
FOWLER, W E , Fretto, L , Hamilton, K , Erickson, H ,McKee, P ,
(1985) "Substructure of human von Willebrand factor" J Clm
Invest , 76 1491-1500
FRIEDLAND, G H , and Klein, R S , (1987) "Transmission of the 
human immunodeficiency virus" NEJM, 317 1125-1133
FUJIMURA, Y , Titani, K , Holland, L Z , Russell, S R , Roberts,
J R , Elder, J H , Ruggen, Z M , and Zimmerman, T S , (1986) 
"von Willebrand factor A reduced and alkylated 52/48 kDa 
fragment beginmg at amino acid residue 449 contains the domain 
interacting with platelet glycoprotein lb" J Biol Chem , 261
381-385
FULCHER, C A , Ruggen, Z M , and Zimmerman, T S , (1983)
"Isoelectric focusing of human von Willebrand Factor m  urea
-agarose gels" Blood, 61(2) 304-310
GAFFNEY, P J , (1972) "Localisation of the carbohydrate m  the 
subunits of human fibrinogen and its plasmm induced fragments"
Biochim Biophys Acta , 262 453-458
225
GARTEN, S , and Wosilait, W D , (1971) "Comparative study of the 
binding of coumarin anticoagulants and serum albumin ” Biochera 
Pharmacol , 20 1661-1668
GAWRYL, M S , and Hoyer, L W , (1982) "Inactivation of Factor 
VIII coagulant activity by two different types of human 
antibodies" Blood, 60(5) 1103-1109
GIDDINGS, J C , and Peake, I R , (1981) "Principles of
immunoassay of haemostatic components " Haemostasis and 
Thrombosis, Ed’s Bloom, A L , and Thomas, D P , Churchill 
Livingston, Edinburgh pp 824-831
GIRMA, J D , Meyer, D , Verweij, C L , Pannekoek, H, and Sixma, 
J J , (1987) "Structure-function relationship of human von
Willebrand factor” Blood, 70(3) 605-611
GITSCHIER, J , Wood, W , Goralka, T , Wion, K , Chen, E , Eaton, 
D , Vehar, G , Capon, D , and Lawn, R , (1984) "Characterisation 
of the human factor VIII gene" Nature (London), 312 326-330
GRIEPENTROG, F , (1973) "Pathologisch-anatomische Befunde zur 
Karzmogenen Wikung von Cumann lm Tierversuch " Toxicology, 1
93-102
GRIFFIN, J H , (1981) "The contact phase of blood coagulation", 
Haemostasis and Thrombosis, Ed's Bloom, A L , and Thomas, D P 
Churchill Livingstone, Edinburgh pp 163-191
GRIGG, G W , (1979) "Induction of DNA breakdown and death m
Escherichia coll by phleomycm Its association with dark-repair 
process " Mol Gen Genet , 104 1-11
deGROOT, PhG , and Sixma, J J , (1986) "Interaction of blood
platelets with the vessel wall” Biology and Pathology of 
platelet vessel wall Interaction, Ed's Jolles, G , Legrand, Y , 
and Nurden, A Academic Press, London pp 39-52
GUIDOTTI, A , Forchetti, C M , Corda, M G , Konkel, D , Bennett,
C D , and Costa, E , (1983) "Isolation, characterization and 
purification to homogeneity of an endogenous polypeptide with
226
HADDEN, J W , (1982) "Immunomodulators in the immunotherapy of
cancer and other diseases" TIPS, Z 191-194
HAEFELY, W , Kulscar, A , Mohler, H , Pieri, L , Pole, P , and
Schaffner, R , (1975) "Possible involvement of GABA m  the
central actions of benzodiazepines 1 In "Mechanisms of action of 
benzodiazepines", Ed's Costa, E , and Greengard, P Raven Press,
New York, pp 131-151
HAEFELY, W , (1983) "Tranquilizers", in "Psychopharmacology 1, 
part 1 Preclmical psychopharmacology " Ed's Grahame-Smith, D G , 
and Cowen, P J , Excerpta Medica Publishing Company, Washington
HAGAN, E C , Hansen, W H , Fitzhugh, 0 G , Jenner, P M , Jones, 
W I , Taylor, J M , Cong, E L , Nelson, A A , and Brouwer, 
J B , (1967) "Food flavouring and compounds of related
structure II Subacute and chronic toxicity " Fd Cosmet 
Toxicol , 5 144-157
HALL, C E , and Slayter, H S , (1959) "The fibrinogen molecule
its size, shape and mode of polymerisation" Biophys Biochem
Cytol , 5 11-15
HAMASHIMA,Y , Harter, J G  , and Coons, A H , (1964) "The
localisation of albumin and fibrinogen in human liver cells" J
Cell Biol , 20 271-273
HAVERKATE, F , and Timan, G , (1979) "Protective effect of 
calcium m  the plasram degradation of fibrinogen and fibrin 
fragments D" Thromb Res , 10 803-812
HAVERKATE, F , Timan, G , and Nieuwenhuizen, W (1972)
"Anticoagulant properties of fragments D from human fibrinogen and 
fibrin" Eur J Clin Invest , 9 253-255
HAZELTON, L W , Tusing, T W, Zeitlen, B R, Theissen, R , and 
Murer, H K , (1956) "Toxicity of coumann " J Pharmacol Exp 
Therapeut , 116 348-358
a g o n i s t i c  a c t i o n  o n  b e n z o d i a z e p i n e  r e c e p t o r s "  P r o c  N a t l  A cad
S c i  (USA), 80 3 5 3 1 -3 5 3 5
227
HERSH, E , Chingos, M , and Mastrangelo, M , (eds) (1981)
"Augmenting agents m  cancer", Raven Press, New York
HINK, J H , Hidalgo, J , Seeberg, V P , and Johnson, F F , (1957) 
"Preparation and properties of a heat treated human plasma protein 
fraction" Vox Sanguinis, 2 174-186
HOYER, L W , (1981) "The factor VIII complex structure and
function" Blood, 58(1) 1-13
HRC REPORT, (1978) "Ames metabolic activation test to assess 
the potential mutagenic effect of Venalot " No SCB 10/78294
HUDSON, L , and Hay, F C , (1980) "Practical Immunology "
Blackwell Scientific Publications, Oxford
JAFFE, E A , Hoyer, L W , and Nachman, R L , (1973) "Synthesis of 
antihemophilic factor antigen by cultured human endothelial
cells" J Clin Invest , 52 2757-2764
JENNER, P M , Hagan, E C , Taylor, J M , Look, E L ,  and
Fitzhugh, 0 G , (1964) "Food flavourings and compounds of
related structure 1 Acute toxicity " Fd Cosmet Toxicol , 2
327-333
JONES, P , Hamilton, P J , Oxley, A , Codd, A , Tedder, R ,
(1985) "Anti-HTLV III positive laboratory reagents" Lancet, l 
1458-1459
KAIDBEG, K H , and Kligman, A M , (1981) "Photosensitization by 
coumann derivatives " Arch Dermatol , 117(5) 258-263
KAIGHEN, M , and Williams, R T , (1961) "The metabolism of
3-14c_C0umarln « j Med Pharm Chem ,3 25-43
KANE, W H , and Davie, E W , (1988) "Blood coagulation factors V
and VIII Structural and functional similarities and their 
relationship to hemorrhagic and thrombotic disorders" Blood, 
71(3) 539-555
228
KIPPS, T J , (1985) "Switching the isotype of monoclonal
antibodies" In "Hybndoma technology in the Biosciences and 
Medicine", Ed , Springer, T A , Plenum Press, New York pp 89-101
KITAGAWA, H , and Iwaki, R , (1963) "Coumarin derivative for
medicinal purposes XVIII Pharmacological studies on coumarin 
derivatives having biological activity " Yakugaku Zasshi , 83 
1124-1134
KOH, M M S , (1979) "Modification of the inflamatory
response " Thesis, Department of Experimental Pathology, St
Bartholomew's Hospital Medical College, University of London
KOHLER, G , and Milstein, C , (1975) "Continuous cultures of
fused cells secreting antibody of predefined specificity" 
Nature (London), 256 495-497
KOPPERT, P W , Koopman, J , Haverkate, F , and Nieuwenhuizen, W ,
(1986) "Production and characterisation of a monoclonal antibody 
reactive with a specific neoantigenic determinant (comprising B
54-118) in degradation products of fibrin and fibrinogen" Blood, 
68(2) 437-441
KRUSKAL, J , Commerford, P , Franks, J , and Kirsch, R , (1987)
"Fibrin and fibrinogen-related antigens m  patients with stable
and unstable coronary artery disease 1 NEJM, 317 1361-1365
LANDSTEINER, K , (1945) "The specificity of serological react­
ions " Harvard university Press, Harvard, USA
LAURELL, C B , (1966) "Quantitative estimation of proteins by
electrophoresis m  agarose gel containing antibodies " Analytical 
Biochem , 15 45-48
LAURENT, T C , and Blomback, B , (1958) "On the significance of
the release of 2 different peptides from fibrinogen during 
clotting" Acta Chem Scand , 12 1875-1877
LEVINE, J D , Harlan, J M , harker, L A , Joseph, M L , and
Counts, R B , (1982) "Thrombin-mediated release of Factor VIII 
antigen from human umbilical vein endothelial cells m  culture”
229
B lo o d ,  6 0 ( 2 )  5 3 1 - 5 3 4
LOLLAR, P , Parker, C , and Tracy, R , (1988) "Molecular
characterization of commercial porcine factor VIII concentrate " 
Blood, 71(1) 137-143
LYNCH, D C , Zimmerman, T S , Collins, C , Brown, M , Morin, M , 
Ling, E , Livingston, D , (1985) "Molecular cloning of cDNA for
human von Willebrand factor Authentication by a new - method " 
Cell, 41 49-56
MACFARLANE, R G , (1964) "An enzyme cascade m  the blood
clotting mechanism and its function as a biochemical amplifier" 
Nature (London), 202 498-499
MARDER, V J , (1971) "Identification and purification of
fibrinogen degradation products produced by plasmm 
considerations on the structure of fibrinogen " Scand J Haem 
Suppl , 13 21-36
MARSHALL, M E , and Hollingsworth, P , (1987) "Effects of
coumann on mitogenic responsiveness on normal human peripheral 
blood (PB) lymphocytes " Proc A A C R , 28 338
MARSHALL, M E , Mendelsohn L , Butler, K , Riley, L , Cantrell, 
J , Wiseman, C , Taylor, R , and MacDonald, J S , (1987a)
"Treatment of metastatic renal cell carcinoma with coumann
(1,2-Benzopyrone) and Cimetidine A pilot study " J Clin One , 
5, 862-866
MARSHALL, M E , Riley, L , Rhoades, J , Eicchorn, T , Jennings, 
D , Cibull^ , M , and Thompson, J , (1987b) "Quantitative effects 
of coumann and cimetidine on peripheral blood lymphocytes and 
natural killer (NK) cells m  patients with advanced malignancies " 
Proc A A C R , 28 186
McCULLOCH, P , and George, W , (1988) "Promotion of metastasis 
by a specific complex of coagulation factors may be independent of 
fibrin formation " Br J Cancer, 5£ 158-162
McKEE, P A , Mattock, P , and Hall, R L , (1970) "Subunit
structure of human fibrinogen, soluble fibrin, and cross-linked
230
i n s o l u b l e  f i b r i n "  P r o c  N a t l  A cad  S c i  (U S A ), 66 7 3 8 - 7 4 4
MERIGAN, T C , (1988) "Human interferon as a therapeutic agent 
a decade passes " NEJM, 318 1458-1460
MERRIL, C R , Goldman, D , and Van Keuren, M L , (1984)
"Silver staining" Meth Enzymol , 104 441-447
MEULY, W C , (1978) Kirk Othmer "Encyclopedia of Chemical
Technology", 3rd edition, 7, John Wiley and Sons, NY p 196-206
MIDDLETON, E , Q984) "The Flavenoids", TIPS, 5 335-338
MIKAELSSON, M E , Forsman, N , and Oswaldsson, U M , (1983)
"Human factor VIII A calcium-linked protein complex" Blood, 
62(5) 1006-1015
MOHLER, H , Battersby, M K , and Richards, J G , (1980) "Benzo­
diazepine receptor protein identified and visualised m  brain 
tissue by a photoaffmity label " Proc Natl Acad Sci (USA), 
77 1666-1670
MOHLER, H , and Okada, T , (1977) "Benzodiazepine receptors 
demonstration in the central nervous system " Science, 198 849-
851
MONTGOMERY, R R , Kunicki, T J , Glode, L M , (1986) "Use of 
monoclonal antibody to increase the sensitivity and specificity of 
precipitating immunoassays and cell surface binding immunoassays" 
Meth Enzymol , 121 702-717
MORAN, E , 0'Kennedy, R , and Thornes, R D , (1987) "Analysis of 
coumarin and its urinary metabolites by high performance liquid 
chromatography " J Chromatog, 416 165-169
NEWMAN, J , Johnson, A , Karpatkm, M , and Puszkin, S , (1971) 
"Methods for the production of clinically effective mtermediate- 
and high-punty factor VIII concentrates" Br J Haematol , 21 
1-20
NIEUWENHUIZEN, W , and Gravesen, M , (1981) "Anticoagulant and 
calcium binding propeties of high molecular weight derivatives of
231
human fibrinogen, produced by plasmin (fragments X)" Biochim
Biophys Acta , 668 81-88
NXJTT, D , (1986) "Benzodiazepine-dependence in the clinic
reason for anxiety7" TIPS, 7 457-460
OHTA, J , Watanabe, K , Monya, M , Shirasu, Y , and Kada, T , 
(1983) "Anti-mutagenic effects of coumann and umbelliferone on
mutagenesis induced by 4-nitroqumolme-l-oxide or uv-irradiation
in E coli " Mutat Res , 1T7 135-138
0'KENNEDY, R , Bator, J , and Reading, C L , (1988) "A
microassay for the determination of iodide and its application for 
the measurement of the lodination of proteins and the catalytic 
activities of lodo-compounds " Submitted to Analytical Biochem
O'REILLY, R A , (1971) "The interaction of several coumann
compounds with human and canine plasma albumin " Mol Pharmacol , 
7, 209-212
PARENTE, L , Koh, M S , Willoughby, D A , and Kitchen, A ,
(1979) "Studies on cell motility m  mflamation II The in vivo 
effect of anti-inflammatory and anti-rheumatic drugs on chemotaxis 
in vitro " Agents Actions, 9(2) 196-200
PERKIN, W H , (1868) J Chem Soc , 21 53
PESKAR, B , and Spector, S , (1973) "Quantitative determination
of diazepam in blood by radioimmunoassay" J Pharmacol Exp 
Therapeut , 186 167-172
PFLUG, J J , and Taylor, L M , (1975) "An experimental assessment 
of the action of a drug for the swollen leg " Folia Angiologica, 
XXIV 72-77
PHILLIS, J W , and O'Reagan, M H , (1988) "Benzodiazepine
interaction with adenosine systems explains some anomalies m  GABA
hypothesis " TIPS, 9 153-154
PILLER, N B , (1976a) "The influence of coumann on blood levels 
of radiolabelled protein and radiolabelled polyvinyl- pyrolidme 
m  thermally injured rats " Res Exp Med , 168 165-172
232
PILLER, N B , (1976b) "A comparison of the effect of
benzopyrones and other drugs with antnnflamatory properties on 
acid and neutral protease activity level m  various tissues after 
thermal injury " Br J Exp Pathol , 57 411-418
PILLER, N B , (1976c) "The ineffectiveness of coumann
treatment on thermal oedema of macrophage-free rats " Br J Exp 
Pathol , 57 170-178
PILLER, N B , (1977) "Further evidence for the induction of
proteolysis by coumann m  rats with various high protein 
oedemas " Arzneim-Forsch (Drug Res ), 27(1) 860-864
PILLER, N B ,(1978) "A morphological assessment of the
stimulatory effect of coumarin on macrophages " Br J Exp 
Pathol ,59 93-96
PILLER, N B , and Casley-Smith, J R , (1975) "The effect of
coumarin on protein and PVP-clearance from rat legs with* various 
high protein lymphoedemas " Br J Exp Pathol , 56 439-443
PILLER, N B , and Clodius, L (1976) "The use of a tissue
tonometer as a diagnostic aid m  extremity lymphoedema a
determination of its conservative treatment with benzopyrones " 
Lymphology, 9 127-132
PILLER, N B , and Clodius, L , (1979) "A morphological
assessment of macrophages attaching to subcutaneously implanted 
coverslips m  dogs with chronic lymphoedema " Br J Exp Pathol , 
60(3) 328-334
PISANO, J J , Fmlayson, J S , Peyton, M P , and Nagai, Y , 
(1971) " -( -glutamyl)-lysine in fibrin lack of cross link
formation in factor XIII deficiency Proc Natl Acad Sei 
(USA), 68 770-772
PREUSS-UBERSCHAR, Uberschar, S , and Grote, W , (1984) "Repro- 
duktionstoxikologische Untersuchungen an Ratten nach Oraler Verab­
reichung eines Benzopyron-Präparates " Arzneim-Forsch (Drug-Res ), 
34(10) 1305-1313
233
PROSSER, E , Cox, D , O'Kennedy, R , and van der Putten, W , 
(1988) "The effects of coumanns, haematoporphorms, and 
acndme orange on the viability of Landshutz Ascites Tumour 
Cells, in the presence and abscence of photoradiation " In
preparation
RAPPAPORT, A M, (1969) "Diseases of the liver", 3rd edition 
Ed Schiff, L J B Lippincott Co, Philadelphia pp 1-49
RAPPAPORT, A M, (1976) "The microcirculatory acinar con- cept
of normal and pathological hepatic structure " Beitr Path , 157 
215-243
READING, C L , Bator, J M  , and O'Kennedy, R , (1988)
"Applications of bifunctional antibodies m  Immunoassay and m  
tumour diagnosis and therapy " Interferon and Biotechnology, m  
Press
deRITIS, F , Coltonti, M , and Giusti, E, (1955) Min Med , 46 
34
RITSCHEL, W A , (1984) "Therapeutic concentration of coumann and 
predicted dosage regimens " Arzneim-Forsch (Drug Res ), 34 907-
910
RITSCHEL, W A , Brady, M E ,  Tan, H S I , Hoffman, K A , Yiu,
I M , and Grummich, K W , (1977) "Pharmacokinetics of coumann 
and its 7-hydroxy metabolites upon intravenous and peroral 
administration of coumann m  man " Eur J Clin Pharmacol , 12 
456-461
RITSCHEL, W A , and Hoffman, K A , (1981) "Pilot study on 
bioavailability of coumann and 7-hydroxycoumann upon peroral 
administration of coumann m  a sustained release dosage form " J 
Clm Pharmacol , 21(7) 294-300
RITSCHEL, W A , Alcorn, G J , and Ritschel-Beurlin, G , (1982) 
"Antipyretic and pharmacokinetic evaluation of coumann m  the 
rabbit after endotoxin administration " Meth and Find Exptl 
Clm Pharmacol , 4(6) 407-411
234
RITSCHEL, W A , Alcorn, G J , and Ritschel, G B , (1984)
"Therapeutic concentration of coumann as an antipyretic " Meth 
and Find Exptl Clm Pharmacol , 6(7) 363-365
RODRIGUEZ-FLORES, J , O'Kennedy, R , and Smyth, M R , (1988a)
"Adsorptive stripping voltammmetry of human chorionic gonadotropin 
and two of its specific antibodies” Biosensors, In press
RODRIGUEZ-FLORES, J , 0"Kennedy, R , and Smyth, M R , (1988b)
"Voltametnc investigation of the interaction of Concanavalm A 
with mannose" Analyst, 113 525-526
ROE, F J C, and Salaman, M H , (1955) "Further studies on the 
incomplete carcinogenesis Tnethylene melamme (TEH) ,
1,2-benzanthracene and B-propiolactone as initiators of skin 
tumour formation m  the mouse 1 Br J Cancer, 9 177-203
RONNEBERGER, H , (1986) " Need for additional safety assays for
heat-treated plasma protein fractions" TIPS, 7 130-131
ROTH, G J , Titani, K , Hoyer, L W , and Hickey, M J , (1986) 
"Localisation of binding sites withm human von Willebrand factor 
for monomeric type III collagen" Biochemistry, 25 8357-8361
RUGGERI, Z M , and Zimmerman, T S , (1981) "The complex multi-
menc composition of Factor VUI/von Willebrand Factor" Blood, 
57(6) 1140-1143
RUGGERI, Z M , Nilsson, I M , Lombardi, R , Holmberg, L , and 
Zimmerman, T S  , (1982) "Aberrant multimeric structure of von 
Willebrand factor m  a new variant of von Willebrand1s disease 
(type He)" J Clm Invest , 70(5) 1124-1127
SADLER, J W , Shelton-Inloes, B , Sorace J , Harlan, J , Titani,
K , Davie, E , (1985) "Cloning and characterisation of the cDNAs
coding for human von Willebrand factor " Proc Natl Acad Sci , 
(USA), 82 6394-6398
SCHEUER, P J, (1968) "Liver biopsy interpretation" Baillere, 
Tindall and Cassell pp 30-47
235
SCHILLING, W H , Crampton, R F , and Longland, R C , (1969) 
"Metabolism of coumann m  man " Nature (London), 221 664-665
SCHLOM, J , (1986) "Basic principles and application of
monoclonal antibodies m  the management of carcinomas The Richard 
and Hind Rosenthal Foundation Award lecture " Cancer Res , 46 
3225-3238
SCHMIDT, F W, and Schmidt, E, (1986) "Fundamentals of 
Diagnostic Immunology " Boehringer Mannheim GmbH, W , Germany
SCHMIDT, R F , Vogel, M E , and Zimmerman, M , (1967) "Die
Wirkung von Diazepam auf die prasynaptische Hemmung und andere
Ruckenmarksreflexe " Naunyn-Schmied Arch Exp Pathol Pharmakol ,
258 69-75
SEIDEL, G , and Kreuser, A F , (1979) "Untersuchungen über die
Wirkung von Cumarin auf die Leber von DBA/2J und CH3/HeJ mausen " 
Arzneim-Forsch (Drug-Res), 29(11) 1134-1140
SHAPIRO, G A , Andersen, J C , Pizzo, S V , and McKee, P A , 
(1973) "The subunit structure of normal and haemophilic factor 
VIII" J Clin Invest , 52 2198-2210
SHERLOCK, S, (1986) "The spectrum of hepatotoxicity due to
drugs" Lancet 11 440-444
SHOHAM, J , (1985) "Specific safety problems of inappropriate
immune responses to immunostimulating agents 1 TIPS, 6 178-182
SIGEL, E , Stephenson, F A , Mamalaki, C , and Barnard, E A ,
(1983) "A gamma ammobutync acid benzodiazepine receptor complex 
of bovine cerebral cortex-punfication and partial character­
ization" J Biol Chem , 258 6965-6971
SINCLAIR, N , and Panoskaltsis, A , (1988) ".The
immunoregulatory apparatus and autoimmunity " Immunology Today, 
9 260-265
SMITH, T W , Butler, V P , Haber, E , Fozzard, H , Marcus, F I , 
Bremmer, W F , Schulman, I , C , and Phillips, A , (1982)
236
"Treatment of life-threatening digitalis intoxication with digoxm 
-specific Fab fragments Experience m  26 cases" NEJM, 307 
1357-1362
SMYTH, M R , Buckley, E , Rodriguez-Flores, J , and O'Kennedy, R , 
(1988) "Application of adsorptive stripping voltammetry for a 
study of the reaction of mouse Ig with anti-mouse Ig" Analyst, 
113 31-33
STERNER, W , and Korn, W-D , (1981) "Micronucleus test on
venalot in mice " IBR Forschungs GmbH, 6-1-252-81
STEEL, R G, and Torrie, J H , (1980) "Principles and procedures 
of statistics A Biometric Approach " McGraw-Hill Inc , New York
STRICKER, B H Ch and Spoelstra, P, (1985) "Drug-induced 
disorders", vol 1 "Drug induced hepatic injury " Ed Dukes, M 
N G , Elsevier, Amsterdam
SZENT-GYORGYI, I , Rusznyak, I , (1936) "Vitamin P
Flavenoids as vitamins ", Nature (London), 138 27
*
TAKAHASHI, H , Handa, M , Watanabe, K , Ando, Y , Nagayama, R , 
Hatton, A , Shibata, A , Fedenci, A B , Ruggerl, Z M , and 
Zimmerman, T S , (1984) "Further characterisation of platelet- 
type von Willebrand's disease m  Japan" Blood, 64(6) 1254-1262
TAKAHASHI, Y , Kalafatis, M , Girma, J P , Sewenn, K ,
Andersson, L 0 , and Meyer, D , (1987) "Localisation of a
Factor VIII-binding domain on a 34 kDa fragment of the N-terminal
portion of von Willebrand Factor" Blood, 70(5) 1679-1682
THORNES, R D , (1975) "Adjuvant therapy of cancer via the
cellular immune mechanisms or fibrin by induced fibrinolysis and 
oral anticoagulants " Cancer, 35 91-97
THORNES, R D , (1977) "The anergy of chronic human brucellosis " 
J Ir Med Assoc , 70 480-483
THORNES, R D , Lynch, G , and Sheehan, M V , (1982)
"Cimetidme and coumann therapy of melanoma " Lancet, (11) 328
237
THORNES, R D , (1983a) "Acquired immune suppression in chronic
brucellosis " Ir Med J , 76(5) 225
THORNES, R D , (1983b) "Combination of cimetidme with other
drugs for treatment of cancer " NEJM, 308(10) 591
TITANI, K , Kumar, S , Takio, K , Ericsson, L , Wade, R ,
Ashida, K , Walsh, K , Chopek, M , Sadler, J , and Fujikawa, K ,
(1986) "Ammo acid sequence of human von Willebrand factor "
Biochemistry, 25 3171-3184
TOOLE, J , Knopf, J , Wozney, J , Sultzman, L , Buecker, J ,
Pittman, D , Kaufman, R , Brown, E , Shoemaker, C , Orr, E ,
Amphlett, G , Foster, W , Coe, M L , Knutson, G , Fass, D , and
Hewick, R , (1984) "Molecular cloning of a cDNA encoding human
antihaemophilic factor" Nature (London), 312 342-347
TSENG, A , Snyder, J , Lee, W , Cadman, E , Krosten, E ,
Hakem, A , and Kun, E , (1986) "Prevention of tumorlgenesis
of inducible EJ-ras oncogene containing rat-1 cells with drugs 
that interact with the poly(ADP-nbose) polymerase system Proc 
A A C R , 27 145
TUNG, A , (1982) "Production of large amounts of antibodies,
nonspecific immunoglobins, and other serum proteins in ascitic 
fluids ofindividual mice and guinea pigs " Meth Enzymol , 93 
12-23
UENO, I , and Hirono, I , (1981) "Non-carcinogenic response to
coumann m  syrian golden hamsters " Fd Cosmet Toxicol , 19
353-355
URBA, W , Longo, D , Lombardo, F , and Weiss, R , (1988)
"Enhancement of Natural Killer cell activity in human peripheral 
blood by flavone acetic acid " J Natl Can Inst , 80 521-525
VEHAR, G A , Keyt, B , Eaton, D , Rodriguez, H , O'Brein, D , 
Rotblat, F , Oppermann, H , Keck, R , Wood, W , Harkins, R ,
Tuddenham, E , Lawn, R , and Capon, D , (1984) "Structure
of human factor VIII1* Nature (London), 312 337-342
238
VERWEIJ, C , deVries, C , Distel, B , van Zonneveld, A-J , van 
Ke s s e1, A , van Mourlk, J , Pannekoek, H , (1985)
"Construction of cDNA coding for human von Willebrand factor using 
antibody probes for colony screening and mapping of the
chromosomal gene " Nucleic Acids Res , 13 4699-4717
 ^VOGEL, A , (1820) Gilberts Annalen der physik, 64 163
WALLER, A R , and Chasseaud, L F , (1981) "The metabolic fate
of [^C] -coumann m  baboons " Fd Cosmet Toxicol ,19 1-6
WARD, J W , Holmberg, S , Allen, J , Cohn, D , Cntchley, S ,
Kleinman, S , Lenes, B , Ravenholt, 0 , Davis, J , Quinn, M , and 
Jaffe, H , (1988) "The transmission of Human Immunodeficiency 
virus (HIV) by blood tansfusions sreened as negative for HIV 
antibodies " NEJM, 318 473-478
WARE, J , Toomey, J , and Stafford, D , (1988) "Localization of
a factor VIII-inhibiting antibody epitope to a region between 
residues 338 and 362 of factor VIII heavy chain " Proc Nat 
Acad Sci (USA), 85, 3165-3169
WATTENBERG, L W, Tam, L K, and Fladmoe, A V , (1979) "Inhibition 
of chemical carcinogen-induced neoplasia by coumarins and a-angel- 
icalactone " Cancer Res , _39 1651- 1654
WESTERWOUDT, R J , (1986) "Factors affecting production of mono­
clonal antibodies" Meth Enzymol , 121 3-18
WILLIAMS, W J , Beutler, E , Erslev, A J , and Rundles, R W , 
(1977) "Haematology" Blakiston, New York
WION, K L , Kelly, D , Summerfield, J A , Tuddenham, E G D , and
Lawn, R M , (1985) "Distribution of factor VIII mRNA and antigen
m  human liver and other tissues" Nature (London), 317 726-729
WOOD, A W , and Conney, A H , (1974) "Genetic variations in
coumann hydroxylase activity m  the mouse (Mus muscuius) "
Science, 185 612-614
239
WOOD, W , Capon, D , Simonsen, C , Eaton, D , Gitschier, J , Keyt,
B , Seeburg, P , Smith, D , Hollmgshead, P , Wion, K , Delwart, 
E , Tuddenham, E , Vehar, G , and Lawn, R , (1984) "Expression of 
active human factor VIII from recombinant DNA clones" Nature, 
(London) 312 330-337
WRIGHT, I S , (1962) "The nomenclature of blood clotting
factors" Thromb Diath Haemorh , 7 381-388
ZANKER, K S , Blumel, G , Lange, J , and Siewert, J R , (1984) 
"Coumann in melanoma patients an experimental and clinical 
study " Drugs Exptl Clm Res , X(II) 767-774
ZELECHOWSKA, M G , van Mounk, J A , and Brodniewicz-Proba, T , 
(1985) "Ultrastructural localisation of factor VIII procoagulant 
antigen in human liver hepatocytes" Nature (London), 317 729-730
ZIMMERMAN, H J, (1972) "International encyclopedia of pharmacol­
ogy and therapeutics", Section 75, vol 1 "Hypersensitivity to 
drugs" Ed's Samter, M , and Parker, C W , Pergman Press, Oxford
ZIMMERMAN, H J, (1978) "Hepatotoxicity The adverse effects 
of drugs and other chemicals on the liver" Appleton 
-Century-Crofts , NY
ZIMMERMAN, T S , Hoyer, L W , Dickson, L , and Edgington, T S , 
(1975) "Determination of the von Willebrand's disease antigen 
(factor VIII-related antigen) in plasma by quantitative 
Immunoelectrophoresis" J Clm Med , 8j5 152-159
ZUR, M , and Nemerson, Y , (1981) "Tissue factor pathways of 
blood coagulation", Haemostasis and Thrombosis, Ed's Bloom, A L , 
and Thomas, D P Churchill Livingstone, Edinburgh pp 124-139
240
